STATE AND CONSUMERS AFFAIRS AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
ARNOLD SCHWARZENEGGER, GOVERNOR

June 15, 2007

To: Enforcement Committee

Subject: Meeting Materials for the June 20, 2007 Enforcement Meeting

1. Workgroup on E-Pedigree

During the meeting, several presentations are planned, and additional comments are encouraged during the meeting. At this time, I have no presentation materials to share.

In Attachment 1, I am enclosing various articles about electronic pedigrees I have encountered in the media.

2. Enforcement Committee

- a. Ethics Course: an update at the meeting will be provided. No materials on this item are included in this packet.
- b. Proposed Modified Disciplinary Guidelines

The bulk of the material in this packet is the modified Disciplinary Guidelines (Attachment 2).

The board's staff has been in the process of updating the guidelines for two years, and we are nearing the end of process. If the committee believes the guidelines are ready to be provided to the board, they will be included in the July board packet. When the board is ready, the board will need to adopt these guidelines as an amendment to section 1760:

§1760. Disciplinary Guidelines.

In reaching a decision on a disciplinary action under the Administrative Procedure Act (Government Code section 11400 et seq.) the board shall consider the disciplinary guidelines entitled "Disciplinary Guidelines" (Rev. 1/2001 10/2007), which are hereby incorporated by reference.

Deviation from these guidelines and orders, including the standard terms of probation, is appropriate where the board, in its sole discretion, determines that the facts of the particular case warrant such a deviation--the presence of mitigating factors; the age of the case; evidentiary problems.

c. Disposal of Drugs from Assisted Living Facilities

At the last Enforcement Meeting, an inquiry was made about how an assisted care living facility can dispose of unwanted medicine. One option mentioned was to seek a legislative solution as there was a related bill pending in the California legislature. At this meeting, the committee will be updated.

d. Self-Assessment Forms for Community and Hospital Pharmacies Updated

The board has modified its two pharmacy self assessment forms to reflect current law. There is one form for community pharmacies and one for inpatient pharmacies. These self assessment forms are now available online.

The board will modify section 1715 (which actually requires the self assessment of a pharmacy by the PIC whenever the PIC changes or in July of each odd-numbered year) via a "section 100" change in the next few weeks to specify completion of the 2007 revised forms. However, until the regulation is finalized, the board cannot require the 2007 version of the self-assessment to be completed; we can only require the 2005 version (which is required in the regulation). Since compliance with the 2005 requirements will in some cases still mean the pharmacy is in violation of new laws, it makes no sense to require that only the 2005 form be used.

As such, the board will print the following notice in our next newsletter and online to educate licensees about which self-assessment form to use:

California Code of Regulations section 1715 requires each pharmacy to complete a self-assessment before July 1 of every odd numbered year, or within 30 days of a change in pharmacist in charge or the opening of a new pharmacy. This section currently requires completion of the 2005 version of the form.

The board has recently updated the pharmacy self assessment forms incorporate changes made to Pharmacy Law since 2005 and has added these forms onto the board's Web site.

However, regulation section 1715 has not yet been amended to require completion of the 2007 form.

To remain compliant with section 1715, each community and hospital pharmacy must complete the 2005 version as stated in the regulation.

While the board cannot mandate the completion of the 2007 form, the board encourages that the pharmacist-in-charge use the 2007 version of the form when completing the self assessment to make the self assessment process more meaningful.

When the board inspects a pharmacy, an inspector will ask to see the self-assessment form. If there is no self assessment form on file, this is a violation of pharmacy law.

The board will accept the pharmacy as being in compliance if there is either a 2007 or 2005 version of the self assessment, signed by the current PIC.

Meanwhile, the board is pursuing the formal process to officially require the 2007 form in regulation, which should be completed in the near future.

e. Enforcement Statistics

Citation and fine statistics for the fiscal year (as of June 1, 2007) are provided in Attachment 3.

Attachment 1

& Eubount



For Immediate Release

Media: Tara Schumacher

(614) 757-6250

tara.schumacher@cardinal.com

Investors: Bob Reflogal

(614) 757-7542

bob.reflogal@cardinal.com

CARDINAL HEALTH ANNOUNCES PLAN TO DEPLOY RFID TECHNOLOGY IN CALIFORNIA

Following Cardinal Health's industry-first, end-to-end RFID pilot, company leverages RFID technology to prepare for California pedigree legislation

DUBLIN, Ohio, May 3, 2007 — Cardinal Health announced today that it will integrate radio frequency identification (RFID) technology into the operations of its Sacramento, Calif. pharmaceutical distribution center by Fall 2007, to prepare for California's pedigree legislation that will require all drugs distributed within the state to be tracked and traced as they move throughout the supply chain.

The announcement, which was made at the RFID Journal Live! conference, hosted this week in Orlando, Fla., is part of Cardinal Health's ongoing efforts to protect the safety and efficiency of the nation's drug supply.

The announcement comes just months after Cardinal Health shared the results of its RFID pilot program, which was the health-care industry's first end-to-end test of RFID in a real-world setting. Data collected from the pilot confirmed that RFID technology using UHF as a single frequency is a feasible solution to track and trace the possession of pharmaceuticals at the unit, case and pallet levels. The pilot also confirmed that RFID technology offers significant promise to provide an added layer of safety within the pharmaceutical supply chain, by enabling item-level pedigrees to be tracked and traced as they pass from manufacturer to wholesaler to pharmacy.

The recently passed state legislation in California requires pharmaceutical manufacturers to originate item-level pedigrees for drugs distributed within the state's borders. This legislation also requires companies within the pharmaceutical supply chain (including companies that distribute drugs, like Cardinal Health) to update item-level drug pedigrees upon each change of ownership.

Cardinal Health operates dozens of pharmaceutical distribution centers nationwide. The company will start implementing RFID technology in its Sacramento, Calif. distribution center, as a means to receive and produce the electronic drug pedigrees needed to meet the requirements of the California legislation.

"While the Sacramento project is designed to support the pedigree legislation in California, it's also an extension of the end-to-end RFID pilot that we completed last year," said Steve Inacker, executive vice president of Global Supplier Services for Cardinal Health. "We look forward to leveraging this work to further validate the effectiveness and viability of RFID technology in real-world settings, should it be adopted as an industry standard."

As part of this effort, Cardinal Health will also leverage the new data, made available by RFID technology, to identify efficiency opportunities in key areas including returns and order accuracy, which can deliver value to the entire pharmaceutical supply chain.

Cardinal Health identifies next steps needed to facilitate industry-wide RFID adoption As Cardinal Health integrates RFID technology into its California operations, the company also said that industry standards and technology issues need to be addressed by the health-care industry as a whole, before RFID technology can be adopted industry-wide.


First, according to California law, product serialization must be initiated by the manufacturer, at the unit level, to allow tracking from the beginning to the end of the supply chain. For this to occur, Cardinal Health said the pharmaceutical supply chain industry must first agree on a standards-based approach and a single RFID protocol and technology. This will avoid the significant process and cost inefficiencies that would be created without such standards.

The company also said that technology and process improvements are needed to consistently achieve acceptable read rates at all packaging levels, and that industry acceptance is also needed for standard practices like accepting barcode technology as a complementary and redundant technology to RFID, and accepting unit-level "inference" when unit-level read rates are not possible.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an \$80 billion, global company serving the health-care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, MedMined® data mining software and the CareFusion® patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500 and No. 1 in its sector on Fortune's ranking of Most Admired firms, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at www.cardinalhealth.com.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: competitive pressures in its various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; changes in the distribution patterns or reimbursement rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings; difficulties, delays or additional costs in implementing the company's global restructuring program; and general economic and market conditions. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.





Jena University Hospital Prescribes RFID to Reduce Medication Errors

The German hospital is beginning a pilot designed to track individual antibiotic prescriptions from the pharmacy to the patient.

By Rhea Wessel

June 1, 2007—After more than a year of preparation, Germany's Jena University Hospital will launch a pilot this month to track medication for patients in the intensive care unit (ICU). The pilot will use high-frequency (HF) RFID tags to track antibiotics from the point of dispensing in the hospital's pharmacy until administration to patients. About 150 tags per day will be used on medication for 25 patients.

Jena designed the system together with SAP and Intel Solution Services, based on SAP's NetWeaver software and its Auto-ID Infrastructure platform. The hospital, which has more than 1,000 beds, is implementing the tracking system to improve the efficiency of its treatment process and enhance drug-handling safety—that is, to ensure patients get the correct doses of the right drugs (see German Hospital Expects RFID to Eradicate Drug Errors).



Martin J. Specht

In mid-2006, the hospital's RFID project team began selecting hardware vendors and integrating the RFID system with its patient information database and other back-end software. The implementation was initially slated for completion in October 2006, but the hospital has since made several changes to the project.

For example, says Martin Specht, formerly a head doctor in the hospital's anesthesiology and intensive care clinics and now the head of the electronic data processing division, Jena had intended to use UHF tags so it could perform bulk tag reads on medications. However, since many medications are liquids—which can interfere with RF signals—read rates were not as high as the hospital had hoped for. The project team then tested tags operating at high frequency and decided to employ HF tags

instead of UHF. Using HF tags from UPM Raflatac, Specht says, the hospital has now achieved accurate reads on individual items 98 percent of the time.

The hospital had designed the RFID system to work in conjunction with its in-house transport system, a network of conveyor belts linking various medical units. That, however, would have required RFID portals to be positioned over the conveyor belts, which Specht says would have been too costly to permit expansion of the RFID system throughout the hospital. "Using portal readers," he explains, "would have meant we had to, in the end, equip three doors—i.e., the three possible entrances to the intensive-care ward."

Instead, the hospital opted to utilize handheld and fixed RFID interrogators, relying on robots that push supplies around the hospital in trolleys to transport the drugs from the pharmacy to the ICU.

Jena's doctors submit patient prescriptions into the hospital's electronic prescriptions system, implemented nine years ago in an effort to reduce medication errors. The in-house pharmacists access the prescriptions via computer, then prepare each patient's correct medication dosage. With the new system, pharmacists will affix RFID tags, encoded using a Zebra printer, to each sealed packet of an individual dose of medication or bottle of medicine. The packets and bottles will then be put into plastic containers, which will also be tagged.

Once a container is full, all the tags (both on individual prescriptions and on the container) will be read by a fixed interrogator provided by Deister Electronic. The reader will document the prescriptions, exact pill counts, intended patients and other details in the patient information database. The containers will be loaded into a trolley (also tagged), and a pharmaceutical assistant will use a handheld interrogator made by Datalogic to read the tags applied on the containers and the trolley. The patient information database will then be updated with the time of departure for all medications.

RELATED ARTICLES

>Mercy Medical Tracks Cardiovascular Consumables >DHL, AeroScout, Microlise Team to Track Temperature for Pharma Maker >Alzheimer's Care Center to Carry

Out VeriChip Pilot

>RFID Journal LIVE! 2007 Report ☆

When the antibiotics arrive at the ICU, nurses will use handheld readers to scan the trolleys once more, documenting the medications' arrival. The nurses will then unload the containers and bring the appropriate medications to the patients' beds. At bedside, nurses will use the handheld scanners to read the RFID tags on their employee ID badges, as well as the tag on each dose of medication and the patient's RFID-enabled wristband. All the tags' unique identification numbers will be cross-checked in the hospital's patient information system to ensure the nurses administer the correct medicine to the right patient at the proper time. The system will then be updated to show that the antibiotics have been administered.

As the pilot gets underway, Jena University Hospital hopes it will better understand how well RFID technology can work within the hospital's workflow. "We are curious to see how the new system will be accepted by nurses," Specht says, "but we are very optimistic after the positive pretests with our head nurse."

Back to normal page view | Send this article to a friend |

Copyright © 2002 - 2007 RFID Journal, Inc. All Rights Reserved



Mercy Medical Tracks Cardiovascular Consumables

The Des Moines, Iowa, hospital is employing passive HF tags to inventory its supply of stents, balloons and other devices used in its catheterization lab—and, eventually, to bill patients.

By Beth Bacheldor

June 5, 2007—Mercy Medical Center, a 917-bed hospital in Des Moines, Iowa, is using an RFID system to help track its inventory of cardiovascular stents, balloons, filter wires, thrombectomy devices and many other medical consumables in its six-room catheterization laboratory.

The RFID system, provided by WaveMark, leverages passive 13.56 MHz tags; intelligent cabinets with built-in RFID that read items on the shelves every 12 minutes; point-of-service (POS) fixed RFID readers that companies can install in places where items are used in order to track actual usage; and Web-based software to monitor, analyze and manage inventory. Based in Boxborough, Mass., WaveMark manages the system as a hosted service in a secure data center in Dallas. Edwards Lifesciences, an Irvine, Calif., maker of heart valves and other health-care products, introduced Mercy to WaveMark and participated in the initial testing of the system by supplying pre-tagged items.

Mercy is a member of Catholic Health Initiatives and Mercy Health Network. The hospital is employing the system to track 1,600 items ranging in value from about \$100 to \$2,500 in 16 intelligent cabinets, according to Lynda Wilson, Mercy's administrative project analyst. Six of the cabinets are in the hospital's peripheral vascular storeroom, with five in the cardiac storeroom and one apiece in its four catheterization procedure rooms. Wilson says the hospital also plans to install a cabinet in each of its two electrophysiology procedure rooms. POS interrogators have been placed in two control rooms, where hospital personnel document each patient's case.

Hospital employees affix two RFID tags to the sides of each device's outer box. Tags are not reused. "We suggest using two tags per box because we insist on 100 percent read rates," explains Carola Endicott, WaveMark's VP of hospital services. Each tag contains its own unique ID number. The ID numbers are associated with a bar-code number applied by the device's manufacturer before shipment; hospital employees scan the bar code with a bar-code reader, and that data is correlated with the RFID tag numbers. The cabinet readers and the POS devices are connected to the Internet, and both update the status of all tagged products in the WaveMark system, three times per hour.

Because the cabinets automatically read all the tags numerous times daily, the system has a near-real-time count of inventory levels, which continually change whenever an item is removed or put into the intelligent cabinets. This enables the hospital to track which stents are pulled out for patients, which are ultimately used and which are put back. Typically, more than one stent is pulled for a patient because physicians don't know the exact type and/or size of stent that will be used until the implantation begins.

Once the procedure is completed, employees return the unused stents to the cabinets. Sometimes, however, unused stents aren't returned to the cabinets and turn up missing. By checking the WaveMark Web-based application, inventory personnel can determine approximately when the stents were removed, making it easier to track them down.

The RFID system replaces labor-intensive, manual inventory processes requiring hospital personnel to hand-count and restock items—a time-consuming task prone to errors. The manual inventory counts used to reconcile financial records, for example, took approximately three days.

The hospital has been using an inventory management system from enterprise application provider <u>Lawson Software</u>, but that system is imprecise because it depends on inventory data collected manually. "Although it is an okay system, it is very manually intensive," says Wilson. "If the computer says you have five of something on the shelf, it's not telling you what you really have. It's just telling you what it thinks you have."

Now, the intelligent cabinets automatically count inventory. With that information easily accessible, the hospital knows what is going on with its inventory at all times, and can compare that data with the par level—a set quantity of a product determined to be the proper amount to keep on hand. Using the WaveMark software, the hospital can analyze product usage and cut back on, or get rid of, products it doesn't use. It can also keep better track of lot numbers and expiration dates, removing items that are expired or are about to expire, and in some cases returning them to the vendors at no cost (many of the medical devices are on consignment, so Mercy Medical Center pays only for those it uses).

Drug-eluting stents, for example—which contain pharmaceuticals that are released over time—typically have a shelf life of only three months, Endicott explains. Keeping track of expiration dates also ensures that the hospital stays in compliance with the Joint Commission on the Accreditation of Healthcare Organizations, which makes regular, unscheduled visits to check quality and expiration dates, among other things. The WaveMark software enables the hospital to identify items that have expired, or are expected to expire within 30 days. The inventory analysis has also enabled the hospital to establish more accurate par levels.

"We use the reporting a lot," Wilson says. During a recent audit using the system, for instance, the hospital analyzed four months of data collected from the cabinet and POS RFID readers, as well as the patient billing system and WaveMark inventory software. In doing so, it discovered several items that had been scanned for particular patients but never charged for. "We found out, after the fact, that the items couldn't be used for those patients, and while they were supposed to be returned to inventory, they weren't," Wilson says. "We might have been able to return those items to the vendor, but didn't. And now, those are lost dollars."

RELATED ARTICLES

>Search Teams Put RFID to the Rescue to Help Find the Missing >Jena University Hospital Prescribes RFID to Reduce Medication Errors >Bangalore Heart Center Uses Passive RFID Cards to Track Outpatients

To prevent such a problem from happening again, the hospital plans to integrate the RFID system with its materials and patient billing systems within the next few months. Thus, whenever a product is pulled from a cabinet and actually used, it will automatically be charged to a patient bill. "Right now," Wilson says, "there is no direct connection between inventory and charges." Though plans are still being formulated, the likely scenario will enable nurses and physicians to input the patient's ID number into a procedure room computer, then utilize a POS reader to scan the RFID tag on the medical device actually used for that patient.

While the process will still require the manual inputting of the patient ID number, it will replace the current practice of literally peeling off the bar code from the box of the device used, then sticking it onto the patient's chart so personnel can later scan the bar codes while reconciling patient charts and bills. Once that new process is instituted, there will be an electronic record of the exact item used on a particular patient, which can be compared with actual inventory at any given time. That would make it easier for the hospital to track items pulled from the shelves but ultimately not used or returned to inventory.

Back to normal page view | Send this article to a friend |

Copyright © 2002 - 2007 RFID Journal, Inc. All Rights Reserved






SecureRF Announces Temperature-Logging EPC Tag with Data Protection

The semi-passive tag uses the company's Algebraic Eraser and public and private keys to encrypt temperature history or other data an end user might want to secure.

By Mary Catherine O'Connor

April 6, 2007—In late 2005, SecureRF, a data security startup in Westport, Conn., says it created a breakthrough design that will provide strong data security for EPC tags. To bring such a tag to market, the company is now developing a silicon chip with the additional memory required to support its data security engine, the Algebraic Eraser. The company has just unveiled its first product: a semi-passive LIghtweight Multistream Encryption (LIME) EPC tag with an integrated temperature sensor. The tag's sensor measures the temperature periodically, then logs those readings in onboard memory.

SecureRF says the LIME tag is well suited for pharmaceutical supply chain applications, or others in which end users require or benefit from data security in addition to temperature tracking. The company is currently offering the LIME tag as a collection of discrete components, combined onto an 8-by-3-centimeter circuit board. This includes an off-the-shelf EPC Gen 2 inlay, a temperature sensor, a field-programmable gate array (a device containing programmable logic components and programmable interconnects), a microprocessor (on which the Algebraic Eraser software resides) and a battery. SecureRF claims the Algebraic Eraser is faster, requires less computing power and consumes less energy than existing methods of encrypting data (see SecureRF Creates New Encryption Method).



The LIME tag is a collection of discrete components, combined onto an 8-by-3-centimeter circuit board.

While data saved to standard Gen 2 tags can be locked, it cannot be encrypted because the EPC protocol requires that the EPC be available for singulating tags. For a SecureRF tag—either the LIME tag or any future tag the company might develop—to be used in an EPC network, it must be readable just like any other Gen 2 tag. Thus, explains Mike McGregor, SecureRF's vice president of engineering, the LIME tag does not encrypt its EPC data. The additional data saved to the tag, however—primarily its temperature history, or other data an end user might want to protect, such as a drug identification or other identification codes—can be encrypted using SecureRF's asymmetric encryption.

This requires a public key, stored in the EPC tag's user memory and presented to the reader, and a private key, encoded into the Algebraic Eraser software running on the tag's microprocessor. It also calls for both public and private keys stored in SecureRF software called the secure reader host. This software can be deployed either on a reader's user memory (assuming the interrogator has enough processing power to support it), or on the server, running middleware linking the tag data to back-end systems. Alternatively, the secure reader host can run on a separate piece of hardware, on a network appliance situated between the reader and the middleware.

The tag and secure reader host each use their private keys to read the public key and the data it protects.

RELATED ARTICLES


- >Gun Maker Hits the Mark with
- >AT&T Expands Its RFID, Sensor
- Service Offerings
- >Avery Dennison Acquires Paxar
- >RFID Journal LIVE! Europe 2006
- Report ゆ

According to Louis Parks, SecureRF's president and CEO, his company plans to work with pharmaceutical companies and other end users over the next six months to perform pilot tests using the tag. It will then create its final specifications for the tag, based on user feedback, and begin manufacturing an integrated version in which the separate chips and other components will be built into a single IC. Parks says the fully integrated version of the LIME tag should measure 3 cm square. Once the pilot tests are complete and SecureRF has a final design ready, he estimates it will be roughly a year before the integrated version of the tag will be available.

In addition to space savings, Parks notes, the integrated chip will also offer performance improvements over the current discrete-component version. While the discrete-component LIME tag can be read from up to 15 meters away, the integrated version should be readable from up to 50 meters. The cost savings will also be significant once the tag is fully integrated, he adds, from the tag's current price of \$50 apiece to possibly as low as \$2.50 each.

Back to normal page view | Send this article to a friend

Copyright © 2002 - 2007 RFID Journal, Inc. All Rights Reserved





Eliminating the Static

Electrostatic discharges can destroy RFID tags during their conversion to labels, but label makers are finding ways to short-circuit the problem.

Nov. 14, 2005—Six months ago, printing-equipment manufacturer Mark Andy hosted an educational technical program for new and prospective RFID label converters. At one of the presentations, Bill Arnold of RFID inlay maker Omron Electronics told the attentive group, "Congratulations! You are now in the electronics component manufacturing business."

After that short and simple exclamation, we all took a moment to think about what it meant and how it would affect us. RFID is truly a new world, not only for end users of RFID labels, but also for the people who produce them. Label converters must now work with RFID inlays costing 20 to 40 times the price of the label materials. Despite their high cost—and quite unlike the high quality of label materials used by converters—some reels of RFID inlays have failure rates (nonfunctioning RFID chips) of 25 percent. And with new inlays rapidly coming onto the market, converters run a risk of getting stuck with expensive, obsolete inventory. Even more important, being involved in RFID labeling requires converters to adopt new ways of controlling and monitoring product quality.



Prior to the arrival of RFID, label converters had learned to understand some esoteric concepts: web guiding, tension and registration control, release characteristics, peel tests, anilox cell characteristics and UV photo initiation, to name a few. These concepts all apply to production and performance results we can ultimately evaluate with our physical senses. With RFID, however, label converters now have far greater responsibilities for things they cannot so easily detect. They need to rely on RFID interrogators (readers) with near- and far-field antennas to detect RFID label functions. Converters further need to determine reader parameter settings that allow correlation between what the RFID label converter says are 'good' and 'bad' labels and what the inlay manufacturer says are 'good' and 'bad' inlays. In addition, label converters need to detect and identify bad product accurately

at press speeds.

Static electricity, always present in press operations, can destroy RFID tags, either outright, or with latent damage that kills the microchip at some unpredictable point in the future. Surprisingly, inlay providers do not have clear specifications for limiting static buildup, or for prevention of static discharge. Even the packaging in which inlays are shipped often has no printed warning about electrostatic discharge (ESD) risks. As such, it's largely down to the converter to learn enough about static electricity and ESD, and to implement the necessary procedures and countermeasures.

Label converters have probably seen instances where unwinding and rewinding operations produce enough static electricity to throw a strong spark several inches through the air. In such cases, tens of thousands of volts are discharged. That kind of static charge can be dissipated by dragging conductive strands of foil, known as 'tinsel,' over the web of label stock—a crude, but known practice within the industry. Many converters may not realize passing a web over an idler roller can generate 1,000 or more volts, or that a gripper and pacing roller nip used to drive the web can generate well over 5,000 volts. In contrast, some inlay suppliers advise keeping static levels below about 500 volts. Tinsel is effective at dissipating static electricity down to about 5,000 volts, but it is simply not effective in controlling static to the relatively low levels required by inlays.

Fortunately, help is close at hand. Static neutralization equipment has improved substantially over recent years. Modern static neutralization systems include antistatic bars that emit electric charges to air molecules. Positively and negatively charged air molecules, known as ions, surround an antistatic bar. These ions are attracted by opposite charges carried

on webs of inlays and label stock, neutralizing the static charge. Modern antistatic bar designs allow emitted ions to travel substantially farther from the bar, so antistatic bars no longer need to be mounted as close to a web. Even better, a single antistatic bar provides static neutralization for a much larger area.

Modern bars now neutralize both positive and negative charges approximately equally, without the need for bulky air blowers used in earlier designs to propel ions out to increase neutralizing range. Antistatic bars typically attract dust and debris around the ion-emitting electrodes. This dust allows some electrical energy to short to ground, diminishing the number and range of the neutralizing ions. This dust needs to be cleaned off the bars periodically to maintain neutralizing performance. Some power supplies now include monitoring circuitry that indicates system performance and notifies the converter when the bars need to be cleaned. Advanced static control systems may also include a PC interface allowing RFID label converters to monitor system performance over time as part of a wider process control and quality initiative.

The white paper, "Mastering RFID Label Converting," by Mark Blitshteyn of electrostatics management products and services provider Ion Industrial, can give you further understanding of the issues involved in manufacturing RFID labels and controlling potentially harmful static electricity.

David Steidinger is president of <u>Tamarack Products</u>, a provider of applicating equipment for several industries, including equipment for inserting RFID inlays into label stock in-line with flexopress operations.



Back to normal page view | Send this article to a friend |

Copyright © 2003 RFID Journal, Inc. All Rights Reserved

Enfacens



Pilot project confirms the value of EPCglobal Standards

EPCglobal concludes first phase of RFID pilot project to enable sea container visibility between Hong Kong and Japan

BRUSSELS, **Belgium – 30 April**, **2007** – GS1 EPCglobal today announced the completion of the first phase of their Transportation and Logistics Industry Action Group RFID pilot programme. The pilot tracked in real time the location of cargo containers shipped from Hong Kong to Japan.

Phase One of the pilot, which was extensively supported by The Ministry of Economics, Trade and Industry (METI) in Japan, assessed the use of both passive and active EPC tags for seashipment of cartons and containers. The pilot addressed specific business needs of the partners, such as matching tagged products with purchase orders.

This multi-industry, multi-stakeholder initiative extensively tested EPCglobal standards developed in response to specific user requirements. Through the use of the EPC Information Services (EPCIS) standard in particular, true visibility at critical junctions throughout the global supply chain was achieved

"Phase One of the pilot has demonstrated the value of the EPCIS standard which was used to track the progress of cartons and containers across the supply chain between multiple trading partners" said Chris Adcock, President, EPCglobal Inc.

"We strongly recommend EPCglobal as a reliable RFID standard to secure and facilitate global trade," said Tetsuya Hamabe, Director of Distribution and Logistics Policy Division of METI.

Based on this phase of the pilot, ran in collaboration with the consignee, a footwear manufacturer, we can already anticipate that EPCglobal standards users will gain advanced cargo visibility, enabling them to control lead time, inventory and cash flow.

A second phase, scheduled for completion in February 2008, is set to reinforce the EPCIS dimension. Information will be exchanged between potential end users, such as customs administrations for automatic customs clearance. The trade lane to be used in this phase is Shanghai to Long Beach, California.

Pilot participants include several hardware and software companies, government bodies, and global supply chain providers including METI, Maersk Logistics, Schneider National, Inc, APL, DHL, NYK Logistics, GS1 Hong Kong, IBM, BEA Systems, WhereNet, Symbol, Toppan Printing, Toppan Forms, Savi, Allumis, NRI, Oracle, IIJ, NTT COMWARE, Monohakobi Technology Institute, VeriSign and Schenker.

Notes to the Editor:

About EPCglobal Inc

EPCglobal Inc is a not-for-profit standards organisation dedicated to driving global adoption of the Electronic Product Code as a global standard to enable accurate information and visibility about products in the supply chain. More information about EPCglobal Inc can be found at http://www.epcglobalinc.org

About EPCglobal Standards

EPCglobal provides the globally accepted standard that ensures universal applicability and optimal functionality across the globe for all industry sectors. Without such horizontal standards, industries and/or geographic regions would be left to develop their own standards, which would create diverse, incompatible systems that inhibit collaboration across industries, commercial sectors and geography.

About EPCIS

EPCIS is used to track the progress of objects as they move through the supply chain. The data shared at each read point in the supply chain provides the WHAT, WHEN, WHERE and WHY of each EPC event. The EPCIS Standard provides the foundation necessary for the capture, communication and discovery of EPC event data. It enables standard event capture and query interfaces for obtaining and sharing data about unique objects in the supply chain within and across organisations.

For more information contact:

In the United States:

In Brussels:

Jeffery Oddo, GS1 US +1 609 620-4548 Joddo@gs1us.org Audrey Ni Cheallaigh, GS1 Global Office +32 (0) 2 788 7825 Audrey.nicheallaigh@gs1.org

Enfacement



For more information contact:

In the United States: Jeffery Oddo, GS1 US +1 609 620-4548 Joddo@gs1us.org

In Brussels: Audrey Ni Cheallaigh, GS1 Global Office +32 (0)27 88 7825 Audrey.nicheallaigh@gs1.org

EPCglobal Ratifies Low-Level RFID Reader Protocol

New protocol provides standard control & communication interface for wired and wireless network-connected RFID readers

Brussels, Belgium – 24 April 2007 – GS1 EPCglobal Inc today announced the ratification of the Low-Level Reader Protocol (LLRP) standard. Use of LLRP allows readers to be operated to deliver optimal performance resulting in rich, accurate, actionable data and events. The LLRP standard will further foster reader interoperability and create the foundation for technology providers to extend basic capabilities in satisfaction of industry-specific requirements.

This new standard, produced by the EPCglobal Reader Operations Working Group, defines a high-performance, flexible and extensible interface for operating network-connected RFID readers. The protocol is the result of collaboration between over 90 companies including end users, RFID infrastructure vendors, middleware vendors, industry experts, and networking professionals

"The LLRP effort brought together industry leaders with a broad perspective and advanced the state of the RFID industry," said David Husak, Co-chairman of the EPCglobal Reader Operations Working Group, and Chief Technical Officer of Reva Systems Corporation. "In particular, the participation of prominent RFID end users helped to ensure that LLRP will meet the broadest possible range of industry requirements, worldwide."


LLRP supplies the functionality around reader operations in compliance with the EPCglobal Architecture Framework. It is the first interface specification that provides comprehensive support for all control and data features of the EPCglobal Class1 Generation 2 UHF Air Interface Protocol.

"Gen2 was the first big step toward broader adoption of passive RFID and EPC technology, it changed the marketplace by standardizing the tag-to-reader air interface," said Chris Adcock, president of EPCglobal Inc. "By standardizing the next critical architecture layer, the LLRP reader-to-network interface is expected to move the industry another step along the path to wide-scale enterprise adoption."

Notes to the Editor:

About EPCglobal:

EPCgIobal Inc is a subsidiary of the global not-for-profit standards organisation GS1, and supports the global adoption of the Electronic Product Code as a global standard to enable accurate information and visibility about products in the supply chain. More information about EPCglobal Inc. can be found at http://www.epcglobalinc.org.



PRESS RELEASE

EPCglobal Ratifies Global Standard for Secure, Real-Time Data Sharing EPCIS Standard Provides Greater Visibility for the Benefit of Business and Consumers Across Industries and the Globe.

Brussels, 16 April 2007: EPCglobal Inc announced a groundbreaking industry standard providing the capability for unprecedented visibility into the movement, location and disposition of assets, goods and services throughout the world. EPCIS (Electronic Product Code Information Services) allows for the seamless, secure exchange of data at every point in the lifecycle of goods and services

EPCIS, by providing a standard set of interfaces for EPC data, enables a single way to capture and share information, while still allowing the flexibility for industry and organization-specific implementations. The specification supports powerful business cases and consumer benefits such as container tracking, product authentication, promotions management, baggage tracking, electronic proof of delivery, chain of custody, returns management, and operations management.

"With the EPCIS industry standard, the technology supporting visibility into the movement and whereabouts of goods and services is coming of age "said Chris Adcock, president of EPCglobal Inc. "In terms of industry significance, I believe that the EPCIS standard may have much more of a transformational impact on the industry than the [2004] release of the UHF Gen2 Passive RFID standard. Capturing EPC data has proven, well-defined advantages for businesses and consumers, but the technology's true potential will be realized when enterprises begin to share that data about products using the EPCIS standard to improve efficiencies in a controlled setting throughout the supply chain."

Cont.



In October 2006, EPCglobal successfully completed interoperability testing of the platform along with 12 other large and small solution providers from Japan, Korea, and North America, including Auto-ID Labs, Avicon, BEA Systems, Bent Systems, IBM, Globe Ranger, IIJ, NEC, Oracle, Polaris Systems, Samsung, and T3Ci. The interoperability test marked a significant milestone in the development of EPCIS, which is the result of years of effort by more than 150 companies and organizations participating in the EPCIS working group. The positive results of this test and solution provider support have led to the ratification of this standard.

"The EPCIS standard is a major step in the greater adoption of RFID and sensors that can help protect us from counterfeit drugs, secure our ports and provide food traceability," said Craig Asher, IBM WebSphere Product Manager and EPCglobal EPCIS Software Action Group Co-Chair. "This standard has already been deployed in real business scenarios around the world and will facilitate revenue-enhancing and cost-saving collaboration among supply chain trading partners."

EPCIS is the foundational specification for capturing very granular event information across and within organizations. It is anticipated that EPCIS will be built upon, with additional end user and community use cases serving as the driver for enhanced data sharing models.

Notes to the Editor:

About EPCIS:

EPCIS is used to track the progress of objects as they move through the supply chain. The data shared at each read point in the supply chain provides the WHO, WHAT, WHEN, WHERE and WHY of each EPC event. The EPCIS Standard provides the foundation necessary for the capture, communication and discovery of EPC event data. It enables standard event capture and query interfaces for obtaining and sharing data about unique objects in the supply chain within and across organisations.

About EPCglobal:

EPCglobal Inc. is a subsidiary of the global not-for-profit standards organisation GS1, and supports the global adoption of the Electronic Product Code as a global standard to enable accurate information and visibility about products in the supply chain. More information about EPCglobal Inc. can be found at http://www.epcglobalinc.org.

For more information, please contact Eric Decroix I at eric.decroix@gs1.org or on 00 32 2 788 7820.



IMMEDIATE RELEASE

Commission Communication on RFID sets the stage for the EU to realise benefits of applications based on EPCglobal standards

EU should continue to embrace a balanced, enabling approach Industry's responsibilities in informing consumers about RFID are clear

Brussels, 15 March 2007 – The approach outlined today at CeBIT by European Commissioner Viviane Reding paves the way for the EU to enable businesses, consumers, citizens, governments and the whole EU economy to reap the benefits of RFID technology, according to EPCglobal.

EPCglobal Inc, the international not-for-profit user-driven standards organisation, supports the adoption of RFID based on the Electronic Product Code (EPCTM).

In welcoming the Commission's new Communication, Chris Adcock, President of EPCglobal commented:

"The European Commission clearly recognises the value that global standards will bring to the economy and society in general. EPCglobal standards enable accurate information and visibility about products in the supply chain, and as such their deployment can play a critical role in increasing competitiveness levels in the EU.

"Although there are some issues that still require further debate and perhaps clarification, the approach presented today sets the right framework for the discussions to progress and we look forward to playing our part in them"

"The benefits to European consumers of better information about enhanced food safety, product authenticity, stock availability and take-back possibilities, are now only beginning to be known and understood first-hand. Ensuring a clear and responsible approach to managing privacy and security concerns is important – hence our long-standing efforts in this regard".

EPCglobal has developed <u>Guidelines</u> for its members on EPC for Consumer Products, designed to complement all relevant EU data protection legislation. This ensures that consumers have awareness, education, information and choice. In addition, EPCglobal is actively exploring how to further ensure that consumers have confidence in the application of these guidelines. EPCglobal strongly believes that this approach will enable it and EU decision-makers to adequately respond to any reasonable concerns over privacy voiced by its citizens.

EPCglobal therefore urges the other EU institutions, notably the European Parliament and the Council of Ministers, to bear such activities in mind as they start the process in developing their further thoughts and to endorse an enabling, positive approach as the best way for the EU to realise benefits for all stakeholders involved.



Contact

Audrey Ni Cheallaigh, GS1 Global Office +32 788 7825 Audrey.nicheallaigh@gs1.org



Note to Editors

1. Some RFID Facts and Figures

- In 2007, the total RFID market size is \$4.96 bn. (*IDTechEx, RFID Trends and Forecasts*)
- By 2017, the total RFID market size is estimated to grow to \$26.88 bn (IDTechEx, RFID Trends and Forecasts)
- US still has the largest number of RFID projects followed by the UK where the RFID market size is 1/3 of the US market size (IDTechEx, RFID Trends and Forecasts)
- In 2017, the most important sectors by value of tags will roughly equal \$2 billion each and will be
 - o Smart cards
 - o Consumer goods item level
 - o Pallet/case

The second most important sectors will equal at around \$1 billion each and will be

- o Military
- Animals

(IDTechEx, RFID Trends and Forecasts)

Efficiency

- Around 1/3 of retail turnover is tied up in inventory and becomes wasted capital
- In the cosmetics, household & personal care industry, at any given time, 1 in 12 items is out of stock. This results to a 2.6% of annual sales. (Lehman Brothers, Equity Research, 15 September 2006)

Counterfeiting

- The European Commission has estimated that counterfeiting costs the EU € 1.5 billion and is responsible for 200.000 lost jobs per year in Europe (or never created) due to lost sales
 - (European Commission, Taxation and Customs Union website: http://europa.eu.int/comm/taxation_customs/customs/customs_controls/counterfeit_piracy/combating/index_en.htm)
- The World Customs Organisation estimates that counterfeiting accounts for 5% to 7% of global merchandise trade.
- \$39 billion or 11% of global pharmaceutical commerce were counterfeit in 2005
 (Center for Medicines in the Public Interest (CMPI) report released 13
 September 2005)



2. About EPCglobal

- EPCglobal Inc is an international not-for-profit organisation and a subsidiary of GS1 and GS1 USTM
- EPCglobal aims at taking a global leadership role in developing and promoting multi-industry, user-driven standards for utilising the Electronic Product Code (EPC) to enable accurate information and visibility about products in the supply chain.
- EPCglobal currently has 1.100 organisations 193 European companies that represent many sectors (consumer goods, healthcare, transport and logistics, apparel, aerospace, automotive and many providers of services).
- EPCglobal members participate at all levels of the supply chain from manufacturer, to retail and logistic provider.

For further information about EPCglobal you can visit http://www.epcglobalinc.org

3. Facts about EPC Technology

What is the Electronic Product Code (EPCTM)?

The Electronic Product Code (EPC) is a unique number that is used to identify a specific item in the supply chain. The EPC is stored on a radio frequency identification (RFID) tag, which combines a silicon chip and an antenna. Once the EPC is retrieved from the tag, it can be associated with dynamic data held in a secured database such as where an item originated or the date of its production. Much like a Global Trade Item Number (GTIN) or Vehicle Identification Number (VIN), the EPC is the key that unlocks the power of the information systems that are part of the EPCglobal NetworkTM.

What is the EPCglobal Network?

The EPCglobal Network is a set of technologies that enables immediate, automatic identification of items in the supply chain, anywhere in the world. Importantly, the Network allows trading partners to exchange such information about the goods they ship among themselves. In that way, the EPCglobal Network makes organisations more effective by uncovering inefficiencies or reducing such eternal issues as counterfeiting, internal theft, and other drains on productivity and profitability.

What are the components of the EPCglobal Network?

The EPCglobal Network consists of several components that are designed to work together to give maximum visibility to a supply chain. The components are made up of the Electronic Product Code (EPC), tags, readers, and software that helps all of the pieces communicate in a common "language."

The EPC sits on a tag comprised of a silicon chip connected to an antenna, which is physically attached to an item, a case of items, or a pallet of cases of items. The tag



"communicates" its unique number to a reader through radio frequency. The reader then passes the number to a computer that accesses the Object Name Service (ONS). The ONS tells the computer systems where to locate information on the secure network about the object carrying an EPC, including, for example, when the item was produced, and where.

EPC Information Services provide a common set of data elements, a common language for communication, and a set of defined messages for trading partners to use for storing, accessing, and communicating data on objects moving in the supply chain. The key to these information services is the EPC held in the RFID tag on each object. EPC-IS Middleware is a software technology that acts as the central nervous system of the EPCglobal Network. The EPC-IS Middleware manages and moves information in a way that does not overload existing corporate and public networks.

How does the EPCglobal Network deliver value?

The technology helps businesses minimise extra costs from their internal operations, from such issues as internal theft, out-of-stocks, counterfeiting, and other issues that plague them. This in turn drives down the cost of doing business, which helps businesses succeed while applying downward pressure on consumer prices.

For further information, visit http://www.epcglobalinc.org

Attachment 2

State of California

Department of Consumer Affairs

Memorandum

To: ENFORCEMENT COMMITTEE Date: June 15, 2007

From: SUSAN CAPPELLO

Enforcement Coordinator Board of Pharmacy

Subject: Proposed Revisions to the Disciplinary Guidelines

Enclosed with your enforcement committee packet is the suggested revision to the Disciplinary Guidelines for your review.

These guidelines are being revised to clarify language, ensure that terms and conditions are consistent for all license types (where appropriate), to define consequences for non-compliances and to include new terms of probation. Strikeouts indicate deleted language and underlines indicate new language.

Below are summaries of some of the more significant changes made for each license type.

Pharmacist/Intern Conditions; pages 34-56

Significant changes made to standard conditions include:

- No Supervision of Interns, Serving as Pharmacist-in-Charge (PIC) or Designated Representative-in-Charge (DRC), or Serving as a Consultant (pg 36) – better defines the language for this provision. Restricts the pharmacist from serving as DRC in a wholesaler or veterinary food-animal drug retailer. (NOTE: This term has not yet been updated to reflect the DRC language but will be incorporated in advance of the July 2007 board meeting)
- Tolling of Probation (38) These changes were made to require the probationer to work a portion of their probationary period in a traditional dispensing position.

Significant changes made to optional conditions include:

- Pharmacist Examination (pg 40) These changes were made to reflect the new exam structure (CPJE & NAPLEX).
- Mental Health Examination (pg 41) The language makes changes to broaden the
 definition of the licensed health practitioners who can complete the mental health exam.
 Additionally, this term now better defines the conditions under which the ongoing therapy
 must occur, if recommended.
- Psychotherapy (pg 43) These changes were made to broaden the definition of the licensed health practitioners who can complete the mental health exam. Additionally, this term now better defines the conditions under which the ongoing therapy must occur as recommended.

Enforcement Committee Proposed Revisions to the Disciplinary Guidelines June 15, 2007 Page Two

- Medical Evaluation (pg 44) Details more specifically the procedures to carry out this provision.
- Pharmacists Recovery Program (pg 47) This term now includes language that requires the automatic suspension of practice for any confirmed positive test for drugs or alcohol under certain conditions and details the suspension provisions.
- Random Drug Screening (pg 49) Details more specifically the procedures to carry out this provision.
- Abstain from Drugs and Alcohol Use (pg 49) Expands the definition of this term to include the prohibition of physical proximity to persons using illicit substances.
- Tolling of Suspension (pg 55) Details more specifically the procedures to carry out this provision.

New optional conditions of probation are:

- Prescription Coordination and Monitoring of Prescription Use (pg 50) This term will be recommended for individuals whose violations indicate chemical dependencies or psychiatric disorders. Designates a single health care practitioner to coordinate and monitor prescriptions. This term also defines the procedures to carry out this provision.
- Pharmacy Self-Assessment Mechanism (PSAM) (pg 52) This term will be recommended to provide a self-assessment mechanism to aide the pharmacist in identifying deficient areas of practice.
- Surrender of DEA Permit (pg 56) This term will be recommended for pharmacists to prevent him or her from prescribing.

Pharmacy Technician Conditions; pages 63-72

Significant changes made to standard conditions include:

- Obey All Laws (pg 63) This term will be recommended to make consistent with other license types.
- License Surrender While on Probation/Suspension (pg 66) This term was relocated within the standard terms to be consistent with the other license types.
- Tolling of Probation (67) These changes were made to require the probationer to work a portion of their probationary period in a traditional dispensing position.

Significant changes made to optional conditions include:

- Random Drug Screening (pg 69) Details more specifically the procedures to carry out this provision.
- Abstain from Drugs and Alcohol Use (pg 70) Expands the definition of this term to include the prohibition of physical proximity to persons using illicit substances.
- Tolling of Suspension (pg 72) Details more specifically the procedures to carry out this
 provision.

Enforcement Committee Proposed Revisions to the Disciplinary Guidelines June 15, 2007 Page Three

New optional condition of probation is:

 Restitution (pg 72) – This term will be recommended for those cases where drug diversion, theft fraudulent billing or patient harm resulting from negligence or incompetence occurred.

Designated Representative Conditions; pages 80-91

Significant changes made to standard conditions include:

- Reexamination Prior to Resuming Work This term was deleted because an exam is no longer a requirement for licensure.
- Obey All Laws (pg 80) This term will be recommended to make consistent with other license types.
- No Being Designated Representative-in-Charge (pg 83) This term is similar to the No Being PIC and will be recommended to prohibit a designated representative from serving as a DRC in a wholesaler or veterinary food-animal drug retailer.
- License Surrender While on Probation/Suspension (pg 84) This term was relocated within the standard terms to be consistent with the other license types.
- Tolling of Probation (85) These changes were made to require the probationer to work a portion of their probationary period in a traditional dispensing position.

Significant changes made to optional conditions include:

- Random Drug Screening (pg 89) Details more specifically the procedures to carry out this provision.
- Abstain from Drugs and Alcohol Use (pg 90) Expands the definition of this term to include the prohibition of physical proximity to persons using illicit substances.
- Tolling of Suspension (pg 91) Details more specifically the procedures to carry out this provision.

New optional condition of probation is:

 Restitution (pg 91) – This term will be recommended for those cases where drug diversion, theft fraudulent billing or patient harm resulting from negligence or incompetence occurred.

Premises Conditions; pages 115-120

New standard condition of probation is:

 Posted Notice of Probation (pg 118) – This term will be recommended for all premises to post to alert the consumer of the discipline imposed by the board.

DISCIPLINARY GUIDELINES

A Manual of Disciplinary Guidelines and Model Disciplinary Orders



BE AWARE & TAKE CARE: Talk to your pharmacist!

California State Board of Pharmacy Department of Consumer Affairs (Rev. 1/20016/2007)

STATE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS

Steve Litsey William Powers PRESIDENT

John D. Jones, Vice President	Robert H. Elsner
David J. Fong	Stan Goldenberg
Donald W. Gubbins, Jr., PharmD.	Clarence Hiura
William Powers	John Tilley
Caleb Zia	Andrea Zinder

Patricia F. Harris Virginia K. Herold EXECUTIVE OFFICER

400 R Street, Suite 40701625 N. Market Blvd, Suite N-219 Sacramento, CA 958314 (916) 445-5014574-7900

ATSS: 8-485-5014
Fax: (916) 327-6308574-8618 Fax
8-467-6308www.pharmacy.ca.gov

Additional copies of these disciplinary guidelines may be ordered from the downloaded from the board's website address above

BOARD OF PHARMACY

DISCIPLINARY GUIDELINES

TABLE OF CONTENTS

	Introduction	
	Factors to be Considered in Determining Penalties	3
	Mitigating Evidence	4
	Pharmacist/Intern Pharmacist	
	Terms of Probation – Pharmacist/Intern Pharmacist	5
	Categories of Violation and Recommended Penalties	5
	Category I – Penalty	
	Category II – Penalty	1 <u>1</u>
	Category III - Penalty	
	Category IV – Penalty	
	Model Disciplinary Language – Pharmacist/Intern Pharmacist	
	Standard Conditions	
	Optional Conditions	
	Optional Conditions	. 20 <u>21</u>
	Pharmacy Technician	.3442
	Terms of Probation – Pharmacy Technician	
	Category III – Penalty	
	Model Disciplinary Language – Pharmacy Technician	
	Standard Conditions	
	Optional Conditions	
	Optional Conditions	. TZ <u>J I</u>
1	Exemptee Designated Representative	1551
	Terms of Probation — Exemptee Designated Representative	
	Category III – Penalty Model Disciplinary Language – Exemptee Designated Representative	
	Standard Conditions	
	Optional Conditions	. 5∠ 63
ı	Duranica	FF00
	Premises	
	Terms of Probation – Premises	
	Category I – Penalty	
	Category II – Penalty	
	Category III – Penalty	
	Category IV – Penalty	
	Model Disciplinary Language – Premises	. 69 79
	Standard Conditions	. 72 82
	Optional Conditions	.7485

DEPARTMENT OF CONSUMER AFFAIRS STATE BOARD OF PHARMACY

DISCIPLINARY GUIDELINES

(Rev. 1/20016/2007)

INTRODUCTION

The Board of Pharmacy (board) is responsible for the enforcement of statutes and regulations related to the practice of pharmacy (the Pharmacy Law) and to the regulation of controlled substances (the Uniform Controlled Substances Act). The board serves the public by:

- protecting the health, safety, and welfare of the people of California with integrity and honesty;
- advocating the highest quality of affordable pharmaceutical care;
- providing the best available information on pharmaceutical care; and
- promoting education, wellness and quality of life.

Pharmacists are patient advocates who provide pharmaceutical care <u>and exercise clinical</u> <u>judgment</u> for the citizens of California, enlightening them about their drug therapy through effective communicating and listening, assessing, collaborating, understanding and intervening. <u>In addition, eEnforcement officials are provided the resources to act quickly, consistently and efficiently in the public's interest to ensure the safe, effective delivery of these services.</u>

The board recognizes the importance of ensuring the <u>safe and effective</u> delivery of dangerous drugs and controlled substances for therapeutic purposes. At the same time, and given the historical and current abuse and diversion of drugs, particularly controlled substances, the board believes there should be no tolerance for licensees who traffic in drugs or who, in the absence of appropriate evidence of rehabilitation, personally abuse drugs or alcohol.

In accordance with <u>section Section 1760</u> of the California Code of Regulations, the board has produced this booklet for those involved in and affected by the disciplinary process: the general public, attorneys from the Office of the Attorney General, administrative law judges from the Office of Administrative Hearings, defense attorneys, board licensees, the courts, board staff and board members who review and vote on proposed decisions and stipulations.

These guidelines are to be followed in Board of Pharmacy disciplinary actions. Subject to judicial review, the The board has the final authority over the disposition of its cases, and, to complete its work, it uses the services of the Office of the Attorney General and the Office of Administrative Hearings. The board recognizes that individual cases may necessitate a departure from these guidelines. In such cases, the mitigating or aggravating circumstances shall be detailed in any proposed decision or any transmittal memorandum accompanying a proposed stipulation, especially where Category III violations are involved.

The board has found that accusations are rarely filed except in serious cases. In general, the position of the board is that revocation should always be an option whenever grounds for

discipline are found to exist. Board policy is that revocation is generally an appropriate order where a respondent is in default, such as when he or she fails to file a notice of defense or fails to appear at a disciplinary hearing.

Board policy is that a suspension, where imposed, should be at least 30 days for an individual and at least 14 days for a licensed premises.

The board seeks recovery of all investigative and prosecution costs up to the hearing in all disciplinary cases. This includes all charges of the Office of the Attorney General, including, but not limited to, those for legal services, and includes charges by expert consultants. The board believes that the burden of paying for disciplinary cases should fall on those whose conduct requires investigation and prosecution, not upon the profession as a whole.

The board recognizes there may be situations where an individual licensee deserves a stronger penalty than the pharmacy for which he or she works, but the board also believes in holding a pharmacy owner, manager, and/or pharmacist-in-charge responsible for the acts of their employees who operate the pharmacy. Similarly, the board recognizes that in some cases a licensed premises may well be more culpable than any individual licensed by or registered with the board.

For purposes of these guidelines "board" includes the board and/-or its designees.

FACTORS TO BE CONSIDERED IN DETERMINING PENALTIES

Section 4300 of the Business and Professions Code provides that the board may discipline the holder of, and suspend or revoke, any certificate, license or permit issued by the board.

In determining whether the minimum, maximum, or an intermediate penalty is to be imposed in a given case, factors such as the following should be considered:

- 1. actual or potential harm to the public
- 2. actual or potential harm to any consumer
- 3. prior disciplinary record, including level of compliance with disciplinary order(s)
- 4. prior warning(s) of record(s), including but not limited to citation(s) and fine(s), letter(s) of admonishment, and/or correction notice(s)
- 5. number and/or variety of current violations
- 6. nature and severity of the act(s), offense(s) or crime(s) under consideration
- 7. aggravating evidence
- 7.8. mitigating evidence
- 8.9.rehabilitation evidence
- 9.10. compliance with terms of any criminal sentence, parole, or probation
- 40.11. overall criminal record
- <u>41.12.</u> if applicable, evidence of proceedings for case being set aside and dismissed pursuant to section Section 1203.4 of the Penal Code
- 42.13. time passed since the act(s) or offense(s)
- <u>43.14.</u> whether the conduct was intentional or negligent, demonstrated incompetence, or, if the respondent is being held to account for conduct committed by another, the respondent had knowledge of or knowingly participated in such conduct
- 14.15. financial benefit to the respondent from the misconduct.

No single <u>one</u> or combination of the above factors is required to justify the minimum and/<u>or</u> maximum penalty <u>in a given case</u>, as opposed to an intermediate one.

MITIGATING EVIDENCE

A respondent is permitted to present mitigating circumstances at a hearing or in the settlement process and has the burden of demonstrating any rehabilitative or corrective measures he or she has taken. The board does not intend, by the following references to written statements, letters, and reports, to waive any evidentiary objections to the form or admissibility of such evidence. The respondent must produce admissible evidence in the form required by law in the absence of a stipulation to admissibility by the complainant.

The following are examples of appropriate evidence a respondent may submit to demonstrate his or her rehabilitative efforts and competency:

- a. Recent, dated written statements and/or performance evaluations from persons in positions of authority who have on-the-job knowledge of the respondent's current competence in the practice of pharmacy including the period of time and capacity in which the person worked with the respondent. Such reports must be signed under penalty of perjury and will be subject to verification by board staff.
- b. Recent, dated letters from counselors regarding the respondent's participation in a rehabilitation or recovery program, which should include at least a description and requirements of the program, a psychologist's diagnosis of the condition and current state of recovery, and the psychologist's basis for determining rehabilitation. Such letters and reports will be subject to verification by board staff.
- c. Recent, dated letters describing the respondent's participation in support groups, (e.g., Alcoholics Anonymous, Narcotics Anonymous, professional support groups, etc.). Such letters and reports will be subject to verification by board staff.
- Recent, dated laboratory analyses or drug screen reports, confirming abstention from drugs and alcohol. <u>Such analyses and reports will be subject to verification by board</u> staff.
- e. Recent, dated physical examination or assessment report by a licensed physician, confirming the absence of any physical impairment that would prohibit the respondent from practicing safely. Such assessments and reports will be subject to verification by board staff.
- f. Recent, dated letters from probation or parole officers regarding the respondent's participation in and/or compliance with terms and conditions of probation or parole, which should include at least a description of the terms and conditions, and the officer's basis for determining compliance. Such letters and reports will be subject to verification by board staff.

TERMS OF PROBATION - PHARMACIST/INTERN PHARMACIST

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of controlled substances is involved. Terms and conditions are imposed to provide consumer protection and to allow the probationer to demonstrate rehabilitation. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in all-all probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.

CATEGORIES OF VIOLATIONS AND RECOMMENDED PENALTIES

The California Pharmacy Law specifies the identifies offenses for which the board may take disciplinary action against the license. The following are categories of violations used by the board in determining appropriate disciplinary penalties. Included among grounds for discipline are violations of the Pharmacy Law itself, violations of regulations promulgated by the board, and violations of other state or federal statutes or regulations.

The following are categories of possible violations used by the board to determine appropriate disciplinary penalties. These categories represent the judgment of the board as to the perceived seriousness of particular offenses.

Under each category, the board has grouped statutes and regulations where violations would typically merit the recommended range of minimum to maximum penalties for that category. These lists are representative, and are not intended to be comprehensive or exclusive. Where a violation not included in these lists is a basis for disciplinary action, the appropriate penalty for that violation may be best derived by comparison to any analogous violation(s) that are included. Where no such analogous violation is listed, the category descriptions may be consulted.

These categories assume a single violation of each listed statute or regulation. For multiple violations, the appropriate penalty shall increase accordingly. Moreover, if an individual has committed violations in more than one category, the minimum and maximum penalties shall be those recommended in the highest category.

The board also has the authority, pursuant to Business and Professions Code section 4301(n), to impose discipline based on disciplinary action taken by another jurisdiction. The discipline imposed by the board will depend on the discipline imposed by the other jurisdiction, the extent of the respondent's compliance with the terms of that discipline, the nature of the conduct for which the discipline was imposed, and other factors set forth in these guidelines.

CATEGORY I

Minimum: Revocation; Revocation stayed; one year probation. All standard terms and

conditions shall be included and optional terms and conditions as appropriate.

Maximum: Revocation

Category I discipline is recommended for:

violations which are relatively minor but are potentially harmful

repeated violations of a relatively minor nature:

Violations of the following codes are as followsrepresentative of this category:

6

BUSINESS AND PROFESSIONS CODE

Article 3. Scope of Practice and Exemptions

4052.1	Skin Puncture by Pharmacist; Conditions Permitting
4052.5	Pharmacist May Select Different Form of Medication with Same Active Chemical
	Ingredients; Exceptions
4052.7	Repackage Previously Dispensed Drugs; Requirements
4053	Exemptee Supervisionor of Manufacturers, Wholesalers, and Licensed Laboratories;
	Veterinary Food-Animal Drug Retailersetc.: Requirements
4054	Supplying Dialysis Drugs Supply by Manufacturer, etc. of Certain Dialysis Drugs and
	<u>Devices</u>
4055	Sale of Devices to Licensed Clinics, etc.
4056	Exempt Hospitals Purchase of Drugs at Wholesale – Hospital Containing 100 Beds
	<u>or Less</u>
4057	Exempt Articles Exceptions to Application of this Chapter
4058	License to be Displayed Display of Original License
4062	Furnishing Drugs during EmergencyFurnishing Dangerous Drugs During
	<u>Emergency</u>
4064	Emergency Refills of Prescription Without Prescription Authorization
4065	Administration through Injection Card System Injection Card System; Requirements
	of Administration
4066	Furnishing to Ocean VesselFurnishing Dangerous Drugs to Master or First Officer of
	<u>Vessel</u>
4068	Dispense Dangerous Drug or Controlled Substance to Emergency Room Patient;
	Requirements

Article 4. Requirements for Prescription

4070	Reduction of Oral or Electronic Prescription to Writing
4071	Prescriber's Agent Transmitting Prescriptions Prescriber May Authorize Agent to
	Transmit Prescription; Schedule II Excluded
4072	Transmitting Prescriptions from a Health Care FacilityOral or Electronic
	Transmission of Prescription – Health Care Facility
4073	Drug Product Selection Substitution of Generic Drug – Requirements and Exceptions
4074	Drug Warnings Drug Risk: Informing Patient; Providing Consultation for Discharge
	Medications
4076	Prescription Label Requirements Prescription Container – Requirements for Labeling
4077	Labeling Dispensing Dangerous Drug in Incorrectly Labeled Container

Article 5. Authority of Inspectors

4082 Information about Personnel Names of Owners, Managers and Employees Open for Inspection

Article 6. General Requirements

4100	Change of Name or Address or Name – Notification to Board
4102	Skin Puncture for Patient Training
4103	Blood Pressure Measurement - Taking by Pharmacist

Article 7. Pharmacies

4114	Intern Pharmacist Activities: Activities Permitted
4119	Emergency Kit for Licensed Health Care Facilities Furnish Prescription Drug to
	<u>Licensed Health Care Facility – Secured</u>
4119.1	Pharmacy May Provide Services to Health Facility
4119.5	Transferring or Repacking Drugs Transfer or Repackaging Dangerous Drugs by
	Pharmacy
4121	Prescription Price Advertising Advertisement for Prescription Drug: Requirements;
	Restrictions
4122	Requests for Prescription Price Information Required Notice at Availability of
	Prescription Price Information, General Product Availability, Pharmacy Services;
	Providing Drug Price Information; Limitations on Price Information Requests
4123	Pharmacy contracts for Compounding of Parenteral Drugs Compounding Drug for
	Other Pharmacy for Parenteral Therapy; Notice to Board
4124	Contact Lens Dispensing Dispensing Replacement Contact Lenses: Requirements;
	Patient Warnings; Registration with Medical Board; Application of Section to
	Nonresident Pharmacies

Article 9. Hypodermic Needles and Syringes

4141	License RequiredFurnishing Without License
4142	Prescription Required
4143	Exemption: Wholesale Sales Sale to Other Entity, Physician, etc.
4144	Exemption: Industrial Uses Industrial Use Exception
4145	Exemption: Human (Insulin; Adrenaline) or Animal Use Exception: Furnishing for
	Administration of Insulin, Adrenaline, or Specified Animal Uses; Conditions
4146	Hypodermic Register
4148	Confiscation if Found Outside Licensed Premises
4149	Nonresident Sale by Distributor

Article 10. Pharmacy Corporations

4151	<u>Licensure</u> Requirements for Shareholders, Directors, and Officers
4152	Corporate Name Requirements
4153	Shareholder Income While Disqualified
4156	Unprofessional Conduct by Corporation

Article 11. Wholesalers and Manufacturers

4161	Out-of-State Manufacturer or Nonresident Wholesaler: When License Required;
	Application
4162	Registration AgentIssuance or Renewal of Wholesaler License; Surety Bond
4163	Sales to-Unauthorized Persons Furnishing by Manufacturer or Wholesaler

4165	Sale or Transfer of Dangerous Drug or Device Into State: Furnishing Records to
	Authorized Officer on Demand; Citation for Non-compliance
4166	Responsibility Until DeliveryShipping of Dangerous Drugs or Devices – Wholesaler
	or Distributor
4167	Bar on Obtaining More Than Can Be Stored on Licensed Premises Wholesaler: Bar
	on Obtaining Dangerous Drugs or Devices It Cannot Maintain on Licensed Premises

Article 13. Non-Profit or Free Clinics

4180	License Required (Non-Profit, etc Clinics)Purchase of Drugs at Wholesale Only with
	License: Eligible Clinics
4181	License Requirements; Policies and Procedures; Who May Dispense
4182	Application; Consulting Pharmacist Duties of Professional Director; Consulting
	Pharmacist Required
4183	No Medi-Cal-Professional Dispensing Fee
4184	No Schedule II-Dispensing Schedule II Substance Prohibited
4186	Professional Director Automated Drug Delivery Systems

Article 14. Surgical Clinics

4190	Purchase of Drugs at Wholesale: Permitted Uses of Drugs; Required Records and
	Policies; License Required (Surgical Clinic)
4191	License Requirements Compliance with Department of Health Services
	Requirements; Who May Dispense Drugs
4192	Duties of Professional Director; Providing Information to Board
4193	Clinic Not Eligible for Professional No Medi-Cal-Dispensing Fee; Ban on Offering
	Drugs for Sale
4194	No Schedule II Dispensing of Schedule II Substance by Clinic Prohibited; Physician
	May Dispense; Administration Authorized in Clinic

Article 15. Veterinary Food-Animal Drug Retailers

4196	License Required;: Temporary License; Security on Transfer of Ownership; Persons
	Authorized in Storage Area
4197	Minimum Standards; Waiver: Security; Sanitation; Board Regulations; Waivers
4198	Written Policies and Procedures Required: Contents; Training of Personnel; Quality
•	Assurance; Consulting Pharmacist

Article 17. Continuing Education

4231	Renewal Requirements for Renewal of Pharmacist License: Clock Hours;
	Exemption for New Licensee
4232	Course Content of Course

Article 18. Poisons

4240 Application of Act

Article 20. Prohibitions and Offenses

4341	Advertising in Compliance with Sections 651.3Advertisement of Prescription Drugs
	or Devices
4343	Use of Sign with "Pharmacy" or Similar TermsBuildings: Prohibition Against Use of
	Certain Signs Unless Licensed Pharmacy Within

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1704	Change of Address address - reporting a change of address
1705	Notification of Bankruptcy, Receivership or Liquidation - reporting the sale, inventory
	and location of records of dangerous drugs by a pharmacy, wholesaler or
	manufacturer in bankruptcy
1708.2	Discontinuance of Business business - notification to board of a discontinuance of
	business and submission of appropriate forms
1708.4	Pharmacist hHandling rRadioactive dDrugs - training of a nuclear pharmacist
1708.5	Pharmacy Furnishing Radioactive Drugs - nuclear pharmacy requirements
1709	Names of Owners and Pharmacist in Chargepharmacist-in-charge - required
	information on a pharmacy permit, reporting PIC and owners on initial and renewal
	applications, and reporting of corporate officer changes
1712	Use of Pharmacist Identifiers
1714	Operational Standards and Security
1715.6	Reporting dDrug lLoss - reporting loss of controlled substances to the Board within
	thirty (30) day
1716	Variation fFrom pPrescriptions - prescription errors, deviation from prescription
	without consent of prescriber
1717	Pharmaceutical pPractice - dispensing in new containers, pharmacist maintain on
	prescription record: date and initial of pharmacist, brand name of drug or device and
	indication if generic and manufacturer name, refill information, orally transmitted
	prescription requirements, depot of a prescription or a medication, prescription
	transfers, identification of pharmacist responsible for filling a prescription
1717.1	Common Electronic Files - establishing a common electronic file to maintain
''''	required dispensing information
1717.4	Electronic Transmission of Prescriptions - transmitting prescriptions by electronic
', ', '	means from prescriber to the pharmacy
1718.1	Manufacturer's Expiration Date - handling of prescription drugs not bearing a
17 10.1	manufacturer's expiration date pursuant to federal law
1726	Preceptor Supervision of Intern Pharmacists
1727	Intern Pharmacist
1728	Intern Experience - Requirements for Licensure Examination
1732.1	Requirements for Recognized Accredited Providers - requirements to provide
1702.1	continuing education courses as a recognized provider for California pharmacists
1732.3	Coursework Approval for Providers Requirements for Continuing Education Courses
1732.4	Provider Audit Requirements
1732.4	Renewal Requirements for Pharmacist
1732.5	Drug wWarnings - oral or written warnings when a drug should not be taken with
1744	alcohol or when a person should not drive
1746	Emergency Contraception
1740 1751 to	Emergency Contraception
1751.09 a	nd
1751.09 a	
1751.11 «	Compounding Area for Parenteral Solutions - parenteral therapy requirements for
1701.12	pharmacists and pharmacies
1751	•
1751 1751 01	Sterile Injectable Compounding Area Eacility and Equipment Standards for Sterile Injectable Compounding from Non
<u>1751.01</u>	Facility and Equipment Standards for Sterile Injectable Compounding from Non-
1751 02	Sterile Ingredients Policies and Procedures
1751.02 1751.1	
<u>1751.1</u>	Laminar Flow Biological Safety Cabinet

1751.2	Labeling Requirements	
1751.3	Recordkeeping Requirements	
1751.4	Attire	
1751.5	Training of Staff, Patient, and Caregiver	
1751.6	Disposal of Waste Material	
1751.7	Quality Assurance and Process Evaluation	
1751.9	Reference Materials	
1751.11	Furnishing to Home Health Agencies and Licensed Hospices	
1751.12	Obligations of a Pharmacy Furnishing Portable Containers	
1771	Posting notice of sSuspension - suspended pharmacy must post a notice of	
	suspension	
1772	Disciplinary eConditions of sSuspension - suspended pharmacist shall not enter a	
	pharmacy prescription area or perform pharmacy related duties	
1780	Minimum <u>sS</u> tandards for <u>wW</u> holesalers	
1780.1	Minimum Standards for Veterinary Food-Animal Drug Retailers	
1781	Exemption eCertificate - exemptee must be present in a manufacturer's or	
	wholesaler's licensed premises	
1786	Exemptions -return of exemption certificate to board upon termination of employment	
1787	Authorization to Distribute Hemodialysis Drugs and Devices	
1790	790 Assembling and Packaging	
1791	Labeling	
1792	Receipt of for Shipment	

| HEALTH AND SAFETY CODE, TITLE 22

11100	Report of Certain Chemical: Chemicals Included; Exclusions; Penalties controlled substance transaction - reporting sales of restricted chemicals to Department of Justice
11100.1	Report of <u>Chemicals Received controlled substances received from eOutside</u> sState; <u>Penalties – reporting Purchases of restricted chemicals from outside</u> California
11124	Inventory of Controlled Substances
11151	Limitation on Filling Prescriptions From Medical Students Issued By Unlicensed
	Person Lawfully Practicing Medicine
11158	Prescription rRequired for Schedule HII, III, or IV, or V eControlled eSubstance;
	Exception for Limited Dispensing, Administrations - prescriptions for controlled
	substances must comply with requirements prior to dispensing
11159	Chart Order Exemption for Patient in County or Licensed Hospital; Maintaining
	Record for Seven Years - controlled substance orders in hospitals
11159.1	Chart Order Exemption for Clinic Records Patient; Maintaining Record for Seven
	Years
11159.2	Exception to Triplicate Prescription Requirement Terminally III Exception
11167	Emergency dDispensing of Schedule II sSubstance: Circumstances and
	Requirements - emergency oral Schedule II prescriptions; must receive a triplicate
	within seventy-two (72) hours
11167.5	Emergency o'Oral or Electronic pPrescriptions for Scheduled II Controlled
	Substances for Specified iln-patients, Residents, and Home Hospice Patients;
	Requirements - oral orders for Schedule II drugs in a skilled nursing facility,
	intermediate care facility, or a home health care agency providing hospice care;
	pharmacy to obtain special triplicates from Dept. of Justice; facility must forward all
•	

	signed order to the pharmacy
11171	Prescribing, etc. administering, or furnishing cControlled sSubstance Only as
	Authorized — furnishing controlled substances must be consistent with law
11172	Antedating or pPostdating pPrescription Prohibited
11175	Prohibition on Obtaining and or pPossessioning aNonconforming pPrescription;
	Prohibition on eObtaining eControlled sSubstance by nNonconforming pPrescription
11180	Prohibition on Controlled sSubstance oObtained or pPossessed by nNonconforming
	pPrescription - possession of a controlled substance obtained from noncomplying
	prescriptions
11200	Restrictions on <u>dD</u> ispensing or <u>FR</u> efilling; <u>Refill of Schedule II Prescription Barred</u> —
	refill restrictions of controlled substances
11201	Emergency Refill by Pharmacistof Schedule III, IV, or V Prescription; Circumstances;
	<u>Requirements</u>
11205	Maintenance and rRetention of Records in Separate fFile - separate prescription file
	for Schedule II prescriptions
11206	Required information information on Prescription - information required on a
	prescription for controlled substances
11209	Delivery and Receiving Requirements for Schedule II, III, and IV of Controlled
	Substances; Violatoion
11210	<u>Issuing Prescription: By Whom; For What Purpose; Quantity to Be Prescribed under</u>
	authorized project - a prescriber may not prescribe controlled substances to treat
	addiction
11250	Authorized Retail Sale by Pharmacists to Physicians, etc.; Required Order Form
11251	Authorized Wholesale Sale by Pharmacists
11252	Preservation of federally
440=0	maintain records of sales
11253	Duration of FRetention
11255	Actions eConstituting sSale - orders for future delivery constitutes a sale of a
44050	controlled substance
11256	Required Report of Order bBy or Sale to Out-of-State Wholesaler or Manufacturer
1111225 t	
<u>111655</u>	Adulterated or Misbranded Drugs or Devices

CODE OF FEDERAL REGULATIONS, TITLE 21

1301.11	Persons Rrequired to Rregister.
1301.12	Separate Rregistrations for Separate Llocations.
1301.71	Security requirements, generally.
1301.72	Physical security controls for non-practitioners; narcotic treatment programs and
	compounders for narcotic treatment programs; storage areas.
1301.73	Physical security controls for non-practitioners; compounders for narcotic treatment
	programs; manufacturing and compounding areas.
1301.74	Other security controls for non-practitioners; narcotic treatment programs and
	compounders for narcotic treatment programs.
1301.75	Physical security controls for practitioners.
1301.76	Other Security Controls for Practitioners.
1301.90	Employee screening procedures.
1301.91	Employee responsibility to report drug diversion.
1301.92	Illicit activities by employees.
1302.03	Symbol required; exceptions.

1302.04	Location and size of symbol on label and labeling.
1302.05	Effective Dates of Labeling Rrequirements.
1302.06	Sealing of controlled substances.
1302.07	Labeling and packaging requirements for imported and exported substances.
1302.07	Labeling and packaging requirements for imported and exported substances
1304.18	Inventories of importers and exporters
1304.31	Reports from manufacturers importing opium
1304.32	Reports of manufacturers importing medicinal coca leaves
1304.33	Reports to ARCOS
1305.03 to	•
1305.06 an	n d
1305.08 to	
1305.12 an	id
1305.14 to	
1305.16	Distributions requiring order forms; persons entitled to obtain and execute order
	forms; procedure for obtaining order forms; procedure for executing order forms;
	persons entitled to fill order forms; procedure for filling order forms; procedure for
	endorsing order forms; unaccepted and defective order forms; lost and stolen order
	forms; return of unused order forms
1304.11	Inventory requirements.
1304.31	Reports from manufacturers importing narcotic raw materials.
1304.32	Reports of manufacturers importing coca leaves.
1304.33	Reports to ARCOS.
1305.03	Distributions requiring a Form 222 or a digitally signed electronic order.
1305.04	Persons entitled to order Schedule I and II controlled substances.
1305.05	Power of attorney.
1305.06	Persons entitled to fill orders for Schedule I and II controlled substances.
1305.11	Procedure for obtaining DEA Forms 222.
1305.12	Procedure for executing DEA Forms 222.
1305.14	Procedure for endorsing DEA Forms 222.
1305.15	Unaccepted and defective DEA Forms 222.
1305.16	Lost and stolen DEA Forms 222.
1306.03	Persons entitled to issue prescriptions.
1306.05	Manner of issuance of prescriptions.
1306.14	Labeling of substances and filling of prescriptions Schedule II.
1306.24	Labeling of substances and filing of prescriptions Schedule III and IV
1306.25	Transfer between pharmacies of prescription information for of Schedules III, IV, and
	V controlled substances for refill purposes. Prescriptions
1306.26	Dispensing <u>Wwithout a Pprescription.</u>
1307.11	Distribution by dispenser to another practitioner or reverse distributor.
1307.12	<u>Distribution to supplier or Mmanufacture.</u> and distribution of narcotic solutions and
	compounds by a pharmacist
1307.13	Incidental manufacture of controlled substances. Distribution to supplier
1307.21	Procedure for disposaling of controlled substances.
1700.1 to	
1707.15	Child-resistant containers.

MISCELLANEOUS - HEALTH AND SAFETY CODE, TITLE 22

111225 to

111655 Adulterated or misbranded drugs or devices

MISCELLANEOUS - FEDERAL REGULATIONS

16 CFR 1700.1 to 1707.15 Child-resistant containers

CATEGORY II

Minimum: Revocation; Revocation stayed, three years probation (five years probation where

self-administration or diversion of controlled substances is involved). All standard terms and conditions shall be included and optional terms and conditions as

appropriate.

Maximum: Revocation

Category II discipline is recommended for:

violations with a serious potential for harm

violations which involve greater disregard for pharmacy law and public safety

 violations which reflect on ethics, care exercised or competence or a criminal conviction not involving dangerous drugs or controlled substances or involving possession or use of dangerous drugs or controlled substances.

Violations of the following codes are as follows representative of this category:

BUSINESS AND PROFESSIONS CODE

650	Rebates or Discounts for Referral Prohibited
650.1	Lease Prohibition – Hospitals or Prescribers
651	Professional Advertising Requirements

Article 3. Scope of Practice and Exemptions

4051(b)	Conduct Authorized by Pharmacist from Outside Pharmacy
4052	conduct Authorized by PharmacistFurnishing to Prescriber; Permissible Procedures
	by Pharmacist in Health Care Facility or Clinic or for Other Health Care Provider
4060	Possession of Controlled Substance - Prescription Required; Exceptions
4061	Distribution of Drug as Sample; Written Request Required Drugs
4063	Refills of Prescription for Dangerous Drug or Device; Prescriber Authorization
4067	Prescription Dispensing over the Internet; Dispensing Dangerous Drugs or Devices
	without Prescription
4075	Proof of Identity Required – Oral or Electronic Prescription of Recipient for Controlled
	Substance Prescriptions
4078	False or Misleading Labeling on Prescription

Article 6. General Requirements

4101	Termination as Pharmacist in Charge; Notice to Board, Exemptee: Termination of
	Employment; Notification to Board
4104	Licensed Employee:, Theft or Impairment: Pharmacy Procedures
4105	Retaining Records on Premises of Dangerous Drugs and Devices on Licensed
	Premises; Temporary Removal; Waivers; Access to Electronically Maintained
	Records

Article 7. Pharmacies

4112	Non-Rresident Pharmacy: Registration; Provision of Information to Board;
	Maintaining Records; Patient Consultation
4113	Pharmacist in Charge: Notification to Board; Responsibilities
4115	Pharmacy Technician: Activities Permitted; Required Supervision; Activities Limited
	to Pharmacist; Registration; Requirements for Registration; Ratios
4115.5	Pharmacy Technician Trainee; Placement; Supervisions; Requirements
4116	Security of Dangerous Drugs and Devices in Pharmacy: Pharmacist Responsibility
	for Individuals on Premises; Regulations - Pharmacy
4117	Security - Hospital PharmacyAdmission to Area Where Narcotics are Stored, etc
	Who May Enter
4120	Non-Rresident Pharmacy: Registration Required
4125	Pharmacy Quality Assurance Program Required; Records Considered Peer Review
	Documents

Article 9. Hypodermic Needle and Syringes

4140	Unlawful Possession
4147	Disposal of Needle or Syringe

Article 11. Wholesalers and Manufacturers

4160	Wholesaler: License Required
4163	Sales to-Unauthorized Persons Furnishing by Manufacturer or Wholesaler
4164	Reporting by Manufacturer and Wholesalers Reports Required
4169(a)(1)	Prohibited Acts

Article 13. Non-Profit of Free Clinics

4185 Inspections Permitted

Article 14. Surgical Clinics

4195 Inspections Permitted

Article 19. Disciplinary Proceedings

4301	General uUnprofessional eConduct and subsections (a)-(h), (j), and (l) through (q)
4302	Pharmacy Corporation Discipline of Corporate Licensee for Conduct of Officer,
	<u>Director</u> , Shareholder
4303	Nonresident Pharmacy: Grounds for Discipline
4304	Out-of-Sstate Distributors: Authority to Discipline
4305	Disciplinary Grounds: Failure of Pharmacy, Pharmacist to Notify Board of
	Termination of Pharmacist in Charge; Continuing to Operate Operation of Pharmacy
	₩Without a Pharmacist
4305.5	Disciplinary Grounds: Failure of Other Entity Licensed by Board, of Pharmacist or
	Exemptee to Notify Board of Termination of Pharmacist in Charge or Exemptee;
	Continuing to Operate Without Pharmacist or Exempteeto Keep Pharmacist in
	Charge or Exemptee in Charge; Failure to Notify Board of Termination of Same
4306	Violation of Moscone-Knox Professional Corporation Act as Unprofessional Conduct
4306.5	Pharmacist Misuse of Education, etc. by Pharmacist Outside Course of Practice of
	Pharmacy as Unprofessional Conduct

Article 20. Prohibitions and Offenses

4326	Hypodermics: Obtaining Falsely; MisuseMisdemeanor: Obtaining Needle or Syringe
	by Fraud, etc.; Unlawful Use of Needle or Syringe Obtained from Another
4328	Allowing Compounding by Non-pharmacist Misdemeanor: Permitting Compounding,
	Dispensing, or Furnishing by Non-pharmacist
4330	Pharmacy; Failure to Place Pharmacist in Charge-, Subverting Compliance with Law
	by Pharmacist-in- Charge Misdemeanor: Non-pharmacist Owner Failing to Place
	Pharmacist in Charge, Dispensing or Compounding Except by Pharmacist,
	Interfering with Pharmacist in Charge
4331	Veterinary Food-Animal Drug Retailer; Dispensing by Other than Pharmacist or
	Exemptee; Failure to Place Pharmacist or Exemptee in Charge Misdemeanor:
	Medical Device Retailer, Wholesaler, Veterinary Food-Animal Drug Retailer Failing to
	Place Pharmacist or Exemptee in Charge, Permitting Dispensing or Compounding
	Except by Pharmacist or Exemptee
4333	Failure to Maintain Prescription Files Maintaining Prescriptions, Other Drug Records
	on Premises, Open to Inspection; Waiver; Willful Failure to Keep or Permit
	Inspection of Records of Prescriptions, Other Records as Misdemeanor
4340	Advertisement of Pharmacy Services by Unregistered Non-Resident
	Pharmacy Unlawful Advertising by Nonresident Pharmacy Not Registered with Board

Article 22. Unfair Trade Practices

4380 Resale of Preferentially Priced Drugs; Emergency Exception: Prohibition; Exceptions

4381	Violation of Section 4380 as Unfair Competition; Right of Private Action to Enforce
4382	Authority of Board to Audit for Compliance Board May Audit Sales to Walk-in
	Customers

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1707.1	Duty to mMaintain mMedication pProfiles (pPatient mMedication rRecords)-
	requirements for maintenance of patient medication profiles
1707.2	Notice to eConsumers and dDuty to eConsult - requirements of pharmacist to
	consult; posting of notice to consumers
1707.3	Reviewing the patient profile prior to consultation Duty to Review Drug Therapy and
	Patient Medication Record Prior to Delivery
1709.1	Designation of pPharmacist in eCharge
1714.1	Pharmacy Operations dDuring -the Temporary Absence of a Pharmacist
1715	Self-Assessment of a Pharmacy by the Pharmacist-in-Charge
1715.5	Transmitting Schedule II Prescription Information to CURES Implementation of
	Electronic Monitoring of Schedule II Prescriptions
1716.1	Compounding Unapproved dDrugs for pPrescriber oOffice uUse
1716.2	Record rRequirements-when cCompounding for fFuture fFurnishing
1717.2	Notice of Electronic Prescription Files
1717.3	Preprinted, mMultiple eCheck-off pPrescription bBlanks
1723.1	Confidentiality of Examination Questions
1745	Partial fFilling of Schedule II pPrescriptions
1751.10	Furnishing to pParenteral pPatient at hHome - carrying and furnishing dangerous
	drugs to parenteral patients
1761(a)	Erroneous or Uncertain Prescriptions-
1764	Unauthorized dDisclosure of pPrescriptions - revealing the contents of a prescription
	to unauthorized persons
1765	Commissions, gGratuities, and rRebates - commission, gratuity or rebate to a health
	— care facility
1766	False or mMisleading aAdvertising
1775.3	Compliance with Orders of Abatement
1782	Reporting Sales of Drugs Subject to Abuse
1783	Manufacturer or Wholesaler Furnishing <u>Drugs or Devices</u>
1793.1 to	
1793.7	Ancillary personnel - pharmacy technician requirements and tasks
<u>1793.1</u>	Duties of a Pharmacist
1793.2	Duties of a Pharmacy Technician
1793.3	Other Non-Licensed Pharmacy Personnel
1793.7	Requirements for Pharmacies Employing Pharmacy Technicians
<u>1793.8</u>	Technicians in Hospitals with Clinical Pharmacy Programs

HEALTH AND SAFETY CODE, TITLE 22

11103	Report of theft, Loss, or Shipping discrepancy - reporting losses of restricted chemicals to Department of Justice
11123	- Warehouseman License
11124	— Warehouse Inventory
11125	- Warehouseman Bond
11128	Nontransferability of Warehouse License
11129	— Discipline or Denial of Warehouse License
11130	— Disciplinary Grounds for Warehouse License
11131	Disciplinary Grounds for Warehouse License
11150	Issuing Controlled Substance Persons Authorized to Write or Issue a Prescription

11152	Nonconforming pPrescriptions Prohibited - filling a prescription that does not conform to the requirements of the code
11154	Prescription, etc, Must Be for Treatment; Knowing Prescriptions;
	Solicitingation of Unlawful Prescription, etc.
11156	Prescribing, etc. Administering or dispensing eControlled eSubstances to aAddict
	Only as Authorized - prohibition on administering or dispensing a controlled
	substance to an addict or a habitual user
11164	Completion of pPrescriptions for Schedule II, III, IV and V eControlled sSubstances: Form and Content; Record of Practitioner Dispensing Schedule II Controlled
	Substances- prescription requirements for controlled substances
11166	Time Limit Ffor Filling Schedule II Prescriptions; Knowingly Filling Mutilated, Forged,
	or Altered Prescriptions Prohibited
11170	Prohibition on Prescribing, etc. eControlled sSubstance for sSelf use - prohibition on
	prescribing, administering or furnishing controlled substance to self
11179	Retention of Controlled Substance Prescription period - prescription file to be
	maintained' for three (3) years
11207	Filling prescription oOnly by pPharmacist or Intern Authorized to Fill
	Prescriptionpharmacist - dispensing, compounding, filling by pharmacist or intern
	pharmacist only
11209	Delivery and Receiving Requirements for Schedule II, III, & and IV Substances;
	<u>Violation</u>
11350	Possession of <u>sSpecified eControlled sSubstance - illegal possession of a narcotic</u>
11377	Unlawful pPossession of sSpecified sSubstance - illegal possession of a non-
	narcotic controlled substance
11165(d)	CURES Transmission
150204	Surplus Medication Collection and Distribution Program

CODE OF FEDERAL REGULATIONS, TITLE 21

1304.03	Persons required to keep records and file reports.
1304.04	Maintenance of records and inventories.
1304.11	General Inventory requirements for inventories.
1304.21	General requirements for continuing records.
1304.22	Records for manufacturers.
1305.07	Power of attorneySpecial procedure for filling certain orders.
1305.13	Preservation of order forms Procedure for filling DEA Forms 222.
1306.04	Purpose of issue of prescription.
1306.06	Persons entitled to fill prescriptions.
1306.07	Administering or dispensing of narcotic drugs.
1306.11	Requirement of Schedule II Pprescriptions.
1306.12	Refilling prescriptions - Schedule II.
1306.13	Partial filling of prescriptions - Schedule II.
1306.21	Requirement of prescription - Schedule III and IV.
1306.22	Refilling of prescriptions - Schedule III and IV.
1306.23	Partial filling of prescriptions - Schedule III and IV.

CATEGORY III

Minimum: Revocation; Revocation stayed, 90 days actual suspension, three to five years

probation (five years probation where self-administration or diversion of controlled substances is involved). All standard terms and conditions and optional terms and conditions as appropriate.

Maximum: Revocation

Category III discipline is recommended for:

- most criminal convictions involving dangerous drugs or controlled substances
- knowing or willfully violating laws or regulations pertaining to dispensing or distributing dangerous drugs or controlled substances
- fraudulent acts committed in connection with the licensee's practice
- drug shortages
- violation of a licensee's corresponding responsibility.

Violations of the following codes are as follows representative of this category:

BUSINESS AND PROFESSIONS CODE

Article 3. Scope of Practice and Exemptions

4034	Pedigree Pedigree
4051(a)	Conduct Limited To Pharmacist
4059	Furnishing <u>Dangerous Drugs or Devices Prohibited</u> Without Prescription: <u>Exceptions</u>
4059.5	Who May Ordering Dangerous Drugs or Devices: Exceptions

Article 5. Authority of Inspectors

4080	Stock of Dangerous Drugs and Devices Kept Open for Inspection
4081	Records of Acquisition and Dispensing; Inspection Dangerous Drugs and Devices
	Kept Open for Inspection; Maintenance of Records, Current Inventory
4085(a)	Unlawful to Remove, Sell, Dispose of Embargoed Dangerous Drug or Dangerous
	Device

Article 6. General Requirements

4105	Retaining I	Records of	Dangerous I	Drugs and I	Devices on I	Licensed Premises;
	Temporary	Removal;	Waivers; Ac	cess to Elec	ctronically M	laintained Records

Article 7. Pharmacies

4110	Requirement of License; Temporary Licenses Licensed Required; Temporary Permit
	Upon Transfer of Ownership
4111	Ownership by Prescribers Prohibited Restrictions on Prescriber Ownership

Article 11. Wholesalers and Manufacturers

4169(a)(2) to 4169(a)(5) Prohibited Acts

Article 15. Veterinary Food-Animal Retailers

4199 Labeling, Recordkeeping Requirements; Maintaining Prescription Records

Article 19. Disciplinary Proceedings

4301	Unprofessional Conduct - Ssubsections (i) and (k) and (o)
4307	Prohibition Against Association with a License of Association of Individual with Entity
	License by Board: Length of Prohibition; Individuals Covered; Imposition of
	Prohibition Through Administrative Act Proceeding
4308	Notification of Licensee Person is Prohibited from Association;
	Replacement Prohibited Association: Notification of Affected Licensees Known to
	Board

Article 20. Prohibitions and Offenses

4322	False Representation to Obtain Licensure Misdemeanor or Infraction: False
	Representations to Secure License for Self or Others; False Representation of
	Licensure; Penalties
4323	False Representation by Telephone or Electronic Transmission to Obtain a
	DrugMisdemeanor: False Representation of Self as Physician, Agent of Physician,
	etc. to Obtain Drug
4324	Forgery or Alteration Felony or Misdemeanor: Forgery of Prescription; Possession of
	Drugs Obtained Through Forged Prescription
4325	Producing Prescription Blanks Without Authorization Misdemeanor: Manufacture,
	Possession, etc. of False Prescription Blank
4327	Use of Alcohol or Drugs while on DutyMisdemeanor: Sale, Dispensing, or
	Compounding While Under the Influence of Drugs or Alcoholic Beverages
4329	Nonpharmacist Taking Charge Misdemeanor: Non-pharmacist Acting as Manager,
	Compounding, Dispensing or Furnishing Drugs
4332	Failure or Refusal to Produce or Provide Records Misdemeanor: Failure or Refusal to
	Maintain or Produce Required Drug or Device Records; Willful Production of False
	Records
4335 4335	_Failure to Arrange for Transfer of Stock after ClosureVoided License: Knowing
	Failure to Arrange for Disposition of Stock as Misdemeanor
4336 4336	
	Minor to Violate Specified Sections of Pharmacy Law: Exception for Pharmacist
	Furnishing Pursuant to a Prescription

Article 22. Unfair Trade Practices

4380 Resale of Preferentially Priced Drugs: Prohibition; Exceptions

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1707	Waiver Requirements for Off-Site Storage of Records
1718	Current ilnventory dDefined - audit accountability of dangerous drugs
1761(b)	Controlled substance prescriptionprofessional judgmentErroneous or Uncertain
, ,	Prescriptions
1771 to	
1774	Disciplinary conditions of suspension and probation
1771	Posting of Notice of Suspension
1772	Disciplinary Condition of Suspension
1772	
1773	Disciplinary Conditions of Probation of Pharmacist

HEALTH AND SAFETY CODE, TITLE 22

11104	Providing Chemical for Illicit Manufacturing; Evasion of Reporting Requirements;
	Penalties controlled substances for manufacturing
11105	False sStatement in rReport
11122	Storage of controlled substances
11150	Persons aAuthorized to wWrite or ilssue a pPrescription
11153	Responsibility for Legitimacy of controlled substance pPrescription; –
	eCorresponding rResponsibility of a pPharmacist; Knowing Violation
11153.5	Wholesaler or Manufacturer Furnishing a cControlled sSubstance for oOther tThan

	for a Legitimate mMedical pPurpose; Knowing Violation; Factors in Assessing
	<u>Legitimacy</u> - corresponding responsibility of a wholesaler or manufacturer
11157	No False or frictitious prescriptions - issuing a false or fictitious prescription
11162.5	Counterfeiting or pPossession of cCounterfeit Triplicate pPrescription bBlank;
	Penalty
11173	Fraud, dDeceit, mMisrepresentation or fFalse sStatement; False Representation;
	False Label obtaining controlled Substances by fraud or deceit
11174	Prohibition on Providing False aName or aAddress in Connection with Prescription,
	etc false name or address on prescription
11351	Possession or pPurchase for sSale of sSpecified cControlled sSubstance illegal
	possession for sale of a narcotic
11368	Forged or aAltered pPrescriptions-forging a narcotic prescription
11375	Possession for sSale or Selling Sellin
11378	Possession for sSale-illegal possession for sale of a nonnarcotic
11550	Useing or bBeing uUnder the influence of cControlled sSubstance
11167.5	Pharmacy Generated Prescription for Schedule II Controlled Substances in a Skilled
	Nursing Facility
111295	Manufacturing, Selling, or Offering for Sale an Adulterated Drug or Device
111300	Unlawful to Adulterate a Drug
111305	Unlawful to Receive in Commerce an Adulterated Drug
<u>111440</u>	Unlawful Manufacturer, Selling a Misbranded Drug
111445	Unlawful for a Person to Misbrand
<u>111450</u>	Unlawful to Receive into Commerce a Drug that is Misbranded

CATEGORY IV

Penalty: Revocation

Revocation is recommended for violations of the Uniform Controlled Substance Act (Heath and Safety Code 11000 et seq.) when involving:

- possession for sale
- transportation
- importation
- sale
- use of a minor for the unlawful sale of controlled substances

Revocation is also recommended when:

- a respondent fails to file a notice of defense or to appear at a disciplinary hearing where the board has requested revocation in the accusation
- a respondent violates the terms and conditions of probation from a previous disciplinary order
- prior discipline has been imposed, as progressive discipline unless the respondent can demonstrate satisfactory evidence of rehabilitation.

Violations of the following codes are as follows representative of this category:

HEALTH AND SAFETY CODE, TITLE 22

11352	Importing, sSelling, fFurnishing cControlled sSubstance - illegal sale of a narcotic
11353	Adult inducing m inor to v iolate controlled substances p Provisions
11379	Transporting, ilmporting, sSelling controlled sSubstances - illegal sale of a non- narcotic
11380	Adult <u>uUsing</u> , <u>sSoliciting</u> or <u>iIntimidating mMinor for vViolation - violation of non-</u>
	narcotic provisions or the use of a minor

MODEL DISCIPLINARY LANGUAGE - PHARMACIST/INTERN PHARMACIST

The following standardized language shall be used in every decision where the order or condition is imposed.

Revocation - Single Cause		
License number	, issued to respondent	,is revoked.
Respondent shall relinquish his or within 10 days of the effective date board for reinstatement of his or h this decision.	e of this decision. Responden	t may not <u>reapply or</u> petition the
Respondent shall pay to the board \$ within fifteen (15) da	d its costs of investigation and ays of the effective date of this	
Option: Upon As a condition pred respondent shall reimburse the boot of \$ Said amount shall or her license unless otherwise or specified, his or her license shall reference to the control of the	pard for its costs of investigation of the paid in full prior to the read dered by the board. If respon- termain revoked.	on and prosecution in the amount application or reinstatement of his
License number pursuant to Determination of Issue		is revoked eparately and together.
Respondent shall relinquish his or within 10 days of the effective date reinstatement of his or her revoke decision. Respondent shall pay to amount of \$ within	of this decision. Respondent d license for three years from the board its costs of investion	t may not petition the board for the effective date of this gation and prosecution in the
Option: Upon reinstatement of his for its costs of investigation and preshall be paid in full prior to the rein amount specified, his or her license	rosecution in the amount of \$_ estatement of his or her license	Said amount

Suspension - Single Cause

oueponeron omg.			
License number	, issued to respondent	is suspended for a p	period of
As part of	probation, respondent is suspe	ended from the practice of pharm	acy for
		cision. Respondent shall not resu	
practice of pharmacy u	ntil notified by the board.		
		narmacy area or any portion of the	
		g retailer or any other distributor o	
		or where dangerous drugs and de	
		shall not practice pharmacy nor de	
		uring, compounding, dispensing c	
		er, or be a consultant to any licens	
		nufacturing or dispensing of dange	<u>erous</u>
drugs and devices or c	ontrolled substances.		
Barrer Installation	and the second s	to a superior of the superior	
		ires the professional judgment of	
		ny aspect of the practice of pharm	nacy.
	perform the duties of a pharma	cy technician or a designated	
representative for any e	entity licensed by the board.		
Subject to the above re	estrictions, respondent may con	ntinue to own or hold an interest in	n anv
		st at the time this decision becom	
	rise specified in this order.	Stat the time this decision become	103
CHOCKIVE WHICSS OTHERW	isc specifica in this order.		
Failure to comply with t	his suspension shall be consid	dered a violation of probation	
r andro to comply mare	The daspertation of all se contains	zoroa a violation or prosationi	
Suspension - Multip	No Causes		
Odopension manag	no Guases		
License number	issued to respondent	is suspended for a period of	
		, separately and together. All sus	
shall run concurrently.		, separation, and together, 7 in odd	- 51.0.0110
Respondent is suspend	ded from the practice of pharm	acy for beginni	i ng the
effective date of this de		; =	•

Standard Stay/Probation Order

License number	, issued to respondent is revoked-	; however,
the <u>revocation</u>	is stayed and respondent is place ipon the following terms and conditions:	ced on probation for
youro u	per the renewing terms and containents.	
Issuance of Probation	nary License (In cases where a Statement	t of Issues has been filed.)
The application for licensu conditions:	ure of respondent is hereby granted, on t	he following terms and
1.That, responden a license to	nt first meet all statutory and regulatory re	equirements for the issuance o
 That, following revoked, the or a period of 	the satisfaction of #1, respondent's licer rder of revocation being stayed and resp years on the following terms and o	ondent placed on probation for conditions:
shall be issued to respond	atutory and regulatory requirements for is dent and immediately revoked; the order probation for years upon the follo	of revocation is stayed and
Surrender		
Respondent shall relinquis	cense number as of the efforts or her wall license and pocket rendereffective date of this decision.	
board shall constitute the	lent's license and the acceptance of the simposition of discipline against responde shall become a part of respondent's lice	ent. This decision constitutes
	and agrees that if he or she ever files ar in the State of California, the board shall	
years from the effective day for any license from the bound for the interpretation or admitted by respondent we respondent shall satisfy a submitted to the board, Pharmacist Licensure Example 1.	oply for any license, permit, or registration ate of this decision. Respondent stipulat oard on or after the effective date of this petition to revoke probation] shall be decident the board determines whether to graph all requirements applicable to that license including, but not limited to taking and paramination prior to the issuance of a new ort this surrender as disciplinary action.	tes that should he or she apply decision, all allegations set emed to be true, correct and ant or deny the application. e as of the date the application assing the California
	ates that he or she shall reimburse the b tion in the amount of \$ within	
after the effective date of t	ulates that should he or she apply for any this decision the investigation and prosed to the board prior to issuance of the new	cution costs in the amount of

Public Reprimand

It is hereby ordered that a public reprimand be issued against licensee, _____.

Respondent is required to report this reprimand as a disciplinary action.

Adoption of Stipulation

It is understood by respondent that, in deciding whether to adopt this stipulation, the board may receive oral and written communication from its staff and the Attorney General's-Office of the Attorney General. Communications pursuant to this paragraph shall not disqualify the board or other persons from future participation in this or any other matter affecting respondent. In the event this settlement is not adopted by the board, the stipulation will not become effective and may not be used for any purpose, except this paragraph, which shall remain in effect.

STANDARD CONDITIONS - To be included in all probation decisions/orders.

Term Number: (Numbers reflect actual term and condition numbers as listed beginning with page ______)

- 1. Obey <u>aA</u>ll Laws
- 2. Reporting to the Board
- 3. Interview with the Board
- 4. Cooperatione with Board Staff
- 5. Continuing Education
- 6. Notice to Employers
- 7. No Preceptorships, Supervision of Interns, BeingServing as Pharmacist-In-Charge (PIC), or Serving as a Consultant
- 8. Reimbursement of Board Costs
- 9. Probation Monitoring Costs
- 10. Status of License
- 11. License Surrender While on Probation/Suspension
- 12. Notification of <u>a Change in Name, Residence Address, Employment/Mailing Address or Employment-Change</u>
- 13. Tolling of Probation
- 14. Violation of Probation
- 15. Completion of Probation

OPTIONAL CONDITIONS

Term Number: (Numbers reflect actual term and condition numbers as listed beginning with page _______)

- **1.Actual Suspension**
- 2.16. Restricted Practice
- 3.17. Pharmacist Examination
- 4.18. Mental Health Examination
- 5.19. Psychotherapy
- 6.20. Medical Evaluation
- 7.21. Rehabilitation Program Pharmacists Recovery Program (PRP)
- 8.22. Random Drug Screening
- 9.23. Abstain from Drugs and Alcohol Use
- 24. Prescription Coordination and Monitoring of Prescription Use
- 40.25. Community Service Program
- 41.26. Restitution
- 12.27. Remedial Education
- 28. Pharmacy Self-Assessment Mechanism (PSAM)
- 13.29. Pharmacy Intern Pharmacist Experience
- 14.30. Supervised Practice
- 45.31. No Supervision of Ancillary Personnel
- 16.32. No Ownership of Licensed Premises
- 17.33. Separate File of Records
- 48.34. Report of Controlled Substances
- 49.35. No Access to Controlled Substances
- 20.36. Criminal Probation/Parole Reports
- 21.37. Consultant for Owner or Pharmacist-In-Charge

22.38. Tolling of Suspension 39. Surrender of DEA Permit

STANDARD CONDITIONS: TO BE INCLUDED IN ALL PROBATIONS

4.1. Obey All Laws

Respondent shall obey all state and federal laws and regulations substantially related to or governing the practice of pharmacy.

Respondent shall report any of the following occurrences to the board, in writing, within <u>seventy-two</u> (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state and or federal agency which involves respondent's _____ license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, or distribution distributing, or charging for of any drug, device or controlled substance.

Failure to timely report such occurrence shall be considered a violation of probation.

2.2. Reporting to the Board

Respondent shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, Rrespondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, lif the final probation report is not made as directed, probation shall be automatically extended automatically until such time as the final report is made and accepted by the board.

3.3. Interview with the Board

Upon receipt of reasonable <u>prior</u> notice, respondent shall appear in person for interviews with the board <u>or its designee</u>, <u>at such upon request at various</u> intervals <u>and at a locations as are to be</u> determined by the board <u>or its designee</u>. Failure to appear for any scheduled interview without prior notification to board staff, <u>or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation</u>, shall be considered a violation of probation.

4.4. Cooperatione with Board Staff

Respondent shall cooperate with the board's inspectional program and in with the board's monitoring and investigation of respondent's compliance with the terms and conditions of his or her probation. Failure to comply cooperate shall be considered a violation of probation.

5.5. Continuing Education

Respondent shall provide evidence of efforts to maintain skill and knowledge as a pharmacist as
directed by the board or its designee.

	•			
During the period of probation,	Rrespondent shall notify	y all present and p	prospective employers	of

the decision in case number _____ and the terms, conditions and restrictions imposed on respondent by the decision, as follows:-

Notice to Employers

6.

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment, respondent shall cause his or her direct supervisor, pharmacist-in-charge (including each new pharmacist-in-charge employed during respondent's tenure of employment) and/or owner to report to the board in writing acknowledging that the listed individual(s) has/have employer has read the decision in case number _________ and terms and conditions imposed thereby. It shall be respondent's responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

If respondent works for or is employed by or through a pharmacy employment service, respondent must notify the his or her direct supervisor, pharmacist-in-charge, and/or owner at every pharmacy entity licensed by the board of the and terms and conditions of the decision in case number _____ in advance of the respondent commencing work at each pharmacy licensed entity. A record of this notification must be provided to the board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment by or through a pharmacy employment service, respondent shall cause his or her direct supervisor with the pharmacy employment service to report to the board in writing acknowledging that he or she has read the decision in case number ____ and the terms and conditions imposed thereby. It shall be respondent's responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

Failure to timely notify present or prospective employer(s) or to cause that/those employer(s) to submit timely acknowledgments to the board shall be considered a violation of probation.

"Employment" within the meaning of this provision shall include any full-time, part-time, temporary, relief or pharmacy management service as a pharmacist or any position for which a pharmacist license is a requirement or criterion for employment, whether the respondent is considered an employee, or independent contractor or volunteer.

7.7. No Preceptorships, Supervision of Interns, Being Serving as Pharmacist-in-Charge (PIC), or Serving as a Consultant

<u>During the period of probation, Rrespondent shall not supervise any intern pharmacist, or perform any of the duties of a preceptor, nor shall respondent</u> be the pharmacist-in-charge of any entity licensed by the board <u>nor serve as a consultant</u> unless otherwise specified in this order. <u>Assumption of any such unauthorized supervision responsibilities shall be considered a violation of probation.</u>

8.8. Reimbursement of Board Costs

As a condition precedent to successful completion of probation, Rependent shall pay to the board its costs of investigation and prosecution in the amount of \$\\$. Respondent shall

make said	payments a	as follows:	

There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by respondent shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

Option: If respondent fails to make any payment by the directed deadline(s), the stay shall terminate and the license shall be revoked without further notice or opportunity to be heard.

9.9. Probation Monitoring Costs

Respondent shall pay the <u>any</u> costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board <u>at the end of each year of probation</u> on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

10.10. Status of License

Respondent shall, at all times while on probation, maintain an active, current license with the board, including any period during which suspension or probation is tolled. <u>Failure to maintain an active</u>, current license shall be considered a violation of probation.

If respondent's license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof due to tolling or otherwise, upon renewal or reapplication, respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

11.___-License Surrender wWhile on Probation/Suspension

Following the effective date of this decision, should respondent cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her license to the board for surrender. The board <u>or its designee</u> shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation. <u>This surrender constitutes a record of discipline and shall become a part of the respondent's license history with the board.</u>

Upon acceptance of the surrender, respondent shall relinquish his or her pocket <u>and wall license</u> to the board within <u>ten (10)</u> days of notification by the board that the surrender is accepted. Respondent may not reapply for any license from the board for three (3) years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board, <u>including any outstanding costs</u>.

12. Notification of <u>a Change in Name</u>, Residence Address, <u>Employment/Mailing</u>

Address or EmploymentChange

Respondent shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, and/or the address of the new employer, the name of the supervisor or and owner, and the work schedule if known. Respondent shall further notify the board in writing within ten (10) days of a change in name, residence address, mailing address, or phone number.

Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

13.13. Tolling of Probation

Except during periods of suspension, respondent shall, at all times while on probation, be employed as a pharmacist in California for a minimum of _______ hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation.

Should respondent, regardless of residency, for any reason (including vacation) cease practicing pharmacy as a pharmacist for a minimum of ______ hours per calendar month in California, respondent must notify the board in writing within ten (10) days of the cessation of the practice of pharmacy or, and must further notify the board in writing within ten (10) days of the resumption of the practice of pharmacy. Such periods of time shall not apply to the reduction of the probation period. Any failure to provide such notification(s) shall be considered a violation of probation.

It is a violation of probation for respondent's probation to remain tolled pursuant to the provisions of this condition for a <u>total</u> period, <u>counting consecutive and non-consecutive months</u>, exceeding <u>three years thirty-six (36) months</u>.

"Cessation of practice" means any period of time exceeding 30 days-calendar month in during which respondent is not practicing as a pharmacist for at least ______ hours, as defined by Business and Professions Code section 4000 et seq engaged in the practice of pharmacy as defined in Section 4052 of the Business and Professions Code. "Resumption of practice" means any calendar month during which respondent is practicing as a pharmacist for at least ______ hours as a pharmacist as defined by Business and Professions Code section 4000 et seq.

Respondent is required to practice as a pharmacist in a licensed pharmacy setting that dispenses medication. After the first year of probation, the board or its designee may consider a modification of this requirement. If respondent fails to comply with this requirement or a subsequent modification thereto, such failure shall be considered a violation of probation.

Option: Respondent shall work at least 40 hours in each calendar month as a pharmacist and at least an average of 80 hours per month in any six consecutive months. Failure to do so will be a violation of probation. If respondent has not complied with this condition during the probationary term, and respondent has presented sufficient documentation of his or her good faith efforts to comply with this condition, and if no other conditions have been violated, the board, in its discretion, may grant an extension of respondent's probation period up to one year without further hearing in order to comply with this condition.

14.14. Violation of Probation

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended, until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order which that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of the license. If a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction and the period of probation shall be automatically extended, until the petition to revoke probation or accusation is heard and decided.

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty which was stayed.

45.15. Completion of Probation

Upon <u>written notice by the board or its designee indicating</u> successful completion of probation, respondent's license will be fully restored.

OPTIONAL CONDITIONS OF PROBATION

1. Actual Suspension

As part of probation, respondent is suspended from the practice of pharmacy for _______beginning the effective date of this decision.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, **or** be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances.

Respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or an exemptee for any entity licensed by the board. Subject to the above restrictions, respondent may continue to own or hold an interest in any pharmacy in which he or she holds an interest at the time this decision

becomes effective unless otherwise specified in this order.

2.16. Restricted Practice (Where this condition is imposed, optional condition #7 should also be imposed)

Respondent's practice of pharmacy shall be restricted to [specify setting or type of practice] for the first _____ years of probation. Respondent shall submit proof satisfactory to the board of compliance with this term of probation.

Option: Respondent shall not prepare, oversee or participate in the preparation of injectable sterile products during the first ______ year(s) of probation. Respondent shall submit proof satisfactory to the board of compliance with this term of probation. Failure to abide by this restriction or to timely submit proof to the board of compliance therewith shall be considered a violation of probation.

3.17. Pharmacist Examination

Respondent shall take and pass the ______section(s) of the pharmacist licensure examination as scheduled by the Board after the effective date of this decision at respondent's own expense[California Pharmacist Jurisprudence Examination (CPJE) and/or the North American Pharmacist Licensure Examination (NAPLEX)] within six (6) months of the effective date of this decision. If respondent fails to take and pass the examination(s) within six (6) months after the effective of this decision, respondent shall be automatically suspended from practice upon written notice. Respondent shall not resume the practice of pharmacy until he or she takes and passes the same section(s) at a subsequent examination [CPJE and/or NAPLEX] and is notified, in writing, that he or she has passed the examination(s) and may resume practice. Respondent shall bear all costs of the examination(s) required by the board.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, <u>or or</u> be a consultant to any licensee of the <u>Bb</u>oard, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. <u>Respondent shall not resume practice until notified by the board.</u>

<u>During suspension</u>, <u>Rrespondent shall not engage in any activity that requires the professional judgment of a pharmacist</u>. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or <u>an exemptee a designated representative</u> for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any pharmacy-licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

If respondent fails to take and pass the [CPJE and/or NAPLEX] after four attempts, respondent shall successfully complete, at a minimum, sixteen (16) additional semester units of pharmacy education as approved by the board. Failure to complete coursework as required shall be

considered a violation of probation. Failure to take and pass the examination(s) within one (1) year of the effective date of this decision shall be considered a violation of probation. Suspension and probation shall be extended until respondent passes the examination and is notified in writing.

4.18. Mental Health Examination (Appropriate for those cases where evidence demonstrates that mental illness or disability was a contributing cause of the violations.)

Within thirty (30) days of the effective date of this decision, and on a periodic basis as may be required by the board or its designee, respondent shall undergo, at his or her own expense, psychiatric evaluation(s) by a board-appointed or board-approved psychiatrist or psychologist licensed mental health practitioner. The approved evaluator shall be provided with a copy of the board's [accusation or petition to revoke probation] and decision. Respondent shall sign a release authorizing the evaluator to furnish the board with a current diagnosis and a written report regarding the respondent's judgment and ability to function independently as a pharmacist with safety to the public. Respondent shall comply with all the recommendations of the evaluator if directed by the board or its designee.

If the psychiatrist or psychotherapist evaluator recommends, and the board or its designee directs, respondent shall undergo psychotherapy. Respondent shall, within 30 days of written notice of the need for psychotherapy, submit to the board for its prior approval, the recommended program for ongoing psychotherapeutic care. Respondent shall undergo and continue psychotherapy, at respondent's own expense, until further notice from the board. Respondent shall have the treating psychotherapist or psychiatrist submit written quarterly reports to the board as directed. Within thirty (30) days of notification by the board that a recommendation for psychotherapy has been accepted, respondent shall submit to the board or its designee, for prior approval, the name and qualification of a licensed mental health practitioner of respondent's choice. Within thirty (30) days of approval thereof by the board, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved licensed mental health practitioner. Should respondent, for any reason, cease treatment with the approved licensed mental health practitioner, respondent shall notify the board immediately and, within thirty (30) days of ceasing treatment therewith, submit the name of a replacement licensed mental health practitioner of respondent's choice to the board for its prior approval. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved replacement. Failure to comply with any requirement or deadline stated by this paragraph shall be considered a violation of probation.

Upon approval of the initial or any subsequent licensed mental health practitioner, respondent shall undergo and continue treatment with that therapist, at respondent's own expense, until the therapist recommends in writing to the board, and the board or its designee agrees by way of a written notification to respondent, that no further psychotherapy is necessary. Upon receipt of such recommendation from the treating therapist, and before determining whether to accept or reject said recommendation, the board or its designee may require respondent to undergo, at respondent's expense, a mental health evaluation by a separate board-appointed or board-approved evaluator. If the approved evaluator recommends that respondent continue psychotherapy, the board or its designee may require respondent to continue psychotherapy.

Psychotherapy shall be at least once a week unless otherwise approved by the board.

Respondent shall provide the therapist with a copy of the board's [accusation or petition to revoke probation] and decision no later than the first therapy session. Respondent shall take all

necessary steps to ensure that the treating therapist submits written quarterly reports to the board concerning respondent's fitness to practice, progress in treatment, and other such information as may be required by the board or its designee.

If <u>at any time the approved evaluator or therapist determines that respondent is determined to be</u> unable to practice safely or independently as a pharmacist, the licensed mental health practitioner shall notify the board immediately by telephone and follow up by written letter within three (3) working days. Upon notification from the board or its designee of this determination, upon notification, respondent shall immediately cease practice be automatically suspended and shall not resume practice until notified by the board that practice may be resumed.

Option: Commencing on the effective date of this decision, respondent shall not engage in the practice of pharmacy until notified in writing by the board that respondent is has been deemed psychologically fit to practice pharmacy safely, and the board or its designee approves said recommendation.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, <u>or or</u> be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. <u>Respondent shall not resume practice until notified by the board</u>.

<u>During suspension</u>, <u>Rrespondent shall not engage in any activity that requires the professional judgment of a pharmacist</u>. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or <u>an exemptee a designated representative</u> for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any pharmacy-licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

(Option language to be used in addition to standard language)

Option: If recommended by the <u>evaluating psychiatrist or psychotherapist licensed mental</u> <u>health practitioner</u> and approved by the board, respondent shall be suspended from practicing pharmacy until <u>the respondent's</u> treating <u>psychotherapist</u> recommends, in writing, stating the basis therefor, that respondent can safely practice pharmacy, and the board <u>or its designee</u> approves said recommendation.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, <u>er-or</u> be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous

drugs and controlled substances. Respondent shall not resume practice until notified by the board.

<u>During suspension</u>, <u>Rrespondent shall not engage in any activity that requires the professional judgment of a pharmacist</u>. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or <u>an exemptee a designated representative</u> for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any pharmacy-licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

5.19. Psychotherapy (Appropriate for those cases where the evidence demonstrates mental illness or alcohol or drug abuse was involved in the violations.)

Within thirty (30) days of the effective date of this decision, respondent shall submit to the board or its designee, for its-prior approval, the name and qualifications of a licensed mental health practitioner of respondent's choice. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved licensed mental health practitioner. Should respondent, for any reason, cease treatment with the approved licensed mental health practitioner, respondent shall notify the board immediately and, within thirty (30) days of ceasing treatment, submit the name of a replacement psychotherapist or licensed mental health practitioner of respondent's choice to the board for its prior approval. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of psychotherapy with the approved replacement. Failure to comply with any requirement or deadline stated by this paragraph shall be considered a violation of probation.

Upon approval of the initial or any subsequent licensed mental health practitioner, respondent shall undergo and continue treatment with that therapist, at respondent's own expense, until the therapist recommends in writing to the board, and the board or its designee agrees by way of a written notification to respondent, that no further psychotherapy is necessary. Upon receipt of such recommendation from the treating therapist, and before determining whether to accept or reject said recommendation, the board or its designee may require respondent to undergo, at respondent's own expense, a mental health evaluation by a board-appointed or board-approved psychiatrist or psychologist. If the approved evaluator recommends that respondent continue psychotherapy, the board or its designee may require respondent to continue psychotherapy.

Therapy Psychotherapy shall be at least once a week unless otherwise determined approved by the board. Respondent shall provide the therapist with a copy of the board's accusation and decision no later than the first therapy session. Respondent shall take all necessary steps to ensure that the treating therapist submits written quarterly reports to the board concerning respondent's fitness to practice, progress in treatment, and to provide such other information as may be required by the board or its designee.

If <u>at any time</u> the treating therapist <u>finds_determines</u> that respondent cannot practice safely or independently, the therapist shall notify the board immediately by telephone and followed up by written letter within three (3) working days. <u>Upon notification from the board or its designee of this determination</u>, respondent shall be automatically suspended and shall not resume practice

until notified by the board that practice may be resumed.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. Respondent shall not resume practice until notified by the board.

During suspension, respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

Upon approval of the licensed mental health practitioner, respondent shall undergo and continue treatment with that therapist and at respondent's own expense, until the board deems that no further psychotherapy is necessary. The board may require respondent to undergo a mental health evaluation(s) by a board-appointed or board-approved licensed mental health practitioner.

6.20. Medical Evaluation (Appropriate for those cases where the evidence demonstrates that the respondent has had a physical problem/disability which was a contributing cause of the violations and which may affect the respondent's ability to practice.)

Within thirty (30) days of the effective date of this decision, and on a periodic basis thereafter as may be required by the board or its designee, respondent shall undergo a medical evaluation, at respondent's own expense, by a board-appointed or board-approved physician who shall furnish a medical report to the board. The approved physician shall be provided with a copy of the board's [accusation or petition to revoke probation] and decision. A record of this notification must be provided to the board upon request. Respondent shall sign a release authorizing the physician to furnish the board with a current diagnosis and a written report regarding the respondent's ability to function independently as a pharmacist with safety to the public. Respondent shall comply with all the recommendations of the physician if directed by the board or its designee.

If respondent is required by the board the physician recommends, and the board or its designee directs, that respondent to undergo medical treatment, respondent shall, within thirty (30) days of written notice from the board, submit to the board or its designee, for prior approval, the name and qualifications of a licensed physician of respondent's choice. for its prior approval, the name and qualifications of a physician of respondent's choice. Upon board approval of the treating physician, respondent shall undergo and continue medical treatment, with that physician and at respondent's own expense, until further notice from the board. Respondent shall have the treating physician submit written quarterly reports to the board. Should respondent, for any reason, cease treatment with the approved physician, respondent shall notify the board

immediately and, within 30 days of ceasing treatment, submit the name of a replacement physician of respondent's choice to the board for its prior approval. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of treatment with the approved physician. Should respondent, for any reason, cease treatment with the approved physician, respondent shall notify the board immediately and, within thirty (30) days of ceasing treatment, submit the name of a replacement physician of respondent's choice to the board or its designee for prior approval. Within thirty (30) days of approval thereof, respondent shall submit documentation to the board demonstrating the commencement of treatment with the approved replacement. Failure to comply with any deadline stated by this paragraph shall be considered a violation of probation.

Upon approval of the initial or any subsequent physician, respondent shall undergo and continue treatment with that physician, at respondent's own expense, until the treating physician recommends in writing to the board, and the board or its designee agrees by way of a written notification to respondent, that no further treatment is necessary. Upon receipt of such recommendation from the treating physician, and before determining whether to accept or reject said recommendation, the board or its designee may require respondent to undergo, at respondent's own expense, a medical evaluation by a separate board-appointed or board-approved physician. If the approved evaluating physician recommends that respondent continue treatment, the board or its designee may require respondent to continue treatment.

Respondent shall take all necessary steps to ensure that any treating physician submits written quarterly reports to the board concerning respondent's fitness to practice, progress in treatment, and other such information as may be required by the board or its designee.

If at any time an approved evaluating physician or respondent's approved treating physician determines that respondent is unable to practice safely or independently as a pharmacist, the evaluating or treating physician shall notify the board immediately by telephone and follow up by written letter within three (3) working days. Upon notification from the board or its designee of this determination, respondent shall be automatically suspended and shall not resume practice until notified by the board that practice may be resumed.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. Respondent shall not resume practice until notified by the board.

During suspension, respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

(Option language to be used in addition to standard language)

Option: Upon Commencing on the effective date of this decision, respondent shall not engage in the practice of pharmacy until notified in writing by the board of its determination that respondent has been deemed is medically fit to practice safely and independently, and the board or its designee approves said recommendation.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, <u>or or</u> be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs or controlled substances. <u>Respondent shall not resume practice until notified by the board</u>.

<u>During suspension</u>, <u>Rrespondent shall not engage in any activity that requires the professional judgment of a pharmacist</u>. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or <u>an exempteea</u> <u>designated representative</u> for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any pharmacy-licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

(Option language to be used in addition to standard language)

Option: If recommended by the <u>evaluating</u> physician and approved by the board, respondent shall be suspended from practicing pharmacy until the treating physician recommends, in writing, stating the basis therefor, that respondent can safely and independently resume the practice of a pharmacist, and the board <u>or its designee</u> approves said recommendation. Respondent shall not resume practice until notified by the board <u>that practice may be resumed</u>.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, <u>er-or</u> be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. <u>Respondent shall not resume practice until notified by the board</u>.

<u>During suspension</u>, <u>Rrespondent shall not engage in any activity that requires the professional judgment of a pharmacist</u>. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or <u>an exempteea</u> <u>designated representative</u> for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any pharmacy-licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

7.21. Rehabilitation Program - Pharmacists Recovery Program (PRP) (Appropriate for chemical dependency (alcohol, drugs), or psychiatric disorders (mental illness, emotional disturbance, gambling)

Within thirty (30) days of the effective date of this decision, respondent shall contact the Pharmacists Recovery Program (PRP) for evaluation, and shall immediately thereafter enroll, successfully participate in, and complete the treatment contract and any subsequent addendums as recommended and provided by the PRP and as approved by the board or its designee. The costs for PRP participation shall be borne by the respondent.

If respondent is currently enrolled in the PRP, said participation is now mandatory and <u>as of the effective date of this decision</u> is no longer considered a self-referral under Business and Professions Code section <u>43634362(c)(2)</u>, as of the effective date of this decision. Respondent shall successfully participate in and complete his or her current contract and any subsequent addendums with the PRP.

<u>Failure</u> to timely contact or enroll in the PRP, or successfully participate in and complete the treatment contract and/or any addendums, shall be considered a violation of probation.

Probation shall be automatically extended until respondent successfully completes his or her treatment contract the PRP. Any person terminated from the PRP program shall be automatically suspended upon notice by the board. Respondent may not resume the practice of pharmacy until notified by the board in writing.

Any confirmed positive test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment shall result in the automatic suspension of practice by respondent and shall be considered a violation of probation. Respondent may not resume the practice of pharmacy until notified by the board in writing.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. Respondent shall not resume practice until notified by the board.

During suspension, respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

Respondent shall pay administrative fees as invoiced by the PRP or its designee. Fees not timely paid to the PRP shall constitute a violation for probation. The board will collect unpaid administrative fees as part of the annual probation monitoring costs if not submitted to the PRP.

(Option language to be used in addition to standard language)

Option: Respondent shall work in a pharmacy setting with access to controlled substances for six (6) consecutive months before successfully completing probation. If respondent fails to do so, probation shall be automatically extended until this condition has been met. Failure to satisfy this condition within six (6) months beyond the original date of expiration of the term of probation shall be considered a violation of probation.

The board shall retain jurisdiction to institute action to terminate probation for any violation of this term.

8.22. Random Drug Screening (If PRP provision is required, this term is also to be included to allow for continued fluid monitoring by the Board in cases where a respondent successfully completes the PRP before completion of the probation period; terms is also appropriate for those cases where the evidence demonstrates that the respondent may have a problem with chemical dependency (drugs, alcohol) but where the PRP is not required.)

Respondent, at his or her own expense, shall participate in random testing, including but not limited to biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or a-other drug screening program approved as directed by the board or its designee. The length of time shall be for the Respondent may be required to participate in testing for the entire probation period and the frequency of testing will be determined by the board or its designee. At all times, respondent shall fully cooperate with the board or its designee, and shall, when directed, submit to such tests and samples for the detection of alcohol, narcotics, hypnotics, dangerous drugs or other controlled substances as the board or its designee may direct. Failure to timely submit to testing as directed shall constitute be considered a violation of probation. Upon request of the board or its designee, respondent shall provide documentation from a licensed practitioner that the prescription for a detected drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Any confirmed positive test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment shall be considered a violation of probation and drug test shall result in the immediate automatic suspension of practice of pharmacy by respondent. Respondent may not resume the practice of pharmacy until notified by the board in writing.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. Respondent shall not resume practice until notified by the board.

During suspension. respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

9.23. Abstain from Drugs and Alcohol Use

Respondent shall completely abstain from the possession or use of alcohol, controlled substances, dangerous drugs and their associated paraphernalia except when the drugs are lawfully prescribed by a licensed practitioner as part of a documented medical treatment. Upon request of the board or its designee, respondent shall provide documentation from the licensed

practitioner that the prescription for the drug was legitimately issued and is a necessary part of the treatment of the respondent. Respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Failure to timely provide such documentation shall be considered a violation of probation. Respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Any possession or use of alcohol, controlled substances, or their associated paraphernalia not supported by the documentation timely provided, and/or any physical proximity to persons using illicit substances, shall be considered a violation of probation.

24. Prescription Coordination and Monitoring of Prescription Use (Appropriate for chemical dependency (alcohol, drugs), or psychiatric disorders (mental illness, emotional disturbance, gambling)

Within thirty (30) days of the effective date of this decision, respondent shall submit to the board, for its prior approval, the name and qualifications of a single physician, nurse practitioner. physician assistant, or psychiatrist of respondent's choice, who shall be aware of the respondent's history [with the use of alcohol, controlled substances, and/or dangerous drugs, and/or of mental illness, and/or of gambling addiction] and who will coordinate and monitor any prescriptions for respondent for dangerous drugs, controlled substances or mood-altering drugs. The approved practitioner shall be provided with a copy of the board's [accusation or petition to revoke probation] and decision. A record of this notification must be provided to the board upon request. Respondent shall sign a release authorizing the practitioner to communicate with the board about respondent's treatment(s). The coordinating physician, nurse practitioner, physician assistant, or psychiatrist shall report to the board on a quarterly basis for the duration of probation regarding respondent's compliance with this condition. If any substances considered addictive have been prescribed, the report shall identify a program for the time limited use of any such substances. The board may require that the single coordinating physician, nurse practitioner, physician assistant or psychiatrist be a specialist in addictive medicine, or consult a specialist in addictive medicine. Should respondent, for any reason, cease supervision by the approved practitioner, respondent shall notify the board immediately and, within thirty (30) days of ceasing treatment, submit the name of a replacement physician, nurse practitioner, physician assistant, or psychiatrist of respondent's choice to the board or its designee for its prior approval. Failure to timely submit the selected practitioner or replacement practitioner to the board for approval, or to ensure the required reporting thereby on the quarterly reports, shall be considered a violation of probation.

If at any time an approved practitioner determines that respondent is unable to practice safely or independently as a pharmacist, the practitioner shall notify the board immediately by telephone and follow up by written letter within three (3) working days. Upon notification from the board or its designee of this determination, respondent shall be automatically suspended and shall not resume practice until notified by the board that practice may be resumed.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. Respondent shall not resume practice until notified by the

board.

During suspension, respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

40.25. Community Services Program

board or its designee.

Within <u>sixty</u> (60) days of the effective date of this decision, respondent shall submit to the board <u>or its designee</u> , for <u>its-prior</u> approval, a community service program in which respondent shall provide free health-care related services on a regular basis to a community or charitable facility or agency for at least hours per for the first of probation. <u>Within thirty</u> (30) days of board approval thereof, respondent shall submit documentation to the board demonstrating commencement of the community service program. A record of this notification must be provided to the board upon request. Respondent shall report on progress with the community service program in the quarterly reports. Failure to timely submit, commence, or comply with the program shall be considered a violation of probation.
11.26. Restitution (For Pharmacist and Premises) – (Appropriate in cases of drug diversion, theft,
fraudulent billing, or patient harm resulting from negligence or incompetence.)
g
Within days of the effective date of this decision, respondent shall pay restitution to in the amount of \$ Failure to make restitution by this deadline shall be considered a violation of probation.
12.27. Remedial Education
Within [thirty (30), sixty (60), ninety (90)] days of the effective date of this decision, respondent shall submit to the board or its designee, for its prior approval, an appropriate program of remedial education related to [the grounds for discipline]. The program of remedial education shall consist of at least hours, which shall be completed within months/year at respondent's own expense. The period of probation shall be extended until such remedial education is successfully completed and written proof, in a form acceptable to the board, is provided to the board. All remedial education shall be in addition to, and shall not be credited toward, continuing education (CE) courses used for license renewal purposes.
Failure to <u>timely submit or complete</u> the <u>approved remedial education as set forth hereinabove is grounds for the filing of a petition to revoke probation shall be considered a violation of probation. The period of probation will be automatically extended until such remedial education is</u>

Following the completion of each course, the board may administer or its designee may require

successfully completed and written proof, in a form acceptable to the board, is provided to the

the respondent, at his or her own expense, to take an approved an examination to test the respondent's knowledge of the course. If the respondent does not achieve a passing score on the examination, this failure shall be considered a violation of probation. Any such examination failure shall require respondent to take another course approved by the board in the same subject area.

Option: Respondent shall be restricted from the practice of [areas where a serious deficiency has been identified] until the remedial education program has been successfully completed.

28. Pharmacy Self-Assessment Mechanism

Within the first year of probation, respondent shall complete the Pharmacist Self-Assessment Mechanism (PSAM) examination provided by the National Association of Boards of Pharmacy (NABP). Respondent shall submit a record of completion to the board demonstrating he/she has completed this examination. Respondent shall bear all costs for the examination. Failure to timely complete the PSAM or submit documentation thereof shall be considered a violation of probation.

13.29. Pharmacy Intern Pharmacist Experience (For Intern Pharmacist)

Within <u>ninety (90)</u> days of the effective date of this decision, respondent shall submit to the board <u>or its designee</u>, for <u>its-prior</u> approval, a pharmacy intern training program consisting of ______ hours to be served as an intern pharmacist in a community -and/or institutional pharmacy as directed. Respondent shall successfully complete the intern hours within the first year of probation and shall, by no later than one (1) year from the effective date of this decision, submit-a "Pharmacy Intern Experience Affidavit" and "Pharmacy Intern Hours Affidavit" signed by a currently licensed pharmacist not on probation with the board proof satisfactory to the board of completion of this experience signed under penalty of perjury by both the respondent and supervising pharmacist. Failure to timely complete or document the required intern experience shall be considered a violation of probation.

14.30. Supervised Practice

<u>During the period of probation, rRespondent shall practice only under the supervision of a licensed pharmacist not on probation with the board. Upon and after the effective date of this decision, rRespondent shall not practice pharmacy and his or her license shall be automatically suspended until the a supervisor is approved by the board or its designee. The supervision shall be, as required by the board or its designee, either:</u>

Continuous — At least 75% to 100% of a work week
Substantial - At least 50% of a work week
Partial - At least 25% of a work week
Daily Review - Supervisor's review of probationer's daily activities within 24 hours

Within thirty (30) days of the effective date of this decision, respondent shall have his or her supervisor submit notification to the board in writing stating that the supervisor has read the decision in case number _____ and is familiar with the required level of supervision as determined by the board or its designee. It shall be the respondent's responsibility to ensure that his or her employer(s), pharmacist-in-charge and/or supervisor(s) submit timely acknowledgement(s) to the board. Failure to cause the direct supervisor and the pharmacist-in-

charge to submit timely acknowledgements to the board shall be considered a violation of probation.

If respondent changes employment, it shall be the respondent's responsibility to ensure that his or her employer(s), pharmacist-in-charge and/or supervisor(s) submit timely acknowledgement(s) to the board. FRespondent shall have his or her new supervisor, within fifteen (15) days after employment commences, submit notification to the board in writing stating the direct supervisor and pharmacist-in-charge have read the decision in case number and is familiar with the level of supervision as determined by the board.

Respondent shall not practice pharmacy and his or her license shall be automatically suspended until the board or its designee approves a new supervisor. Failure to cause the direct supervisor and the pharmacist-in-charge to submit timely acknowledgements to the board shall be considered a violation of probation.

Within ten (10), days of leaving employment, respondent shall notify the board in writing.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and controlled substances. Respondent shall not resume practice until notified by the board.

During suspension, respondent shall not engage in any activity that requires the professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a designated representative for any entity licensed by the board.

Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

15.31. No Supervision of Ancillary Personnel

<u>During the period of probation, Rrespondent shall not supervise any ancillary personnel, including, but not limited to, registered pharmacy technicians or exemptees designated representatives, ofin any entity licensed by the board.</u>

Failure to comply with this provision shall be considered a violation of probation.

16.32. No Ownership of Licensed Premises

Respondent shall not own, have any legal or beneficial interest in, or serve as a manager, administrator, member, officer, director, <u>trustee</u>, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell or transfer any legal or beneficial interest in any entity licensed by the board within <u>ninety (90)</u> days following the effective date of this decision and shall immediately thereafter provide written proof thereof to the board. <u>Failure to timely divest any legal or beneficial interest(s) or provide documentation thereof shall be considered a violation of probation.</u>

Option: Respondent shall not acquire any new ownership, legal or beneficial interest nor serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any additional business, firm, partnership, or corporation licensed by the board. If respondent currently owns or has any legal or beneficial interest in, or serves as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board, respondent may continue to serve in such capacity or hold that interest, but only to the extent of that position or interest as of the effective date of this decision. Violation of this restriction shall be considered a violation of probation.

47.33. Separate File of Records (For pharmacist owners and pharmacists-in-charge)

Respondent shall maintain <u>and make available for inspection</u> a separate file of all records pertaining to the acquisition or disposition of all controlled substances. <u>Failure to maintain such</u> file or make it available for inspection shall be considered a violation of probation.

48.34. Report of Controlled Substances (For pharmacist owners and pharmacists-in-charge)

Respondent shall submit quarterly reports to the board <u>detailing</u> the total acquisition and disposition of such controlled substances as the board may direct. Respondent shall specify the manner of disposition (e.g., by prescription, due to burglary, etc.) or acquisition (e.g., from a manufacturer, from another retailer, etc.) of such controlled substances. Respondent shall report on a quarterly basis or as directed by the board. The report shall be delivered or mailed to the board no later than <u>ten (10)</u> days following the end of the reporting period. <u>Failure to timely prepare or submit such reports shall be considered a violation of probation</u>.

49.35. No Access to Controlled Substances

<u>During the period of probation and as directed by the board or its designee, Rrespondent shall</u> not order, possess, dispense or otherwise have access to any controlled substance(s) in Schedule II, III, IV or V (Health and Safety Code sections 11055-11058 inclusive). Respondent shall not order, receive or retain any <u>triplicate security</u> prescription forms. <u>Failure to comply with this restriction shall be considered a violation of probation.</u>

20. 36. Criminal Probation/Parole Reports

Respondent shall provide a copy of the conditions of any criminal probation/parole to the board, in writing, within ten (10) days of the issuance or modification of those conditions. Respondent shall provide the name of his or her probation/parole officer to the board, in writing, within ten (10)

days after that officer is designated or a replacement for that officer is designated. Respondent shall provide a copy of all criminal probation/parole reports to the board within ten (10) days after respondent receives a copy of such a report. Failure to timely make any of the submissions required hereby shall be considered a violation of probation.

21.37. Consultant for Owner or Pharmacist-in-Charge

(Option #1 for pharmacist owners - primarily intended for appropriate cases where the respondent is the <u>sole</u> owner and pharmacist<u>-in-charge</u> of his or her own pharmacy, the standard language should be used in most cases.)

During the period of probation, Rrespondent shall not supervise any intern pharmacist, perform any of the duties of a preceptor or serve as a consultant to any entity licensed by the board. Respondent may be a pharmacist-in-charge. However, if during the period of probation respondent serves as a pharmacist-in-charge, respondent shall retain an independent consultant at his or her own expense who shall be responsible for reviewing pharmacy operations on a [monthly/quarterly] basis for compliance by respondent with state and federal laws and regulations governing the practice of pharmacy and for compliance by respondent with the obligations of a pharmacist-in-charge. The consultant shall be a pharmacist licensed by and not on probation with the board and whose name shall be submitted to the board or its designee, for its-prior approval, within thirty (30) days of the effective date of this decision. Respondent shall not be a pharmacist-in-charge at more than one pharmacy or at any pharmacy of which he or she is not the sole owner. Failure to timely retain, seek approval of, or ensure timely reporting by the consultant shall be considered a violation of probation.

(Option #2 - appropriate for pharmacists who are not pharmacy owners, but who wish, because of their current employment, to remain as the pharmacist-in-charge, and have provided documentation documented mitigating evidence to warrant this option.)

During the period of probation, Rrespondent shall not supervise any intern pharmacist, perform the duties of a preceptor-or serve as a consultant to any entity licensed by the board. In the event that the respondent is currently the pharmacist-in-charge of a pharmacy, the pharmacy shall retain an independent consultant at its own expense who shall be responsible for reviewing pharmacy operations on a [monthly/quarterly] basis for compliance by respondent with state and federal laws and regulations governing the practice of pharmacy and for compliance by respondent with the obligations of a pharmacist-in-charge. The consultant shall be a pharmacist licensed by and not on probation with the board and whose name shall be submitted to the board or its designee, for its-prior approval. wwithin thirty (30) days of the effective date of this decision. Respondent shall not be a pharmacist-in-charge at more than one pharmacy or at any pharmacy of which he or she is not the current PIC. The board may, in case of an employment change by respondent or for other reasons as deemed appropriate by the board or its designee, preclude the respondent from acting as a pharmacist-in-charge. Failure to timely retain, seek approval of, or ensure timely reporting by the consultant shall be considered a violation of probation.

22.38. Tolling of Suspension

<u>During the period of suspension, respondent shall not leave California for any period exceeding ten (10) days, regardless of purpose (including vacation). Any such absence in excess of the (10) days during suspension shall be considered a violation of probation. Moreover, any</u>

absence from California during the period of suspension exceeding ten (10) days shall toll the suspension, i.e., the suspension shall be extended by one day for each day over ten (10) days respondent is absent from California. During any such period of tolling of suspension, respondent must nonetheless comply with all terms and conditions of probation.

Respondent must notify the board in writing within ten (10) days of departure, and must further notify the board in writing within ten (10) days of return. The failure to provide such notification(s) shall constitute a violation of probation. Upon such departure and return, respondent shall not resume the practice of pharmacy until notified by the board that the period of suspension has been satisfactorily completed.

If respondent leaves California to reside or practice outside this state, for any period exceeding 10 days (including vacation), respondent must notify the board in writing of the dates of departure and return. Periods of residency or practice outside the state - or any absence exceeding a period of 10 days shall not apply to the reduction of the suspension period.

Respondent shall not practice pharmacy upon returning to this state until notified by the board that the period of suspension has been completed.

39. Surrender of DEA Permit

Within thirty (30) days of the effective date of this decision, respondent shall surrender his or her federal Drug Enforcement Administration (DEA) permit to the DEA, for cancellation. Respondent shall provide documentary proof of such cancellation to the board or its designee. Respondent is prohibited from prescribing until the board has received satisfactory proof of cancellation. Thereafter, respondent shall not apply/reapply for a DEA registration number without the prior written consent of the board or its designee.

Option: Respondent may obtain a DEA permit restricted to Schedule(s) _____controlled substance(s).

Option: Respondent shall not order, receive, or retain any federal order forms, including 222 forms, for controlled substances.

PHARMACY TECHNICIAN

The board files cases against pharmacy technicians where the violation(s) involve significant misconduct on the part of the licensee. The board believes that revocation is <u>typically</u> the appropriate penalty when grounds for discipline are found to exist. Grounds for discipline include, but are not limited to the following violation(s) of law(s) involving:

- Possession of dangerous drugs and/or controlled substances
- Use of dangerous drugs and/or controlled substances
- Possession for sale of dangerous drugs and/or controlled substances
- Personal misuse of drugs or alcohol

If revocation is not imposed, the board recommends a minimum of a Category III level of discipline be imposed on the pharmacy technician. This would include suspension and probation.

In addition, a pharmacy technician would be required to obtain certification from the Pharmacy Technician Certification Board (PTCB)as defined by Business and Professions Code section 4202(a)(4) prior to resuming work as a pharmacy technician. The board believes that certification prior to resuming work is always warranted in cases where a pharmacy technician registration license is disciplined but not revoked.

Pharmacy technicians are issued a registration, license based on minimal education, or training requirements or certification. No examination is required for issuance of the registration. Pharmacy technicians are not independent practitioners and must work under the supervision of a pharmacist. To place a pharmacy technician on probation places an additional burden on the pharmacist (who may or may not be on probation) to ensure that the respondent pharmacy technician complies with the terms and conditions of his or her probation.

TERMS OF PROBATION – PHARMACY TECHNICIAN

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of controlled substances is involved. Terms and conditions are imposed to provide consumer protection and to allow the probationer to demonstrate rehabilitation. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in <u>all-all</u> probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.

CATEGORY OF VIOLATIONS AND RECOMMENDED PENALTIES

CATEGORY III - Penalty

Minimum: Revocation; Revocation stayed, 90 days actual suspension, three years

probation. All standard terms and conditions shall be included and optional terms

and conditions as appropriate.

Maximum: Revocation

Applies to all applicable statutes and regulations

MODEL DISCIPLINARY LANGUAGE - PHARMACY TECHNICIAN

The following standardized language shall be used in every decision where the order of condition is imposed.

Revocation - Single Cause

Pharmacy Ttechnician registration license number is revoked. Respondent shall relinquish his license to the board within ten (10) days of the effective day not reapply or petition the board for reinstatement of his or license for three (3) years from the effective date of this day.	is or her pocket tech ate of this decision. r her revoked techni	nician registration Respondent may
<u>license</u> for three (3) years from the effective date of this de A condition of reinstatement shall be that the respondent is		d in Business and

Professions Code section 4202(a)(4) by the Pharmacy Technician Certification Board (PTCB) and provides satisfactory proof of certification to the board.

Respondent shall pay to the board its costs of investigation and prosecution in the amount of \$_____ within fifteen (15) days of the effective date of this decision.

Revocation - Multiple Causes

Technician registration number ______, issued to respondent ______ is revoked pursuant to Determination of Issues ______, separately and together. Respondent shall relinquish his or her pocket technician registration to the board within 10 days of the effective date of this decision. Respondent may not petition the board for reinstatement of his or her revoked technician registration for three years from the effective date of this decision. A condition of reinstatement shall be that the respondent is certified by the Pharmacy Technician Certification Board (PTCB) and provides satisfactory proof of certification to the board.

Respondent shall pay to the board its costs of investigation and prosecution in the amount of \$ within 15 days of the effective date of this decision.
Option: Upon reinstatement of his or her technician registration respondent shall reimburse the board for its costs of investigation and prosecution in the amount of \$, and said amount shall be paid in full prior to the reinstatement of his or her technician registration. If the respondent fails to pay the amount specified, his or her technician registration shall remain revoked.
Suspension - Single Cause
As part of probation, Technician registration number, issued to-respondent is suspended from working as a pharmacy technician for for a period of beginning the effective date of this decision. Respondent shall not resume work until notified by the board.
During suspension, respondent shall not enter any pharmacy area or any portion of or any other board licensed premises (wholesaler, veterinary food-animal drug retailer or any other distributor of drugs) any drug manufacturer, or any other location where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving drug selection selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, or assist any licensee of the board. Respondent shall not have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances.
Respondent shall not direct, control or perform any aspect of the practice of pharmacy. Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.
Failure to comply with this suspension shall be considered a violation of probation. Suspension - Multiple Causes
Technician registration number, issued to respondent is suspended for a period o pursuant to Determination of Issues, separately and together. All suspensions shall run concurrently. Respondent is suspended from the duties of a pharmacy technician for beginning the effective date of this decision.
Standard Stay/Probation Order
Pharmacy Technician registration license number issued to is revoked; however, the revocation is stayed and respondent is placed on probation for years upon the following terms and conditions:
Issuance of Probationary License (In cases where a Statement of Issues has been filed.)
Upon satisfaction of all statutory and regulatory requirements for issuance of a license, a license shall be issued to respondent and immediately revoked; the order of revocation is stayed and respondent is placed on probation for years upon the following terms and conditions:

Surrender

Respondent surrenders pharmacy technician registration license number	as of
the effective date of this decision. Respondent shall relinquish his or her pocket pharmacy	<u> </u>
technician registration license to the board within ten (10) days of the effective date of this	
decision.	

The surrender of respondent's license and the acceptance of the surrendered license by the board shall constitute the imposition of discipline against respondent. This decision constitutes a record of discipline and shall become a part of respondent's license history with the board.

Respondent understands and agrees that if he or she ever files an application for licensure or a petition for reinstatement in the State of California, the board shall treat it as a new application for licensure.

Respondent may not reapply for any <u>license</u>, <u>permit</u>, <u>or technician</u>-registration <u>ef-from</u> the board for three (3) years from the effective date of this decision. Respondent stipulates that should <u>respondent he or she</u> apply for any <u>technician registration license</u> from the board on or after the effective date of this decision, all allegations set forth in the [accusation or petition to revoke probation] shall be deemed to be true, <u>correct and admitted by respondent when the board determines whether to grant or deny the application</u>. Respondent shall satisfy all requirements applicable to that license as of the date the application is submitted to the board, including, but not limited to certification by a nationally recognized body prior to the issuance of a new license. Respondent is required to report this surrender as disciplinary action. Should respondent apply for any new license, respondent will be subject to all terms and conditions not previously satisfied.

Respondent shall meet all requirements applicable to that technician registration as of the date the application is submitted to the board, including, but not limited to certification by a nationally recognized body prior to the issuance of a new registration.

Respondent further stipulates that he or she shall	I reimburse the board for its	costs of
investigation and prosecution in the amount of \$_	within	_ days of the
effective date of this decision.		

Option: Respondent stipulates that should he or she apply for any technician registration license from the board on or after the effective date of this decision, that investigation and prosecution costs in the amount of \$_____ shall be paid to the board prior to issuance of the technician registration license.

Public Reprimand

It is hereby ordered that a public reprimand be issued against pharmacy technician license,

Respondent is required to report this reprimand as a disciplinary action.

Adoption of Stipulation

It is understood by respondent that, in deciding whether to adopt this stipulation, the board may receive oral and written communication from its staff and the Attorney General's-Office of the Attorney General. Communications pursuant to this paragraph shall not disqualify the board or other persons from future participation in this or any other matter affecting respondent. In the event this settlement is not adopted by the board, the stipulation will not become effective and may not be used for any purpose, except this paragraph, which shall remain in effect.

STANDARD CONDITIONS – To be included in all probation decisions/orders.

- 1. Certification Prior to Resuming Work
- 2. Obey aAll Laws
- 3. Reporting to the Board
- 4. Interview with the Board
- 5. Cooperatione with Board Staff
- 6. Notice to Employers
- 7. Reimbursement of Board Costs
- 8. Probation Monitoring Costs
- 9. Status of License
- 10. License Surrender While on Probation/Suspension
- <u>10.11.</u> Notification of <u>a Change in Name, Residence Address, Employment/Mailing Address or Employment Change</u>
- 41.12. Tolling of Probation
- 12.13. Violation of Probation
- 13.14. Completion of Probation
- 14.License Surrender While on Probation/Suspension

OPTIONAL CONDITIONS

Term Number: (Numbers reflect actual term and condition numbers as listed beginning with page ...

- **1.Actual Suspension**
- 2.15. No Ownership of Licensed Premises
- 3.16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups
- 4.17. Random Drug Screening
- 5.18. Work Site Monitor
- 6.19. Notification of Departure
- 7.20. Abstain from Drugs and Alcohol Use
- 8.21. Tolling of Suspension
- 22. Restitution

STANDARD CONDITIONS: TO BE INCLUDED IN ALL PROBATIONS

4.1. Certification Prior to Resuming Work

Respondent shall be <u>automatically</u> suspended from working as a pharmacy technician until he or she is certified by the Pharmacy Technician Certification Board (PTCB)as defined by Business and Professions Code section 4202(a)(4) and provides satisfactory proof of certification to the board. Failure to achieve certification within one (1) year shall be considered a violation of probation.

During suspension, respondent shall not enter any pharmacy area or any portion of <u>any other</u> <u>board the</u> licensed premises <u>of a-(wholesaler, veterinary food-animal drug retailer or any other distributor of drugs) <u>which is licensed by the board, or any drug</u> manufacturer, or <u>any other location</u> where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, <u>or be a consultant to or assist</u> any licensee of the board, <u>Respondent shall not or-have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances. Respondent shall not resume work until notified by the board.</u></u>

Subject to the above restrictions, respondent may continue to own or hold an interest in any entity-licensed <u>premises</u> by the board in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

2.2. Obey All Laws

Respondent shall obey all state and federal laws and regulations substantially related to or governing the practice of pharmacy.

Respondent shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy
 Law, state and federal food and drug laws, or state and federal controlled substances
 laws
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state or federal agency which involves respondent's _____ license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

3.3. Reporting to the Board

Respondent shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other

requirements, Rrespondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, lif the final probation report is not made as directed, probation shall be automatically extended automatically until such time as the final report is made and accepted by the board.

4.4. Interview with the Board

Upon receipt of reasonable <u>prior</u> notice, respondent shall appear in person for interviews with the board <u>or its designee</u>, <u>upon request</u> at <u>various such</u> intervals <u>and at a locations as are to be</u> determined by the board <u>or its designee</u>. Failure to appear for any scheduled interview without prior notification to board staff, <u>or failure to appear at two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.</u>

5.5. Cooperatione with Board Staff

Respondent shall cooperate with the board's inspectional program and inwith the board's monitoring and investigation of respondent's compliance with the terms and conditions of his or her probation. Failure to cooperate shall be considered a violation of probation.

6.6. Notice to Employers

<u>During the period of probation, Rrespondent shall notify all present and prospective employers of the decision in case number</u> and the terms, conditions and restrictions imposed on respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment, respondent shall cause his or her direct supervisor, pharmacist-in-charge (including each new pharmacist-in-charge employed during respondent's tenure of employment) and owner employer to report to the board in writing acknowledging that the listed individual(s) has/have employer has read the decision in case number ______ and the terms and conditions imposed thereby. It shall be respondent's responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely acknowledgement(s) to the board.

If respondent works for or is employed by or through a pharmacy employment service, respondent must notify the his or her direct supervisor, pharmacist-in-charge and/or owner at every pharmacy of the terms and conditions of the decision in case number _____ in advance of the respondent commencing work at each pharmacy. A record of this notification must be provided to the board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment by or through a pharmacy employment service, respondent shall cause his or her direct supervisor with the pharmacy employment service to report to the board in writing acknowledging that he or she has read the decision in case number _____ and the terms and conditions imposed thereby. It shall be respondent's responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

Failure to timely notify present or prospective employer(s) or to cause that/those employer(s) to submit timely acknowledgements to the board shall be considered a violation of probation.

"Employment" within the meaning of this provision shall include any full-time, part-time, temporary or relief service or pharmacy management service as a pharmacy technician or in any position for which a pharmacy technician license is a requirement or criterion for employment, whether the respondent is considered an employee, or independent contractor or volunteer.

7.7. Reimbursement of Board Costs

As a condition precedent to successful completion of probation, Respondent shall pay to the board its costs of investigation and prosecution in the amount of _____. Respondent shall make said payments as follows: _____. There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by respondent shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

Option: If respondent fails to make any payment by the directed deadline(s), the stay shall

terminate and the license shall be revoked without further notice or opportunity to be heard.

8.8. Probation Monitoring Costs

Respondent shall pay the <u>any</u> costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board at the end of <u>each year of probation</u> on a schedule as directed by the board or its designee. Failure to pay such costs by the <u>deadline(s)</u> as directed shall be considered a violation of probation.

9.9. Status of License

Respondent shall, at all times while on probation, maintain an active, current pharmacy technician registration/certification-license with the board, including any period during which suspension or probation is tolled. Failure to maintain an active, current license shall be considered a violation of probation.

If respondent's <u>pharmacy</u> technician <u>registration/certification_license</u> expires or is cancelled by operation of law or otherwise <u>at any time during the period of probation, including any extensions</u> thereof due to tolling or otherwise, upon renewal or reapplication, respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

10. License Surrender While on Probation/Suspension

Following the effective date of this decision, should respondent cease work due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her pharmacy technician license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the respondent's license history with the board.

Upon acceptance of the surrender, respondent shall relinquish his or her pharmacy technician license to the board within ten (10) days of notification by the board that the surrender is accepted. Respondent may not reapply for any license, permit, or registration from the board for three (3) years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board.

10.11. Notification of <u>a Change in Name, Residence Address, Employment/Mailing</u> Address or EmploymentChange

Respondent shall notify the board in writing within <u>ten (10)</u> days of any change of employment. Said notification shall include the reasons for leaving, <u>and/or</u> the address of the new employer, <u>the name of the</u> supervisor <u>or and owner</u>, and <u>the</u> work schedule, if known. Respondent shall <u>further</u> notify the board in writing within <u>ten (10)</u> days of a change in name, <u>residence address</u> and mailing address, or phone number.

Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

41.12. Tolling of Probation

Except during periods of suspension, respondent shall, at all times while on probation, be employed as a pharmacy technician in California for a minimum of hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation.

It is a violation of probation for respondent to work less than ______ hours per month as a pharmacy technician/exemptee. Should respondent, regardless of residency, for any reason (including vacation) cease practicing working as a pharmacy technician or an exemptee for a minimum of ______ hours per calendar month in California, respondent must notify the board in writing within ten (10) days of cessation of practice work and must further notify the board in writing within ten (10) days of or the resumption of the practice work. Such periods of time shall not apply to the reduction of the probation period. Any failure to provide such notification(s) shall be considered a violation of probation.

It is a violation of probation for respondent's probation to remain tolled pursuant to the provisions of this condition for a <u>total</u> period, <u>counting consecutive and non-consecutive months</u>, exceeding three consecutive years thirty-six (36) months.

"Cessation of practicework" means any period of time exceeding 30 days calendar month during in which respondent is not engaged in the practice of working for at least hours as a pharmacy technician, as defined in section of work" means any calendar month during which respondent is working as a pharmacy technician for at least hours as a pharmacy technician as defined by Business and Professions Code section 4115.

12.13. Violation of Probation

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended, until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order which that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of the license. If a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction, and the period of probation shall be automatically extended, until the petition to revoke probation or accusation is heard and decided.

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to

impose the penalty which was stayed.

13.14. Completion of Probation

Upon <u>written notice by the board indicating</u> successful completion of probation, respondent's pharmacy technician <u>registration</u> license will be fully restored.

14. License Surrender While on Probation/Suspension

Following the effective date of this decision, should respondent cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her license to the board for surrender. The board shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation.

Upon acceptance of the surrender, respondent shall relinquish his or her pocket license to the board within 10 days of notification by the board that the surrender is accepted. Respondent may not reapply for any license from the board for three years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board.

OPTIONAL CONDITIONS OF PROBATION

1.Actual Suspension

As part of probation, respondent is suspended from the duties of a pharmacy technician for beginning the effective date of this decision.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, **or** be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances.

Subject to the above restrictions, respondent may continue to own or hold an interest in any entity licensed by the board in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

During suspension, respondent shall not perform any of the duties of a pharmacy technician as provided by Section 1793.2 of the California Code of Regulations.

2.15. No Ownership of Licensed Premises

Respondent shall not own, have any legal or beneficial interest in, or serve as a manager,

administrator, member, officer, director, <u>trustee</u>, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell or transfer any legal or beneficial interest in any entity licensed by the board within <u>ninety (90)</u> days following the effective date of this decision and shall immediately thereafter provide written proof thereof to the board. <u>Failure to timely divest any legal or beneficial interest(s) or provide documentation thereof shall be considered a violation of probation.</u>

Option: Respondent shall not acquire any new ownership, legal or beneficial interest nor serve as a manager, administrator, member, officer, director, <u>trustee</u>, associate, or partner of any additional business, firm, partnership, or corporation licensed by the board. If respondent <u>currently</u> owns or has any legal or beneficial interest in, or serve as a manager, administrator, member, officer, director, <u>trustee</u>, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board, respondent may continue to serve in such capacity or hold that interest, but only to the extent of that position or interest as of the effective of this decision. Violation of this restriction shall be considered a violation of probation.

3.16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups (Appropriate for those cases with chemical dependency (alcohol, drugs))

Within thirty (30) days of the effective date of this decision, respondent shall begin regular attendance at a board-approved-recognized and established substance abuse recovery support group in California, (e.g., Alcoholics Anonymous, Cocaine-Narcotics Anonymous, etc.;) which has been approved by the board or its designee. Respondent must attend at least one group meeting per week unless otherwise directed by the board or its designee. Respondent shall continue regular attendance and submit signed and dated documentation confirming attendance with each quarterly report for the duration of probation. Failure to attend or submit documentation thereof shall be considered a violation of probation.

4.17. Random Drug Screening (Appropriate for those cases with chemical dependency (alcohol, drugs))

Respondent, at his or her own expense, shall participate in random testing, including but not limited to biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or a other drug screening program approved as directed by the board or its designee. The length of time shall be for the Respondent may be required to participate in testing for the entire probation period and the frequency of testing will be determined by the board or its designee. At all times respondent shall fully cooperate with the board or its designee, and shall, when directed, submit to such tests and samples for the detection of alcohol, narcotics, hypnotics, dangerous drugs or other controlled substances as the board or its designee may direct. Failure to timely submit to testing as directed shall constitute be considered a violation of probation. Upon request of the board or its designee, respondent shall provide documentation from a licensed practitioner that the prescription for a detected drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Any confirmed positive drug-test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment shall be considered a violation of probation and shall result in the immediate automatic suspension of practice work by respondent. Respondent may not resume the practice of pharmacy-work as a pharmacy technician until notified by the board in writing.

During suspension, respondent shall not enter any pharmacy area or any portion of or any other board licensed premises (wholesaler, veterinary food-animal drug retailer or any other distributor

of drugs) any drug manufacturer, or any other location where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, or assist any licensee of the board. Respondent shall not have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances. Respondent shall not resume work until notified by the board.

Respondent shall not direct, control or perform any aspect of the practice of pharmacy. Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed premises in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

5.18. Work Site Monitor (Appropriate for those cases with chemical dependency (alcohol, drugs))

Within ten (10) days of the effective date of this decision, respondent shall identify a work site monitor, for prior approval by the board, who shall be responsible for supervising respondent during working hours. The Respondent shall be responsible for ensuring that the work site monitor shall report reports in writing to the board quarterly. Should the designated work site monitor determine at any time during the probationary period that respondent has not maintained sobriety, he or she shall notify the board immediately, either orally or in writing as directed. Should respondent change employment, a new work site monitor must be designated, for prior approval by the board, within ten (10) days of commencing new employment. Failure to identify an acceptable initial or replacement work site monitor, or to ensure quarterly reports are submitted to the board, shall be considered a violation of probation.

6.19. Notification of Departure (Appropriate for those cases with chemical dependency (alcohol, drugs))

If respondent leaves Prior to leaving the probationary geographic area designated by the board or its designee for a period greater than twenty-four (24) hours, respondent shall notify the board verbally and in writing of the dates of departure and return, prior to leaving. Failure to comply with this provision shall be considered a violation of probation.

7.20. Abstain from Drugs and Alcohol Use (Appropriate for those cases with chemical dependency (alcohol, drugs))

Respondent shall completely abstain from the possession or use of alcohol, controlled substances, dangerous drugs and their associated paraphernalia except when the drugs are lawfully prescribed by a licensed practitioner as part of a documented medical treatment. Upon request of the board or its designee, respondent shall provide documentation from the licensed practitioner that the prescription for the drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Additionally, respondent shall cause the prescribing practitioner to notify the board in writing, indicating their awareness of the chemical dependency. Additionally, respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if

respondent is not personally ingesting the drugs. Any possession or use of alcohol, controlled substances, or their associated paraphernalia not supported by the documentation timely provided, and/or any physical proximity to persons using illicit substances, shall be considered a violation of probation.

8.21. Tolling of Suspension

During the period of suspension, respondent shall not leave California for any period exceeding ten (10) days, regardless of purpose (including vacation). Any such absence in excess of ten (10) days during suspension shall be considered a violation of probation. Moreover, any absence from California during the period of suspension exceeding ten (10) days shall toll the suspension, i.e., the suspension shall be extended by one day for each day over ten (10) days respondent is absent from California. During any such period of tolling of suspension, respondent must nonetheless comply with all terms and conditions of probation.

Respondent must notify the board in writing within ten (10) days of departure, and must further notify the board in writing within ten (10) days of return. The failure to provide such notification(s) shall constitute a violation of probation. Upon such departure and return, respondent shall not return to work until notified by the board that the period of suspension has been satisfactorily completed.

If respondent leaves California to reside or practice outside this state, or for any period exceeding 10 days (including vacation), respondent must notify the board in writing of the dates of departure and return. Periods of residency or practice outside the state or any absence exceeding a period of 10 days shall not apply to the reduction of the suspension period.

Respondent shall not act as a pharmacy technician upon returning to this state until notified by the board that the period of suspension has been completed.

22. Restitution (Appropriate in cases of drug diversion, theft, fraudulent billing, or patient harm resulting from negligence or incompetence.)

Within ______days of the effective date of this decision, respondent shall pay restitution to ______in the amount of \$ _____. Failure to make restitution by this deadline shall be considered a violation of probation.

EXEMPTEEDESIGNATED REPRESENTATIVE

The board files cases against exemptees designated representatives where the violation(s) involve significant misconduct on the part of the licensee. The board believes that revocation is typically the appropriate penalty when grounds for discipline are found to exist. Grounds for discipline include, but are not limited to, the following violation(s) of law(s) involving:

- Possession of dangerous drugs and/or controlled substances
- Use of dangerous drugs and/or controlled substances
- Possession for sale of dangerous drugs and/or controlled substances
- Personal misuse of drugs or alcohol

If revocation is not imposed, the board recommends a minimum of a Category III level of discipline be imposed on the exemptee designated representative. This would include suspension and probation.

An exemptee would be required to be reexamined by the board prior to resuming work as an exemptee.

TERMS OF PROBATION -- EXEMPTEEDESIGNATED REPRESENTATIVE

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of controlled substances is involved. Terms and conditions are imposed to provide consumer protection and to allow the probationer to demonstrate rehabilitation. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in all-all probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.

CATEGORY OF VIOLATIONS AND RECOMMENDED PENALTIES

CATEGORY III - Penalty

Minimum: Revocation; Revocation stayed, 90 days actual suspension, three years

probation. All standard terms and conditions shall be included and optional terms

and conditions as appropriate.

Maximum: Revocation

Applies to all applicable statutes and regulations

MODEL DISCIPLINARY LANGUAGE - EXEMPTEE DESIGNATED REPRESENTATIVE

The following standardized language shall be used in every decision where the order of condition is imposed.

Revocation - Single Cause
Designated Representative license Certification number, issued to respondent, is revoked. Respondent shall relinquish his or her designated representative pocket certification license to the board within ten (10) days of the effective date of this decision. Respondent may not petition the board for reinstatement of his or her revoked certification designated representative license for three (3) years from the effective date of this decision.
A condition of reinstatement shall be that the respondent retake the exemption certification examination.
Respondent shall pay to the board its costs of investigation and prosecution in the amount of \$ within fifteen (15) days of the effective date of this decision.
Option: As a condition precedent to Upon-reinstatement of his or her revoked designated representative license certification respondent shall reimburse the board for its costs of investigation and prosecution in the amount of \$
Revocation - Multiple Causes
Certification number, issued to respondent is revoked pursuant to Determination of Issues, separately and together. Respondent shall relinquish his or her pocket certification to the board within 10 days of the effective date of this decision. Respondent may not petition the board for reinstatement of his or her revoked certification for three years from the effective date of this decision. A condition of reinstatement shall be that the respondent retake the exemption certification examination.
Respondent shall pay to the board its costs of investigation and prosecution in the amount of \$ within 15 days of the effective date of this decision.
Option: Upon reinstatement of his or her certification respondent shall reimburse the board for its costs of investigation and prosecution in the amount of \$, and said amount shall be paid in full prior to the reinstatement of his or her certification. If the respondent fails to pay the amount specified, his or her certification shall remain revoked.
Suspension - Single Cause
As part of probation, Certification number, issued to respondentis suspended from working as a designated representative for beginning the effective date of this decisional period of Respondent shall not resume work until notified by

the board.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs licensed by the board, or any drug manufacturer, or any other location where dangerous drugs and devices or controlled substances are maintained. Respondent shall not perform any of the duties of a designated representative, nor do any act involving drug selection, selection of stock, manufacturing, dispensing; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices and controlled substances. Respondent shall not resume work until notified by the board.

Respondent shall not direct, control or perform any aspect involving the distribution of dangerous drugs and devices and controlled substances. Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed entity in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

Suspension - Multiple Causes Certification number, issued to respondent is suspended for a period of separately and together. All pursuant to Determination of Issues suspensions shall run concurrently. Respondent is suspended from the duties of an exemptee beginning the effective date of this decision. **Standard Stay/Probation Order** Designated representative license Certification number is revoked; however, the revocation is stayed and respondent is placed on probation for ______ years upon the following terms and conditions: Issuance of Probationary License (In cases where a Statement of Issues has been filed.) Upon satisfaction of all statutory and regulatory requirements for issuance of a license, a license shall be issued to respondent and immediately revoked; the order of revocation is stayed and respondent is placed on probation for years upon the following terms and conditions: Surrender Respondent surrenders certification designated representative license number as of the effective date of this decision. Respondent shall relinquish his or her pocket certification-designated representative license to the board within ten (10) days of the effective date of this decision. The surrender of respondent's license and the acceptance of the surrendered license by the board shall constitute the imposition of discipline against respondent. This decision constitutes a record of discipline and shall become a part of respondent's license history with the board. Respondent understands and agrees that if he or she ever files an application for licensure or a petition for reinstatement in the State of California, the board shall treat it as a new application for licensure. Respondent may not reapply for any certification of license, permit or registration from the board

Respondent may not reapply for any certification of license, permit or registration from the board for three (3) years from the effective date of this decision. Respondent stipulates that should he or she respondent apply for any certification license from the board on or after the effective date of this decision, all allegations set forth in the [accusation or petition to revoke probation] shall be deemed to be true, correct and admitted by respondent when the board determines whether to grant or deny the application. Respondent shall satisfy all requirements applicable to that license as of the date the application is submitted to the board prior to issuance of a new license. Respondent is required to report this surrender as disciplinary action. Should respondent apply for any new license, respondent will be subject to all terms and conditions not previously satisfied.

Respondent shall meet all requirements applicable to that certification as of the date the application is submitted to the board, including, but not limited to exemptee reexamination prior to the issuance of a new registration or certification.

Respondent further stipulates that he or she shall reimburse the board for its costs of investigation and prosecution in the amount of \$ within days of the effective date of this decision.
Option: Respondent stipulates that should he or she apply for any <u>certification-license</u> from the board on or after the effective date of this decision, <u>that-investigation</u> and prosecution costs in the amount of \$ shall be paid to the board prior to issuance of the <u>certification new license</u> .
Public Reprimand
It is hereby ordered that a public reprimand be issued against designated representative license, Respondent is required to report this reprimand as a disciplinary action.

Adoption of Stipulation

It is understood by respondent that, in deciding whether to adopt this stipulation, the board may receive oral and written communication from its staff and the Attorney General's Office of the Attorney General. Communications pursuant to this paragraph shall not disqualify the board or other persons from future participation in this or any other matter affecting respondent. In the event this settlement is not adopted by the board, the stipulation will not become effective and may not be used for any purpose, except this paragraph, which shall remain in effect.

STANDARD CONDITIONS – To be included in all probation decisions/orders.

Term Number: (Numbers reflect actual term and condition numbers as listed beginning with page ...)

- 1. Certification Prior to Resuming Work
- 5.1. Obey aAll Laws
- 6.2.—Reporting to the Board
- 7.3. Interview with the Board
- 5. 4. Cooperatione with Board Staff
- 6. Notice to Employers
- 6. No Being Designated Representative-in-Charge
- 9.7. Reimbursement of Board Costs
- 40.8. Probation Monitoring Costs
- 45.9. Status of License
- 10. License Surrender While on Probation/Suspension
- 16.11. Notification of <u>a Change in Name, Residence Address, Employment/Mailing Address or Employment-Change</u>
- 17.12. Tolling of Probation
- 48.13. Violation of Probation
- 19.14. Completion of Probation
- 20.License Surrender While on Probation/Suspension

OPTIONAL CONDITIONS

Term Number: (Numbers reflect actual term and condition numbers as listed beginning with page ...)

- **1.Actual Suspension**
- 2.15. No Ownership of Licensed Premises
- 3.16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups
- 4.17. Random Drug Screening
- 5.18. Work Site Monitor
- 6.19. Notification of Departure
- 7.20. Abstain from Drugs and Alcohol Use
- 8.21. Tolling of Suspension
- 22. Restitution

STANDARD CONDITIONS - TO BE INCLUDED IN ALL PROBATIONS

1.Reexamination Prior to Resuming Work

Respondent shall be suspended from working as an exemptee until he or she takes and passes the exemption examination as scheduled by the board after the effective date of this decision.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the Board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving wholesaling, or repackaging or manufacturing, nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances. Respondent shall not direct or control any aspect of the practice of pharmacy.

Subject to the above restrictions, respondent may continue to own or hold an interest in any pharmacy or wholesaler in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

2.1. Obey All Laws

Respondent shall obey all state and federal laws and regulations substantially related to or governing the practice of pharmacy.

Respondent shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy
 Law, state and federal food and drug laws, or state and federal controlled substances
 laws
- an arrest or issuance of a criminal complaint for violation of any state or federal law
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state or federal agency which involves respondent's _____ license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling or distribution or billing or charging for of any drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

3.2. Reporting to the Board

Respondent shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, Rrespondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, lif the final probation report is not made as directed, probation shall be automatically extended

automatically until such time as the final report is made and accepted by the board.

4.3. Interview with the Board

Upon receipt of reasonable <u>prior</u> notice, respondent shall appear in person for interviews with the board <u>or its designee</u>, upon request at <u>various such</u> intervals <u>at a and</u> locations <u>to be as are</u> determined by the board <u>or its designee</u>. Failure to appear for any scheduled interview without prior notification to board staff, <u>or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.</u>

5.4. Cooperatione with Board Staff

Respondent shall cooperate with the board's inspectional program and in-with the board's monitoring and investigation of respondent's compliance with the terms and conditions of his or her probation. Failure to comply cooperate shall be considered a violation of probation.

6.5. Notice to Employers

During the period of probation, Rrespondent shall notify all present and prospective employers of the decision in case number and the terms, conditions and restrictions imposed on
respondent by the decision, as follows:-
Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment, respondent shall cause his or her direct
supervisor, designated representative-in-charge (including each new designated representative-
in-charge employed during respondent's tenure of employment) and owner employer to report to the board in writing acknowledging that the listed individual(s) has/have employer has read the decision in case number and terms and conditions imposed thereby. It shall be
respondent's responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely acknowledgement(s) to the board.
If respondent works for or is employed by or through a pharmacy employment service, respondent must notify the pharmacist-in-charge his or her direct supervisor, designated
representative-in-charge and/or owner at every pharmacy each entity licensed by the board of
the terms and conditions of the decision in case number in advance of the respondent commencing work at each pharmacy licensed entity. A record of this notification must be
provided to the board upon request.
Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15)
days of respondent undertaking any new employment by or through a pharmacy employment
service, respondent shall cause his or her direct supervisor with the pharmacy employment
service to report to the board in writing acknowledging that he or she has read the decision in case number and the terms and conditions imposed thereby. It shall be the respondent's
responsibility to ensure that his or her employer(s) and/or supervisor(s) submit timely
acknowledgment(s) to the board.
Failure to timely notify present or prospective employer(s) or to cause that/those employer(s) to
submit timely acknowledgements to the board shall be considered a violation of probation.
"Employment" within the meaning of this provision shall include any full-time, part-time,
temporary or relief service or pharmacy management service as a pharmacy technician
designated representative or in any position for which a designated representative license is a requirement or criterion for employment, whether the respondent is considered an
employee or independent contractor or volunteer.
6. No Being Designated Representative-in-Charge
o. No being besignated representative in onarge
During the period of probation, respondent shall not be the designated representative-in-charge
of any entity licensed by the board unless otherwise specified in this order. Assumption of any such unauthorized supervision responsibilities shall be considered a violation of probation.
such unauthorized supervision responsibilities shall be considered a violation of probation.
7Reimbursement of Board Costs
As a condition precedent to successful completion of probation, Rrespondent shall pay to the
board its costs of investigation and prosecution in the amount of \$ Respondent shall make said payments as follows: There shall be no deviation from this schedule

absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by respondent shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

Option: If respondent fails to make any payment by the directed deadline(s), the stay shall terminate and the license shall be revoked without further notice or opportunity to be heard.

8. - Probation Monitoring Costs

Respondent shall pay the any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board at the end of each year of probation on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

9. -Status of License

Respondent shall, at all times while on probation, maintain an active, current certification designated representative license with the board, including any period during which suspension or probation is tolled. Failure to maintain an active, current license shall be considered a violation of probation.

If respondent's <u>certification</u> <u>designated representative license</u> expires or is cancelled by operation of law or otherwise at any time <u>during the period of probation</u>, including any extensions <u>thereof due to tolling or otherwise</u>, upon renewal or reapplication, respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

10. License Surrender While on Probation/Suspension

Following the effective date of this decision, should respondent cease work due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her designated representative license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the respondent's license history with the board.

Upon acceptance of the surrender, respondent shall relinquish his or her designated representative license to the board within ten (10) days of notification by the board that the surrender is accepted. Respondent may not reapply for any license, permit, or registration from the board for three (3) years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board.

10.11. Notification of <u>a Change in Name, Residence Address, Employment/Mailing</u>
Address or EmploymentChange

Respondent shall notify the board in writing within <u>ten (10)</u> days of any change of employment. Said notification shall include the reasons for leaving and/or the address of the new employer, supervisor <u>or and</u> owner and work schedule, if known. Respondent shall <u>further</u> notify the board in writing within <u>ten (10)</u> days of a change in name, <u>residence address and mailing address</u>, or phone number.

Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

11.12. Tolling of Probation

Except during periods of suspension, respondent shall, at all times while on probation, be employed as a designated representative in California for a minimum of _______ hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation.

It is a violation of probation for respondent to work less than ______ hours per month as an exemptee. Should respondent, regardless of residency, for any reason (including vacation) cease practicing working as an exemptee designated representative for a minimum of hours in California, respondent must notify the board in writing within ten (10) days of cessation of practice work and must further notify the board in writing within ten (10) days of or the resumption of the practice work. Any failure to provide such notification(s) shall be considered a violation of probation. Such periods of time shall not apply to the reduction of the probation period.

It is a violation of probation for respondent's probation to remain tolled pursuant to the provisions of this condition for a <u>total</u> period, <u>counting consecutive and non-consecutive months</u>, exceeding <u>three consecutive years</u> thirty-six (36) months.

"Cessation of practicework" means any period of time exceeding 30 days_calendar month during in-which respondent is not engaged in the practice of a pharmacy technician-working as a designated representative for at least _______ hours as a designated representative as defined in section _______ of the by Business and Professions Code section 4053 or as an exemptee as defined in section ______ of the Business and Professions Code. "Resumption of work" means any calendar month during which respondent is working as a designated representative for at least _____ hours as a designated representative as defined by Business and Professions Code section 4053.

12.13. Violation of Probation

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order which that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of the license. If

a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction, and the period of probation shall be <u>automatically</u> extended, until the petition to revoke probation or accusation is heard and decided.

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty which was stayed.

13.14. Completion of Probation

Upon <u>written notice by the board indicating</u> successful completion of probation, respondent's <u>certificate</u> designated representative license will be fully restored.

14. License Surrender while on Probation/Suspension

Following the effective date of this decision, should respondent cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his or her license to the board for surrender. The board shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation.

Upon acceptance of the surrender, respondent shall relinquish his or her pocket license to the board within 10 days of notification by the board that the surrender is accepted. Respondent may not reapply for any license from the board for three years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board.

OPTIONAL CONDITIONS OF PROBATION

1.Actual Suspension

As part of probation, respondent is suspended from the duties of a pharmacy technician for ______ beginning the effective date of this decision.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices or controlled substances are maintained. Respondent shall not do any act involving drug selection, selection of stock, manufacturing, compounding or dispensing; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices or controlled substances.

Subject to the above restrictions, respondent may continue to own or hold an interest in any entity licensed by the board in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

During suspension, respondent shall not perform any of the duties of a pharmacy technician as provided by Section 1793.2 of the California Code of Regulations.

2.15. No Ownership of Licensed Premises

Respondent shall not own, have any legal or beneficial interest in, or serve as a manager, administrator, member, officer, director, <u>trustee</u>, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell or transfer any legal or beneficial interest in any entity licensed by the board within <u>ninety (90)</u> days following the effective date of this decision and shall immediately thereafter provide written proof thereof to the board. <u>Failure to timely divest any legal or beneficial interest(s) or provide documentation thereof shall be considered a violation of probation.</u>

Option: Respondent shall not acquire any new ownership, legal or beneficial interest nor serve as a manager, administrator, member, officer, director, <u>trustee</u>, associate, or partner of any additional business, firm, partnership, or corporation licensed by the board. If respondent <u>currently</u> owns or has any legal or beneficial interest in, or serve as a manager, administrator, member, officer, director, <u>trustee</u>, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board, respondent may continue to serve in such capacity <u>or hold that interest</u>, but only to the extent of that position or interest as of the <u>effective date of this decision</u>. <u>Violation of this restriction shall be considered a violation of probation</u>.

3.16. Attend Substance Abuse Recovery Relapse Prevention and Support Groups (Appropriate for those cases with chemical dependency (alcohol, drugs))

Within thirty (30) days of the effective date of this decision, respondent shall begin regular attendance at a board-approved recognized and established substance abuse recovery support group in California, (e.g., Alcoholics Anonymous, Cocaine-Narcotics Anonymous, etc.,) which has been approved by the board or its designee. Respondent must attend at least one group

meeting per week <u>unless otherwise directed by the board or its designee</u>. Respondent shall continue regular attendance and submit signed and dated documentation confirming attendance with each quarterly report for the duration of probation. <u>Failure to attend or submit documentation thereof shall be considered a violation of probation.</u>

4.17. Random Drug Screening (Appropriate for those cases with chemical dependency (alcohol, drugs))

Respondent, at his or her own expense, shall participate in random testing, including but not limited to biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or a-other drug screening program approved as directed by the board or its designee. The length of time shall be for the Respondent may be required to participate in testing for the entire probation period and the frequency of testing will be determined by the board or its designee. At all times respondent shall fully cooperate with the board or its designee, and shall, when directed, submit to such tests and samples for the detection of alcohol, narcotics, hypnotics, dangerous drugs or other controlled substances as the board or its designee may direct. Failure to timely submit to testing as directed shall constitute be considered a violation of probation. Upon request of the board or its designee, respondent shall provide documentation from a licensed practitioner that the prescription for a detected drug was legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely provide such documentation shall be considered a violation of probation. Any confirmed positive drug-test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a documented medical treatment shall be considered a violation of probation and shall result in the immediate automatic suspension of practice work by respondent. Respondent may not resume the practice of pharmacy work as a designated representative until notified by the board in writing.

During suspension, respondent shall not enter any pharmacy area or any portion of the licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of drugs licensed by the board, or any drug manufacturer, or any other location where dangerous drugs and devices or controlled substances are maintained. Respondent shall not perform any of the duties of a designated representative, nor do any act involving drug selection, selection of stock, manufacturing, dispensing; nor shall respondent manage, administer, or be a consultant to any licensee of the board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs and devices and controlled substances. Respondent shall not resume work until notified by the board.

Respondent shall not direct, control or perform any aspect involving the distribution of dangerous drugs and devices and controlled substances. Subject to the above restrictions, respondent may continue to own or hold an interest in any licensed entity in which he or she holds an interest at the time this decision becomes effective unless otherwise specified in this order.

Failure to comply with this suspension shall be considered a violation of probation.

5.18. Work Site Monitor (Appropriate for those cases with chemical dependency (alcohol, drugs))

Within ten (10) days of the effective date of this decision, respondent shall identify a work site monitor, for prior approval by the board, who shall be responsible for supervising respondent during working hours. Respondent shall be responsible for ensuring that The work site monitor shall report reports in writing to the board quarterly. Should the designated work site monitor determine at any time during the probationary period that respondent has not maintained sobriety, he or she shall notify the board immediately, either orally or in writing as directed.

Should respondent change employment, a new work site monitor must be designated, for prior approval by the board, within <u>ten (10)</u> days of commencing new employment. <u>Failure to identify an acceptable initial or replacement work site monitor, or to ensure quarterly reports are submitted to the board, shall be considered a violation of probation.</u>

6.19. Notification of Departure (Appropriate for those cases with chemical dependency (alcohol, drugs))

If respondent leaves Prior to leaving the probationary geographic area designated by the board or its designee for a period greater than twenty-four (24) hours, respondent shall notify the board verbally and in writing of the dates of departure and return, prior to leaving. Failure to comply with this provision shall be considered a violation of probation.

7.20. Abstain from Drugs and Alcohol Use (Appropriate for those cases with chemical dependency (alcohol, drugs))

Respondent shall completely abstain from the possession or use of alcohol, controlled substances, dangerous drugs and their associated paraphernalia except when the drugs are lawfully prescribed by a licensed practitioner as part of a documented medical treatment. Upon request of the board or its designee, respondent shall provide documentation from the licensed practitioner that the prescription for the drug was legitimately issued and is a necessary part of the treatment of the respondent. Respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Additionally, respondent shall cause the prescribing practitioner to notify the board in writing, indicating their awareness of the chemical dependency. Additionally, respondent shall cause the prescribing physician to notify the board in writing, indicating their awareness of the chemical dependency. Failure to timely provide such documentation shall be considered a violation of probation. Respondent shall ensure that he or she is not in the same physical location as individuals who are using illicit substances even if respondent is not personally ingesting the drugs. Any possession or use of alcohol, controlled substances, or their associated paraphernalia not supported by the documentation timely provided, and/or any physical proximity to persons using illicit substances, shall be considered a violation of probation.

8.21. Tolling of Suspension

During the period of suspension, respondent shall not leave California for any period exceeding ten (10) days, regardless of purpose (including vacation). Any such absence in excess of ten (10) days during suspension shall be considered a violation of probation. Moreover, any absence from California during the period of suspension exceeding ten (10) days shall toll the suspension, i.e., the suspension shall be extended by one day for each day over ten (10) days respondent is absent from California. During any such period of tolling of suspension, respondent must nonetheless comply with all terms and conditions of probation.

Respondent must notify the board in writing within ten (10) days of departure, and must further notify the board in writing within ten (10) days of return. The failure to provide such notification(s) shall constitute a violation of probation. Upon such departure and return, respondent shall not resume work until notified by the board that the period of suspension has been satisfactorily completed.

If respondent leaves California to reside or practice outside this state, or for any period exceeding 10 days (including vacation), respondent must notify the board in writing of the dates of departure and return. Periods of residency or practice outside the state or any absence exceeding a period of 10 days shall not apply to the reduction of the suspension period.

Respondent shall not act as a pharmacy technician upon returning to this state until notified by the board that the period of suspension has been completed.

22. Restitution (Appropriate in cases of drug diversion, theft, fraudulent billing, or patient harm resulting from negligence or incompetence.)

Within _____ days of the effective date of this decision, respondent shall pay restitution to _____ in the amount of \$ _____ . Failure to make restitution by this deadline shall be considered a violation of probation.

TERMS OF PROBATION – PREMISES

A minimum three-year probation period has been established by the board as appropriate in most cases where probation is imposed. A minimum five-year probation period has been established by the board as appropriate where self-administration or diversion of controlled substances is involved has occurred at a licensed premises. Terms and conditions are imposed to provide consumer protection and to allow the probationer to demonstrate rehabilitation. A suspension period may also be required as part of the probation order. The board prefers that any stayed order be for revocation rather than for some period of suspension.

Probation conditions are divided into two categories: (1) standard conditions that shall appear in all-all probation cases, and (2) optional conditions that depend on the nature and circumstances of a particular case. These conditions may vary depending on the nature of the offense(s).

The board may also impose any other condition appropriate to the case where the condition is not contrary to public policy.

CATEGORIES OF VIOLATIONS AND RECOMMENDED PENALTIES

The California Pharmacy Law specifies the identifies offenses for which the board may take disciplinary action against a license. The following are categories of violations used by the board in determining appropriate disciplinary penalties. Included among grounds for discipline are violations of the Pharmacy Law itself, violations of regulations promulgated by the board, and violations of other state or federal statutes or regulations.

The following are categories of possible violations used by the board to determine appropriate disciplinary penalties. These categories represent the judgment of the board as to the perceived seriousness of particular offenses.

Under each category, the board has grouped statutes and regulations where violations would typically merit the recommended range of minimum to maximum penalties for that category. These lists are representative, and are not intended to be comprehensive or exclusive. Where a violation not included in these lists is a basis for disciplinary action, the appropriate penalty for that violation may be best derived by comparison to any analogous violation(s) that are included. Where no such analogous violation is listed, the category descriptions may be consulted.

These categories assume a single violation of each listed statute or regulation. For multiple violations, the appropriate penalty shall increase accordingly. Moreover, if an individual has committed violations in more than one category, the minimum and maximum penalties shall be those recommended in the highest category.

The board also has the authority, pursuant to Business and Professions Code section 4301(n), to impose discipline based on disciplinary action taken by another jurisdiction. The discipline imposed by the board will depend on the discipline imposed by the other jurisdiction, the extent of the respondent's compliance with the terms of that discipline, the nature of the conduct for which the discipline was imposed, and other factors set forth in these guidelines.

CATEGORY I

Minimum: Revocation; Revocation stayed; one-year probation. All standard terms and

conditions shall be included and optional terms and conditions as appropriate.

Maximum: Revocation

Category I discipline is recommended for:

violations which are relatively minor but are potentially harmful

repeated violations of a relatively minor nature:

Violations of the following codes are as follows representative of this category:

BUSINESS AND PROFESSIONS CODE

Article 3. Scope of Practice and Exemptions

4053	Exemptee Supervision of Manufacturers, etc.: Requirements Wholesalers, and Licensed Laboratories; Veterinary Food-Animal Drug Retailers
4054	Supplying Dialysis Drugs Supply by Manufacturer, etc. of Certain Dialysis Drugs and
	Devices
4056	Exempt Hospitals Purchase of Drugs at Wholesale – Hospital Containing 100 Beds
	<u>or Less</u>
4057	Exempt Articles Exceptions to Application of this Chapter
4058	License to be Displayed Display of Original License
4062	Furnishing Drugs during EmergencyFurnishing Dangerous Drugs During
	Emergency
4064	Emergency Refills of Prescription Without Prescriber Authorization
4065	Administration through Injection Card System Injection Card System; Requirements
	for Administration
4066	Furnishing to Ocean Dangerous Drugs to Master or First Officer of Vessel

Article 4. Requirements for Prescription

4070	Reduction of Oral or Electronic Prescription to Writing
4071	Prescriber's May Authorize Agent to Transmitting Prescriptions; Schedule II
	Excluded
4072	Oral or Electronic Transmitting Transmission of Prescriptions from a - Health Care
	Facility
4073	Substitution of Generic Drug Product Selection- Requirements and Exceptions
4074	Drug Warnings Risk: Informing Patient; Providing Consultation for Discharge
	<u>Medications</u>
4076	Prescription Container - Label Requirements for Labeling
4077	Labeling Dispensing Dangerous Drug in Incorrectly Labeled Container

Article 5. Authority of Inspectors

4082 Information about Personnel Names of Owners, Managers and Employees Open for Inspection

Article 6. General Requirements

4100	Change of Name or Address or Name – Notification to Board
4102	Skin Puncture for Patient Training
4103	Blood Pressure Measurement- Taking by Pharmacist

Article 7. Pharmacies

4114	Intern Pharmacist: Activities Permitted
4120Eme	ergency Kit for Licensed Health Care Facilities
4119.5	Transferring or Repackaging Dangerous Drugs by Pharmacy
4120	Nonresident Pharmacy: Registration Required
4121	Advertisement for Prescription Price Advertising Drug: Requirements; Restrictions
4122	Requests for Required Notice at Availability of Prescription Price Information,
	General Product Availability, Pharmacy Services; Providing Drug Price Information;
	Limitations on Price Information Requests
4123	Pharmacy contracts for Compounding of Parenteral Drugs Compounding Drug for
	Other Pharmacy for Parenteral Therapy; Notice to Board
4124	Contact Lens Dispensing Replacement Contact Lenses: Requirements; Patient
	Warnings; Registration with Medical Board; Application of Section to Nonresident
	<u>Pharmacies</u>

Article 9. Hypodermic Needles and Syringes

4141	Furnishing Without License Required
4142	Prescription Required
4143	Exemption: Wholesale Sales to Other Entity, Physician, etc.
4144	Exemption: Industrial Uses Exception
4145	Exemption: Human (Insulin; Adrenaline) or Animal UseException: Furnishing for
	Administration of Insulin, Adrenaline, or Specified Animal Uses; Conditions
4146	Hypodermic Register
4148	Confiscation if Found Outside Licensed Premises
4149	Nonresident Sale by Distributor

Article 10. Pharmacy Corporations

4151	<u>Licensure</u> Requirements for Shareholders, Directors, and Officers
4152	Corporate Name Requirements
4153	Shareholder Income wWhile Disqualified
4156	Unprofessional Conduct by Corporation

Article 11. Wholesalers and Manufacturers

4161	Out-of-State Manufacturer or Nonresident Wholesaler: When License Required;
	<u>Application</u>
4162	Registration Agent ssuance or Renewal of Wholesaler License; Surety Bond
4164	Sales to Unauthorized Persons Reports Required
4165	Sale or Transfer of Dangerous Drug or Device Into State: Furnishing Records to
	Authorized Officer on Demand; Citation for Non-compliance
4166	Responsibility until DeliveryShipping of Dangerous Drugs or Devices – Wholesaler

	or Distributor
4167	Wholesaler: Bar on Obtaining Dangerous Drugs or Devices It More Than Cannot
	Maintain Be Stored on Licensed Premises

Article 13. Non-Profit or Free Clinics

4182Lice	ense Required (Non-Profit, etc Clinics)
4183Lice	ense Requirements
4180	Purchase of Drugs at Wholesale Only with License: Eligible Clinics
4181	License Requirements; Policies and Procedures; Who May Dispense
4182	Application Duties of Professional Director; Consulting Pharmacist Required
4183	No Medi-CalProfessional Dispensing Fee
4184	No Schedule II-Dispensing Schedule II Substance Prohibited
4186	Professional Director Automated Drug Delivery Systems

Article 14. Surgical Clinics

4190	Purchase of Drugs at Wholesale: Permitted Uses of Drugs; Required Records and
	Policies; License Required (Surgical Clinic)
4191	License Compliance with Department of Health Services Requirements; Who May
	Dispense Drugs
4192	Duties of Professional Director; Providing Information to Board
4193	No Medi-CalClinic Not Eligible for Professional Dispensing Fee; Ban on Offering
	Drugs for Sale
4194	No Schedule II Dispensing of Schedule II Substance by Clinic Prohibited; Physician
	May Dispense; Administration Authorized in Clinic

Article 15. Veterinary Food-Animal Drug Retailers

4196	License Required;: Temporary License on Transfer of Ownership; Persons
	Authorized in Storage Area; Security
4197	Minimum Standards;: Security; Sanitation; Board Regulations; Waivers
4198	Written Policies and Procedures Required;: Contents; Training of Personnel; Quality
	Assurance; Consulting Pharmacist

Article 17. Continuing Education

4233Renewal Requirements	
4234Course Content	
4231	Requirements for Renewal of Pharmacist License: Clock Hours; Exemption for New
	Licensee
4232	Content of Courses

Article 18. Poisons

4240 Application of Act

Article 20. Prohibitions and Offenses

4341	Advertising in Compliance with Sections 651.3 Advertisement of Prescription Drugs
	or Devices
4343	Use of Sign with "Pharmacy" or Similar TermsBuildings: Prohibition Against Use of
	Certain Signs Unless Licensed Pharmacy Within

CALIFORNIA CODE OF REGULATIONS, TITLE 16

	1704	Change of aAddress - reporting a change of address
	1705	Notification of Bankruptcy, Receivership or Liquidation - reporting the sale, inventory
		and location of records of dangerous drugs by a pharmacy, wholesaler or
		manufacturer in bankruptcy
	1708.2	Discontinuance of bBusiness - notification to board of a discontinuance of business
		and submission of appropriate forms
	1708.4	Pharmacist hHandling rRadioactive dDrugs - training of a nuclear pharmacist
	1708.5	Pharmacy Furnishing Radioactive Drugs - nuclear pharmacy requirements
	1709	Names of Owners and pPharmacist-in-eCharge - required information on a
		pharmacy permit, reporting PIC and owners on initial and renewal applications, and
		reporting of corporate officer changes
	1714	Building Operational Standards and Security
	1715.6	Reporting dDrug Loss - reporting loss of controlled substances to the Board within
		thirty (30) day
	1716	Variation from <u>PP</u> rescriptions <u>- prescription errors, deviation from prescription</u>
		without consent of prescriber
	1717	Pharmaceutical Pharmaceutical pPractice - dispensing in new containers,
		pharmacist maintain on prescription record: date and initial of pharmacist, brand
		name of drug or device and indication if generic and manufacturer name, refill
		information, orally transmitted prescription requirements, depot of a prescription or a
		medication, prescription transfers, identification of pharmacist responsible for filling a
		prescription
	1717.1	Common Electronic Files - establishing a common electronic file to maintain
		required dispensing information
	1717.4	Electronic Transmission of Prescriptions - transmitting prescriptions by electronic
		means from prescriber to the pharmacy
	1718.1	Manufacturer's Expiration Date - handling of prescription drugs not bearing a
		manufacturer's expiration date pursuant to federal law
	1726	Preceptor Supervision of Intern Pharmacists
	1727	Intern Pharmacist
	1728	Intern Experience - Requirements for Licensure Examination
	1732.1	Requirements for Recognized Accredited Providers - requirements to provide
	4=00.0	continuing education courses as a recognized provider for California pharmacists
	1732.3	Coursework Approval for Providers Requirements for Continuing Education Courses
ı	1732.4	Provider Audit Requirements

1732.5	Renewal Requirements for Pharmacist
1744	Drug wWarnings - oral or written warnings when a drug should not be taken with
	alcohol or when a person should not drive
1751 to	
1751.09 a	nd
1751.11 to)
1751.12	Compounding Area for Parenteral Solutions - parenteral therapy requirements for
	pharmacists and pharmacies
1751	Sterile Injectable Compounding Area
1751.01	Facility and Equipment Standards for Sterile Injectable Compounding from Non-
	Sterile Ingredients
1751.02	Policies and Procedures
<u>1751.11</u>	Furnishing to Home Health Agencies and Licensed Hospices
<u>1751.12</u>	Obligations of a Pharmacy Furnishing Portable Containers
1771	Posting of nNotice of sSuspension - suspended pharmacy must post a notice of
	suspension
1772	Disciplinary eConditions of sSuspension - suspended pharmacist shall not enter a
	pharmacy prescription area or perform pharmacy related duties
1780	Minimum <u>sS</u> tandards for <u>wW</u> holesalers
1780.1	Minimum Standards for Veterinary Food-Animal Drug Retailers
1781	Exemption eCertificate - exemptee must be present in a manufacturer's or
	wholesaler's licensed premises
1786	Exemptions -return of exemption certificate to board upon termination of employment
1787	Authorization to Distribute Hemodialysis Drugs and Devices
1790	Assembling and Packaging
1791	Labeling
1792	Receipt of for Shipment

HEALTH AND SAFETY CODE, TITLE 22

11100	Report of <u>Certain Chemical: Chemicals Included; Exclusions; Penalties controlled</u> substance transaction - reporting sales of restricted chemicals to Department of
	Justice
11100.1	Report of Chemicals controlled substances rReceived from eOutside sState;
	Penalties - reporting Purchases of restricted chemicals from outside California
11124	Inventory of Controlled Substances
11151	<u>Limitation on Filling Prescriptions From Medical Students Issued By Unlicensed</u>
	Person Lawfully Practicing Medicine
11158	Prescription FRequired for Schedule I, II, III, or IV, or V eControlled SSubstances
	prescriptions for controlled substances must comply with requirements prior to
	dispensing; Exception for Limited Dispensing, Administration
11159	Chart Order Exemption for pPatient in cCounty or Licensed hHospital; Maintaining
	Record for Seven Years - controlled substance orders in hospitals
11159.1	Chart Order Exemption for Clinic Records Patient; Maintaining Record for Seven
	<u>Years</u>
11159.2	Exception to Triplicate Prescription Requirement Terminally III Exception
11167	Emergency <u>dDispensing</u> of Schedule II <u>sSubstance</u> : <u>Circumstances and</u>
	Requirements - emergency oral Schedule II prescriptions; must receive a triplicate
	within seventy-two (72) hours
11167.5	Emergency oOral or Electronic pPrescriptions for Schedule II Controlled Substance

I	for Specified iln-patients, Residents, and Home Hospice Patients; Requirements-
	oral orders for Schedule II drugs in a skilled nursing facility, intermediate care facility,
	or a home health care agency providing hospice care; pharmacy to obtain special
	triplicates from Dept. of Justice; facility must forward all signed order to the
	pharmacy
11171	Prescribing, etc. Controlled Substance Only as Authorizedadministering, or
,	furnishing controlled substance – furnishing controlled substances must be
	consistent with law
11172	Antedating or pPostdating pPrescription Prohibited
11175	Prohibition on Obtaining and or pPossession ng nNonconforming pPrescription;
	Prohibition on eObtaining eControlled sSubstance by aNonconforming pPrescription
11180	Prohibition on Controlled sSubstance eObtained or pPossessed by aNonconforming
	pPrescription - possession of a controlled substance obtained from noncomplying
	prescriptions
11200	Restrictions on dDispensing or rRefilling; Refill of Schedule II Prescription Barred-
	refill restrictions of controlled substances
11201	Emergency Refill by Pharmacistof Schedule III, IV, or V Prescription; Circumstances;
	Requirements
11205	Maintenance and rRetention of Records in Separate fFile separate prescription file
	for Schedule II prescriptions
11206	Required information on Prescription - information required on a prescription for
	controlled substances
11209	Delivery of Controlled and Receiving Requirements for Schedule II, III, and IV
	Substances; Violation
11210	<u>Issuing Prescription: By Whom; For What Purpose; Quantity to Be Prescribed under</u>
	authorized project - a prescriber may not prescribe controlled substances to treat
44050	addiction
11250	Authorized Retail Sale by Pharmacists to Physicians, etc.; Required Order Form
11251	Authorized Wholesale Sale by Pharmacists
11252	Preservation of f <u>F</u> ederally <u>fR</u> equired f <u>F</u> orms - a wholesaler or manufacturer must maintain records of sales
11253	Duration of rRetention
11255	Actions constituting sSale - orders for future delivery constitutes a sale of a
11255	controlled substance
11256	Required Report of Order bBy or Sale to Out-of-State Wholesaler or Manufacturer
11230 111225 to	Troquirod Tropoit of Order BDy of Odic to Odi-of-Otate Wholesalet of Mandacture
111655	Adulterated or Misbranded Drugs or Devices

CODE OF FEDERAL REGULATIONS, TITLE 21

1301.13	Persons Required to Register Application for registration; time for application;
	expiration date; registration for independent activities; application forms, fees,
	contents and signature; coincident activities.
1301.14	Separate Registration for Separate Locations Filing of application; acceptance for
	filing; defective applications.
1301.71	Security requirements, generally.
1301.72	Physical security controls for non-practitioners; narcotic treatment programs and
	compounders for narcotic treatment programs; storage areas.
1301.73	Physical security controls for non-practitioners; compounders for narcotic treatment
	programs; manufacturing and compounding areas.

compounders for narcotic treatment programs. Physical-sSecurity controls for practitioners/feight forwarding facilities. 1301.78Other-Seoutity Controls for Practitioners 1301.90	1301.74	Other security controls for non-practitioners; narcotic treatment programs and
 1301.78Other Security Centrols for Practitioners 1301.90 Employee screening procedures; 1301.91 Employee responsibility to report drug diversion. 1302.03 Symbol required; exceptions. 1302.04 Location and size of symbol on label and labeling. 1302.05 Effective Ddates of Ljabeling R; requirements. 1302.06 Sealing of controlled substances. 1302.07 Labeling and packaging requirements for imported and exported substances. 1304.18 Inventories of Importers and exporters 1304.19 Inventory requirements. 1304.31 Reports from manufacturers importing epiumnarcotic raw material. 1304.32 Reports of manufacturers importing medicinal-coca leaves. 1305.03 Reports of ARCOS. 1306.03 Reports of ARCOS. 1306.04 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for endorsing order forms; unaccepted and defective order forms; recodure for importance in procedure for endorsing order forms; unaccepted and defective order forms; procedure for endorsing order forms; unaccepted and defective order forms; procedure for substances. 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to right orders forms 222. 1305.11 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Procedure for executing DEA Forms 222. 1305.17 Procedure for executing DEA Forms 222. 1305.18 Procedure for executing DEA Forms 222. 1305.19 Procedure for executing DEA Forms 222. 1305.11 Procedure for substances and filling of prescriptions, Schedule III and IV and V Prescriptions. 1306.		compounders for narcotic treatment programs.
Employee screening procedures,	1301.77	Physical s Security controls for practitioners freight forwarding facilities.
Employee responsibility to report drug diversion.	1301.78Ot	her Security Controls for Practitioners
Employee responsibility to report drug diversion.	1301.90	Employee screening procedures.
 1301.92 Illicit activities by employees. 1302.03 Symbol required; exceptions. 1302.05 Effective Ddates of Ljabeling Rrequirements. 1302.06 Sealing of controlled substances. 1302.07 Labeling and packaging requirements for imported and exported substances. 1304.18 Inventories of importers and exporters. 1304.31 Reports from manufacturers importing epiumnarcotic raw material. 1304.32 Reports from manufacturers importing medicinal-coca leaves. 1304.33 Reports to ARCOS. 1305.06 and 1305.04 beta 1305.14 to 1305.14 Distributions requiring order forms; persons entitled to obtain and execute order forms; precedure for obtaining order forms; procedure for forms; precedure for endorsing order forms; procedure for forms; precedure for endorsing order forms; procedure for forms; procedure for endorsing order forms; procedure for forms; precedure for endorsing order forms; procedure for forms; precedure for endorsing order forms; procedure for forms; precedure for endorsing order forms; procedure for forms; procedure for endorsing order forms. 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.15 Power of attorney. 1305.16 Procedure for obtaining DEA Forms 222. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for substances and filling of prescriptions. 1306.15 Lost and stolen DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1305.17 Unaccepted and defective DEA Forms 222. 1305.18 Labeling of substances and filling of prescriptions. 1306.24 Labeling of substances and	1301.91	
1302.03 Symbol required; exceptions, 1302.05 Effective Đṛḍates of Liabeling Rṛequirements; 1302.06 Sealing of controlled substances, 1302.07 Labeling and packaging requirements for imported and exported substances, 1304.18 Inventories of importers and exporters 1304.11 Inventorir requirements. 1304.31 Reports from manufacturers importing opium_narcotic raw material. 1304.32 Reports of manufacturers importing medicinal-coca leaves, 1304.33 Reports to ARCOS. 1305.06 and 1305.08 to 1305.14 to 1305.14 to 1305.15 Distributions requiring order forms; persons entitled to obtain and execute order forms; persons entitled to fill order forms; procedure for executing order forms; persons entitled to obtain and execute order forms; persons entitled to fill order forms; procedure for forms; procedure for endorsing order forms; procedure for filling order forms; procedure for endorsing order forms; procedure for filling order forms; procedure for endorsing order forms; procedure for forms; persons entitled to order forms; persons entitled to order forms; procedure for executing order forms; persons entitled to fill orders for Schedule I and II controlled substances. 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.14 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1305.17 Procedure for executing DEA Forms 222. 1306.19 Persons entitled to issue prescriptions. 1306.04 Substances and filling of prescriptions. — Schedule III. And IV and V controlled substances and filling of prescriptions. — Schedule III. IV, and V controlled substances and elling of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV,	1301.92	
1302.04 Location and size of symbol on label and labeling. Effective Didates of Liabeling Requirements. Sealing of controlled substances. Labeling and packaging requirements for imported and exported substances. 1304.11 Inventory requirements. 1304.13 Reports from manufacturers importing epi-umnarcotic raw material. 1304.32 Reports from manufacturers importing epi-umnarcotic raw material. 1304.33 Reports to ARCOS. 1305.03 Reports to ARCOS. 1305.04 Possible to state the state of the sta		· · · · -
1302.05 Effective Dates of Liabeling Rrequirements. Sealing of controlled substances. Labeling and packaging requirements for imported and exported substances. 1304.18 Inventories of importers and exporters 1304.11 Reports from manufacturers importing epiumnarcotic raw material. 1304.32 Reports of manufacturers importing medicinal-coca leaves. Reports of manufacturers importing medicinal-coca leaves. 1304.33 Reports to ARCOS. 1305.06 and 1305.08 to 1305.08 to 1305.14 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for endorsing order forms; procedure for endorsing order forms; procedure for filling order forms; persons entitled to obtain and execute order endorsing order forms; unaccepted and defective order forms; post order forms; persons entitled to order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.04 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for executing DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1305.17 Derecture for endorsing DEA Forms 222. 1306.18 Derecture for endorsing DEA Forms 222. 1306.19 Derecture for substances and filling of prescriptions.—Schedule II. 1306.20 Labeling of substances and filling of prescriptions.—Schedule III. 1306.21 Labeling of substances and filling of prescriptions.—Schedule III. 1306.22 Transfer of Schedule III, IV, and V Prescriptions. 1306.25 Dispensing Wwithout a Pprescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.11 Distribution to supplier or manufacturer of controlled substances. 1307.21 Procedure for disposaling of controlled substances.		
1302.06 Sealing of controlled substances. Labeling and packaging requirements for imported and exported substances. 1304.11 Inventory requirements. 1304.31 Reports from manufacturers importing opiumnarcotic raw material. 1304.32 Reports of manufacturers importing medicinal-coca leaves. 1304.33 Reports to ARCOS. 1305.03 to 1305.04 to 1305.04 to 1305.14 to 1305.16 Distributions requiring order forms; procedure for executing a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for executing DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.05 Manner of issuance of prescriptions. 1306.06 Manner of issuance of prescriptions. 1306.07 Schedule III, IV, and V Prescriptions. 1306.08 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances and filling of prescriptions. 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. Dispensing Wwithout a Pprescription of narcetic solutions and compounds by a pharmacietto supplier or manufacturer of	1302.05	· · · · · · · · · · · · · · · · · · ·
1302.07 Labeling and packaging requirements for imported and exported substances. 1304.18 Inventory requirements. 1304.31 Reports from manufacturers importing epiumnarcotic raw material. 1304.32 Reports of manufacturers importing medicinal-coca leaves. 1304.33 Reports to ARCOS. 1305.03 to 1305.03 to 1305.04 Distributions requiring order forms; persons entitled to obtain and execute order forms; persons entitled to fill order forms; procedure for executing order forms; persons entitled to fill order forms and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attomey. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for endorsing DEA Forms 222. 1305.12 Procedure for endorsing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.05 Manner of issuance of prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.05 Manner of issuance and filling of prescriptions.—Schedule III. 1306.26 Transfer of Schedule III, IV, and V Prescriptions 1306.27 Transfer between pharmacies of prescriptions.—Schedule III and IV and V Description on the prescription of prescriptions. 1306.26 Dispensing Wwithout a Pprescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.13 Distribution to eupplierIncidental manufacture of controlled substances. 1700.1 to		
1304.11 Inventory requirements. 1304.31 Reports from manufacturers importing epiumnarcotic raw material. 1304.32 Reports to MRCOS. 1304.33 Reports to ARCOS. 1305.03 te 1305.03 te 1305.04 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; procedure for material and effective order forms; procedure for obtaining order forms; procedure for endorsing order forms; procedure for obtaining order forms; procedure for endorsing order forms; procedure for material and effective order forms; procedure for endorsing order forms; procedure for material and effective order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; esturn of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for executing DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.13 Procedure for endorsing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1305.17 Labeling of substances and filling of prescriptions.—Schedule III. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III. 1306.25 Transfer of Schedule III, IV, and V Prescriptions 1306.26 Transfer of Schedule III, IV, and V Prescriptions 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.13 Distribution to supplier or manufacturer. 1307.14 Distribution to supplier in manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.		<u>-</u>
1304.11 Inventory requirements. 1304.31 Reports from manufacturers importing opiumnarcotic raw material. 1304.32 Reports of manufacturers importing medicinal-coca leaves. 1304.33 Reports to ARCOS. 1305.03 Reports to ARCOS. 1305.06 and 1305.06 and 1305.08 to 1305.14 to 1305.14 to 1305.15 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for filling order forms; persons entitled to fill order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for executing DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.05 Transfer of Schedule III, IV, and V Prescriptions. 1306.26 Dispensing Wwithout a Pprescription 1306.26 Dispensing Wwithout a Pprescription of reverse distributor. 1307.11 Distribution by dispenser to another practitioner or reverse distributor. 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacietto supplier or manufacturer. 1307.13 Distribution to supplierIncidental manufacture of controlled substances. 1700.1 to		
1304.31 Reports from manufacturers importing epiumnarcotic raw material. 1304.32 Reports of manufacturers importing medicinal-coca leaves. 1304.33 Reports to ARCOS. 1305.03 te 1305.06 and 1305.08 te 1305.14 to 1305.14 to 1305.14 to 1305.14 to 1305.16 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for endorsing order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.12 Procedure for obtaining DEA Forms 222. 1305.14 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions.—Schedule III. 1306.25 Transfer of Schedule III, IV, and V Prescriptions 1306.26 Dispensing Wwithout a Pprescription information for Schedules III, IV, and V controlled substances for refill purposes. 1307.21 Distribution by dispenser to another practitioner or reverse distributor.—Manufacture and dDistribution of narcotic solutions and compounds by a pharmacist o supplier or manufacturer. 1307.13 Distribution to supplierIncidental manufacture of controlled substances. 1700.1 to		·
1304.32 Reports of manufacturers importing medicinal-coca leaves. 1304.33 Reports to ARCOS. 1305.03 to 1305.03 to 1305.08 to 1305.08 to 1305.08 to 1305.14 to 1305.14 to 1305.14 to 1305.14 to 1305.15 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for endorsing order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.17 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.26 Transfer of Schedule III, IV, and V Prescription 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacietto supplier or manufacturer. 1307.21 Distribution to supplier Incidental manufacture of controlled substances. 1700.1 to		
1304.33 Reports to ARCOS. 1305.03 to 1305.04 eand 1305.08 to 1305.14 to 1305.16 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for forms; procedure for endorsing order forms; unaccepted and defective order forms; persons entitled to fill order forms; procedure for forms; persons entitled to mused order forms; 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for executing DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.17 Persons entitled to issue prescriptions. 1306.03 Persons entitled to issue prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.25 Manner of issuance of prescriptions. 1306.16 Lost and stolen DEA Forms 222. 1306.17 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.26 Transfer of Schedule III, IV, and V Prescriptions 1306.26 Dispensing Wwithout a Pprescription information for Schedules III, IV, and V controlled substances for refill purposes. 1307.21 Distribution by dispenser to another practitioner or reverse distributor.— 1307.13 Distribution to supplier or manufacturer. 1307.14 Distribution to supplier or manufacturer of controlled substances. 1307.21 Procedure for disposaling of controlled substances.		
 4305.03 te 4305.08 and 4305.12 and 4305.14 te 4305.16 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for filling order forms; persons entitled to fill order forms; procedure for filling order forms; persons entitled to fill order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.05 Manner of issuance of prescriptions. 1306.04 Labeling of substances and filling of prescriptions. — Schedule II. 1306.24 Labeling of substances and filling of prescriptions. — Schedule III and IV 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1307.11 Distribution by dispenser to another practitioner or reverse distributor. — Manufacture and dDistribution of narcotic solutions and compounds by a pharmacietto supplier or manufacturer. 1307.13 Distribution to supplier or manufacture. 1307.11 Distribution for disposaling of controlled substances. 1700.1 to 		· · · · · · · · · · · · · · · · · · ·
4305.06 and 4305.08 to 4305.12 and 4305.14 to 1305.16 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.25 Transfer of Schedule III, IV, and V Prescription 1306.26 Dispensing Wwithout a Persoription 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcetic solutions and compounds by a pharmaciesto supplier or manufacturer. 1307.11 Distribution to supplierIncidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 1307.21 Procedure for disposaling of controlled substances.		· · · · · · · · · · · · · · · · · · ·
 4305.08 te 4305.14 to 1305.16 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions. — Schedule II. 1306.25 Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1307.12 Distribution by dispenser to another practitioner or reverse distributor. — Manufacture and dDistribution of narcotic solutions and compounds by a pharmacietto supplier or manufacturer. 1307.21 Distribution to supplierIncidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 		
1305.12 and 1305.14 to 1306.16 Distributions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.13 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.05 Manner of issuances and filling of prescriptions.—Schedule II. 1306.26 Transfer of Schedule III, IV, and V Prescription 1306.27 Transfer between pharmacies of prescription information for Schedules III, IV, and V Controlled substances for refill purposes. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcotic solutions and compounds by a pharmacietto supplier or manufacturer. Distribution to supplierIncidental manufacture of controlled substances. Procedure for disposaling of controlled substances.		
1305.14 biestibutions requiring order forms; persons entitled to obtain and execute order forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions.—Schedule II. 1306.25 Transfer of Schedule III, IV, and V Prescriptions 1306.26 Dispensing Wwithout a Person fill purposes. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcotic solutions and compounds by a pharmaciesto supplier or manufacturer. Distribution to supplier or manufacture of controlled substances. Procedure for disposaling of controlled substances.		
forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.25 Transfer of Schedule III, IV, and V Prescription 1306.26 Dispensing Wwithout a Pgrescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcetic solutions and compounds by a pharmaciesto supplier or manufacturer. Distribution to supplier Incidental manufacture of controlled substances. Procedure for disposaling of controlled substances.	1305.14 to	
forms; procedure for obtaining order forms; procedure for executing order forms; persons entitled to fill order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for executing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.25 Transfer of Schedule III, IV, and V Prescription 1306.26 Dispensing Wwithout a Pgrescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcetic solutions and compounds by a pharmaciesto supplier or manufacturer. Distribution to supplier Incidental manufacture of controlled substances. Procedure for disposaling of controlled substances.	1305.16	Distributions requiring order forms; persons entitled to obtain and execute order
persons entitled to fill order forms; procedure for filling order forms; procedure for endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1307.12 Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. Distribution to supplier Incidental manufacture of controlled substances. Procedure for disposaling of controlled substances. Procedure for disposaling of controlled substances.		
endorsing order forms; unaccepted and defective order forms; lost and stolen order forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.25 Transfer of Schedule III, IV, and V Prescriptions 1306.26 Dispensing \(\frac{\pmathbf{W}_{\text{without}}}{\pmathbf{W}_{\text{inthout}}}\) Procedure for refill purposes. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcotic solutions and compounds by a pharmaciesto supplier or manufacturer. Distribution to supplier Incidental manufacture of controlled substances. Procedure for disposaling of controlled substances.		
forms; return of unused order forms 1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.25 Transfer of Schedule III, IV, and V Prescriptions 1306.26 Dispensing Wwithout a Pprescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcotic solutions and compounds by a pharmaciesto supplier or manufacturer. Distribution to supplier Incidental manufacture of controlled substances. Procedure for disposaling of controlled substances.		
1305.03 Distributions requiring a Form 222 or a digitally signed electronic order. 1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.04 Labeling of substances and filling of prescriptions. Schedule II. 1306.24 Labeling of substances and filling of prescriptions. Schedule III. 1306.25 Transfer of Schedule III, IV, and V Prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing Wwithout a Pprescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor. Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier incidental manufacture of controlled substances. 1307.15 Procedure for disposaling of controlled substances.		
1305.04 Persons entitled to order Schedule I and II controlled substances. 1305.05 Power of attorney. 1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1306.06 Persons entitled to issue prescriptions. 1306.07 Manner of issuance of prescriptions. 1306.08 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions. Schedule III. 1306.24 Labeling of substances and filling of prescriptions. Schedule III and IV 1306.26 Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing Wwithout a Pprescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor. Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1305.03	Distributions requiring a Form 222 or a digitally signed electronic order.
1305.06 Persons entitled to fill orders for Schedule I and II controlled substances. 1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.26Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacist of supplier or manufacturer. 1307.13 Distribution to supplier ncidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 1700.1 to	1305.04	
1305.11 Procedure for obtaining DEA Forms 222. 1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.26 Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplierIncidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 1700.1 to	1305.05	Power of attorney.
1305.12 Procedure for executing DEA Forms 222. 1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III. 1306.26 Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\psi_{\text{winthout in prescription}}\) 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcetic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1300.1 to	1305.06	Persons entitled to fill orders for Schedule I and II controlled substances.
1305.14 Procedure for endorsing DEA Forms 222. 1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III and IV 1306.26Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\frac{\psi}{\psi}\) without a \(\frac{\psi}{\psi}\) prescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and d\(\frac{\D}{\D}\) istribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. Procedure for disposaling of controlled substances. 1300.1 to	1305.11	Procedure for obtaining DEA Forms 222.
1305.15 Unaccepted and defective DEA Forms 222. 1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III. and IV. 1306.26 Transfer of Schedule III, IV, and V Prescriptions. 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\frac{\psi}{\psi}\) without a \(\frac{\psi}{\psi}\) prescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcetic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 1700.1 to	1305.12	Procedure for executing DEA Forms 222.
1305.16 Lost and stolen DEA Forms 222. 1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions. Schedule II. 1306.24 Labeling of substances and filling of prescriptions. Schedule III and IV 1306.26Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\frac{\psi}{\psi}\) without a \(\frac{\psi}{\psi}\) prescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor. Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1305.14	Procedure for endorsing DEA Forms 222.
1306.03 Persons entitled to issue prescriptions. 1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions. — Schedule II. 1306.24 Labeling of substances and filling of prescriptions. — Schedule III and IV 1306.26Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\psi_{\text{without}}\) ithout a \(\text{Pprescription}_{\text{2}}\) 1307.11 Distribution by dispenser to another practitioner or reverse distributor. — 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacistto supplier or manufacturer. 1307.13 Distribution to supplierIncidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1305.15	Unaccepted and defective DEA Forms 222.
1306.05 Manner of issuance of prescriptions. 1306.14 Labeling of substances and filling of prescriptions.—Schedule II. 1306.24 Labeling of substances and filling of prescriptions.—Schedule III. 1306.26 Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V 1306.26 Controlled substances for refill purposes. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplierIncidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1305.16	Lost and stolen DEA Forms 222.
 Labeling of substances and filling of prescriptions Schedule II. Labeling of substances and filling of prescriptions Schedule III and IV Labeling of substances and filling of prescriptions Schedule III and IV 1306.26 Transfer of Schedule III, IV, and V Prescriptions Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. Dispensing Wwithout a Pprescription. Distribution by dispenser to another practitioner or reverse distributor Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. Distribution to supplier Incidental manufacture of controlled substances. Procedure for disposaling of controlled substances. 	1306.03	Persons entitled to issue prescriptions.
1306.24 Labeling of substances and filing of prescriptions. Schedule III and IV 1306.26Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\frac{\psi}{\psi}\) without a \(\frac{\psi}{\psi}\) prescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 \(\frac{\psi}{\psi}\) Manufacture and d\(\frac{\psi}{\psi}\) istribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1306.05	Manner of issuance of prescriptions.
1306.24 Labeling of substances and filing of prescriptions. Schedule III and IV 1306.26Transfer of Schedule III, IV, and V Prescriptions 1306.25 Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\frac{\psi}{\psi}\) without a \(\frac{\psi}{\psi}\) prescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 \(\frac{\psi}{\psi}\) Manufacture and d\(\frac{\psi}{\psi}\) istribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1306.14	Labeling of substances and filling of prescriptions Schedule II.
Transfer between pharmacies of prescription information for Schedules III, IV, and V controlled substances for refill purposes. 1306.26 Dispensing \(\frac{\psi}{\psi}\) without a \(\frac{\psi}{\psi}\) prescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and d\(\D\) istribution of narcotic solutions and compounds by a pharmacist o supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1306.24	
controlled substances for refill purposes. Dispensing Wwithout a Pprescription. Distribution by dispenser to another practitioner or reverse distributor.— Manufacture and dDistribution of narcotic solutions and compounds by a pharmacistto supplier or manufacturer. Distribution to supplierIncidental manufacture of controlled substances. Procedure for disposaling of controlled substances.	1306.26Tr	ansfer of Schedule III, IV, and V Prescriptions
1306.26 Dispensing Wwithout a Pprescription. 1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacisto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances.	1306.25	Transfer between pharmacies of prescription information for Schedules III, IV, and V
1307.11 Distribution by dispenser to another practitioner or reverse distributor.— 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacistto supplier or manufacturer. 1307.13 Distribution to supplier or manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 1700.1 to		controlled substances for refill purposes.
 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacistto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 	1306.26	
 1307.12 Manufacture and dDistribution of narcotic solutions and compounds by a pharmacistto supplier or manufacturer. 1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 	1307.11	
1307.13 Distribution to supplier Incidental manufacture of controlled substances. 1307.21 Procedure for disposaling of controlled substances. 1700.1 to	1307.12	
1307.21 Procedure for disposaling of controlled substances. 1700.1 to		
<u>1700.1 to</u>	1307.13	Distribution to supplier Incidental manufacture of controlled substances.
	1307.21	Procedure for disposaling of controlled substances.
1707.15 Child-resistant containers.		
	<u>1707.15</u>	Child-resistant containers.

MISCELLANEOUS - HEALTH AND SAFETY CODE, TITLE 22

111225 to

111655 Adulterated or misbranded drugs or devices

MISCELLANEOUS-FEDERAL REGULATIONS

16 CFR 1700.1 to

1707.15 Child-resistant containers

CATEGORY II

Minimum: Revocation; Revocation stayed, three years probation (five years probation where

self-administration or diversion of controlled substances is involved occurred at the licensed premises). All standard terms and conditions shall be included and

optional terms and conditions as appropriate.

Maximum: Revocation

Category II discipline is recommended for:

violations with a serious potential for harm

• violations which involve greater disregard for pharmacy law and public safety

 violations which reflect on ethics, care exercised or competence or a criminal conviction not involving dangerous drugs or controlled substances or involving possession or use of dangerous drugs or controlled substances. Violations of the following codes are as follows representative of this category:

BUSINESS AND PROFESSIONS CODE

650	Rebates or Discounts for Referral Prohibited
650.1	Lease Prohibition – Hospitals or Prescribers
651	Professional Advertising Requirements

Article 3. Scope of Practice and Exemptions

4051(b)	Conduct Authorized by Pharmacist from Outside Pharmacy	
4052	conduct Authorized by PharmacistFurnishing to Prescriber; Permissible Procedures	
	by Pharmacist in Health Care Facility or Clinic or for Other Health Care Provider	
4060	Possession of Controlled Substance – Prescription Required; Exceptions	
4061	Distribution of Sample Drugs as Sample; Written Request Required	
4064	Emergency Refills of Prescription Without Prescriber Authorization	
4067	Internet; Prescription Dispensing over the Internet Dangerous Drugs or Devices	
	without Prescription	
4076Proof of Identity of Recipient for Controlled Substance Prescriptions		
4079False or Misleading Labeling		
4075	Proof of Identity Required – Oral or Electronic Prescription	
4078	False or Misleading Label on Prescription	

Article 6. General Requirements

4101	Termination as Pharmacist in Charge, Exemptee: Termination of Employment; ;	
	Notice Notification to Board	
4106Licensed Employee:Theft or Impairment		
4107Retaining Records on Premises		
4104	Licensed Employee, Theft or Impairment: Pharmacy Procedures	
4105	Retaining Records of Dangerous Drugs and Devices on Licensed Premises;	
	Temporary Removal; Waivers; Access to Electronically Maintained Records	

Article 7. Pharmacies

4113Non-	Resident Pharmacy Registration
4112	Nonresident Pharmacy: Registration; Provision of Information to Board; Maintaining
	Records; Patient Consultation
4113	Pharmacist in Charge: Notification to Board; Responsibilities
4115	Pharmacy Technician: Activities Permitted; Required Supervision; Activities Limited
	to Pharmacist; Registration; Requirements for Registration; Ratios
4116Phar	macy Technician Activities
4115.5	Pharmacy Technician Trainee; Placement; Supervision; Requirements
4116	Security of Dangerous Drugs and Devices in —Pharmacy: Pharmacist
	Responsibility for Individuals on Premises; Regulations
4117	Security - Hospital PharmacyAdmission to Area Where Narcotics are Stored, etc
	Who May Enter
4120	Non-Rresident Pharmacy: Registration Required
4125	Pharmacy Quality Assurance Program Required; Records Considered Peer Review

Documents

Article 9. Hypodermic Needle and Syringes

4140	Unlawful Possession
4147	Disposal of Needle or Syringe

Article 11. Wholesalers and Manufacturers

4161	Nonresident Wholesaler: When License Required; Application
4163	Sales to-Unauthorized Persons Furnishing by Manufacturer or Wholesale
4164	Reporting by Manufacturer and Wholesalers Reports Required
4169(a)(1)	Prohibited Acts

Article 13. Non-Profit of Free Clinics

4185 Inspections Permitted

Article 14. Surgical Clinics

4195 Inspections Permitted

Article 19. Disciplinary Proceedings

4301	General uUnprofessional eConduct and -subsections (a)-(h), (j), and (l) through- (q)
4302	Pharmacy Corporation Discipline of Corporate Licensee for Conduct of Officer,
	Director, Shareholder
4303	Nonresident Pharmacy: Grounds for Discipline
4304	Out-of-Sstate Distributor:s Authority to Discipline
4307Failur	re to Notify Board of Termination of Pharmacist in Charge; Operation of Pharmacy
without a l	Pharmacist Control of the Control of
4305	Disciplinary Grounds: Failure of Pharmacy, Pharmacist to Notify Board of
	Termination of Pharmacist in Charge; Continuing to Operate Without Pharmacist
4305.5	Disciplinary Grounds: Failure of Other Entity Licensed by Board, ofto Keep
	Pharmacist in Charge or Exemptee in Charge; Failure to Notify Board of Termination
	of SamePharmacist in Charge or Exemptee; Continuing to Operate Without
	Pharmacist or Exemptee
4308Violat	tion of Moscone-Knox Professional Corporation Act
4306	Violation of Professional Corporation Act as Unprofessional Conduct
4306.5	Pharmacist Misuse of Education, etc. by Pharmacist Outside Course of Practice of
	Pharmacy as Unprofessional Conduct

Article 20. Prohibitions and Offenses

4326	Hypodermics: Obtaining Falsely; MisuseMisdemeanor: Obtaining Needle or Syringe
	by Fraud, etc.; Unlawful Use of Needle or Syringe Obtained from Another
4328	Allowing Compounding by Non-pharmacist Misdemeanor: Permitting Compounding,
	Dispensing, or Furnishing by Non-pharmacist
4330	Pharmacy; Failure to Place Pharmacist in Charge-, Subverting Compliance with Law
	by Pharmacist-in- Charge Misdemeanor: Non-pharmacist Owner Failing to Place

	Pharmacist in Charge, Dispensing or Compounding Except by Pharmacist,
	Interfering with Pharmacist in Charge
4331	Veterinary Food-Animal Drug Retailer; Dispensing by Other than Pharmacist or
	Exemptee; Failure to Place Pharmacist or Exemptee in Charge Misdemeanor:
	Medical Device Retailer, Wholesaler, Veterinary Food-Animal Drug Retailer Failing to
	Place Pharmacist or Exemptee in Charge, Permitting Dispensing or Compounding
	Except by Pharmacist or Exemptee
4333	Failure to Maintain Prescription Files Maintaining Prescriptions, Other Drug Records
	on Premises, Open to Inspection; Waiver; Willful Failure to Keep or Permit
	Inspection of Records of Prescriptions, Other Records as Misdemeanor
4340	Advertisement of Pharmacy Services by Unregistered Non-Resident
	Pharmacy Unlawful Advertising by Nonresident Pharmacy Not Registered with Board

Article 22. Unfair Trade Practices

4380	Resale of Preferentially Priced Drugs; Emergency Prohibition; Exceptions
4381	Violation of Section 4380 as Unfair Competition; Right of Private Action to Enforce
4382	Authority of Board to May Audit for Compliance Sales to Walk-in Customers

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1707.1	Duty to mMaintain mMedication pProfiles (pPatient mMedication rRecords) -
	requirements for maintenance of patient medication profiles
1707.2	Notice to eConsumers and dDuty to eConsult—requirements of pharmacist to
	consult; posting of notice to consumers
1707.3	Reviewing the patient profile prior to consultation Duty to Review Drug Therapy and
	Patient Medication Record Prior to Deliver
1709.1	Designation of pPharmacist in cCharge
1714.1	Pharmacy Operation <u>dDuring Temporary</u> Absence of <u>a Pharmacist</u>
1716Self-/	Assessment of a Pharmacy by the Pharmacist-in-Charge
<u>1715</u>	Self-Assessment of a Pharmacy by the Pharmacist-in-Charge
1715.5	Transmitting Schedule II Prescription Information to CURES Implementation of
	Electronic Monitoring of Schedule II Prescriptions
1716.1	Compounding <u>Unapproved dDrugs</u> for <u>pPrescriber oOffice uUse</u>
1716.2	Record <u>FR</u> equirements <u>-when cC</u> ompounding for <u>Future Frunishing</u>
1717.2	Notice of Electronic Prescription Files
1717.3	Preprinted, mMultiple eCheck-off pPrescription bBlanks
1723.1	Confidentiality of Examination Questions
1745	Partial fFilling of Schedule II pPrescriptions
1751.10	Furnishing to pParenteral pPatient at hHome - carrying and furnishing dangerous
	drugs to parenteral patients
1761(a)	Erroneous or Uncertain Prescriptions-
1764	Unauthorized dDisclosure of pPrescriptions - revealing the contents of a prescription
	to unauthorized persons
1765	Commissions, gGratuities, and rRebates - commission, gratuity or rebate to a health
	care facility
1766	False or mMisleading aAdvertising
1775.3	Compliance with Orders of Abatement
1782	Reporting Sales of Drugs Subject to Abuse
1783	Manufacturer or Wholesaler Furnishing Drugs or Devices

1775.4Compliance with Orders of Abatement	
1784Reporting Sales of Drugs Subject to Abuse	
1785Manu	facturer or Wholesaler Furnishing
1793.1 to	•
1793.7	Ancillary personnel - pharmacy technician requirements and tasks
1793.1	Duties of a Pharmacist
1793.2	Duties of a Pharmacy Technician
1793.3	Other Non-Licensed Pharmacy Personnel
1793.4	Qualifications for Registration as a Pharmacy Technician
1793.7	Requirements for Pharmacies Employing Pharmacy Technicians
1793.8	Technicians in Hospitals with Clinical Pharmacy Programs

HEALTH AND SAFETY CODE, TITLE 22

11103	Report of <u>tTheft</u> , <u>tLoss</u> , or <u>sShipping dDiscrepancy - reporting losses of restricted chemicals to Department of Justice</u>
11123	- Warehouseman License
11124	Warehouse Inventory
11125	- Warehouseman Bond
11128	Nontransferability of Warehouse License
11129	Discipline or Denial of Warehouse License
11130	Disciplinary Grounds for Warehouse License
11131	Disciplinary Grounds for Warehouse License
11150	Issuing Controlled Substance Prescription Persons Authorized to Write or Issue a Prescription
11152	Nonconforming pPrescriptions Prohibited - filling a prescription that does not conform to the requirements of the code
11154	Issuing Prescriptions, etc. Must Be for Treatment; Knowing Soliciting of Unlawful Prescription, etc.
11156	Prescribing, etc. Administering or dispensing cControlled sSubstances to aAddict Only as Authorized - prohibition on administering or dispensing a controlled substance to an addict or a habitual user
11164	Completion of pPrescriptions for Schedule II, III, IV and V eControlled sSubstance: Form and Content; Record of Practitioner Dispensing Schedule II Controlled Substance - prescription requirements for controlled substances
11165(d)	CURES Transmission
11166	Time <u>Limit</u> <u>Ff</u> or Filling Schedule II Prescriptions; <u>Knowingly Filling</u> Mutilated, Forged, or Altered Prescriptions <u>Prohibited</u>
11170	Prohibition on <u>Prescribing, etc.</u> <u>eC</u> ontrolled <u>sS</u> ubstance for <u>sS</u> elf-use - <u>prohibition on</u> <u>prescribing, administering or furnishing controlled substance to self</u>
11179	Retention of Controlled Substance Prescription period - prescription file to be maintained for three (3) years
11207	Filling prescription oOnly by pPharmacist or iIntern Authorized to Fill Prescription pharmacist - dispensing, compounding, filling by pharmacist or intern pharmacist only
11209	Delivery and Receiving Requirements for Schedule II, III, and & IV Substances; Violation
11350	Possession of sSpecified cControlled sSubstance - illegal possession of a narcotic
11377	Unlawful pPossession of sSpecified sSubstance - illegal possession of a non- narcotic controlled substance

CODE OF FEDERAL REGULATIONS, TITLE 21

1304.03	Persons required to keep records and file reports.
1304.04	Maintenance of records and inventories.
1304.11	General Inventory requirements for inventories
1304.21	General requirements for continuing records.
1304.22	Records for manufacturers, distributors, dispensers, researchers, importers and
	exporters.
1305.07	Power of attorneySpecial procedures for filling certain orders.
1305.13	Preservation of order formsProcedure for filling DEA Forms 222.
1306.04	Purpose of issue of prescription.

```
1306.06 Persons entitled to fill prescriptions.

1306.08Administering or dispensing of narcotic drugs
1306.11 ——Requirement of Schedule II Pprescriptions.

1306.12 Refilling prescriptions.—Schedule II
1306.13 Partial filling of prescriptions.—Schedule II
1306.21 Requirement of prescription.—Schedule III and IV
1306.22 Refilling of prescriptions.—Schedule III and IV
1306.23 Partial filling of prescriptions.—Schedule III and IV
```

CATEGORY III

Minimum: Revocation; Revocation stayed, 90 days actual suspension, three to five years

probation (five years probation where self-administration or diversion of controlled substances is involved occurred at the licensed premises). All standard terms

and conditions and optional terms and conditions as appropriate.

For a licensed premises, a minimum 14-28 days actual suspension.

Maximum: Revocation

Category III discipline is recommended for:

- most criminal convictions involving dangerous drugs or controlled substances
- knowing or willfully violating laws or regulations pertaining to dispensing or distributing dangerous drugs or controlled substances
- fraudulent acts committed in connection with the licensee's practice
- drug shortages
- violation of a licensee's corresponding responsibility.

Violations of the following codes are as follows representative of this category:

BUSINESS AND PROFESSIONS CODE

Article 3. Scope of Practice and Exemptions

4051(a)	Conduct Limited I to Pharmacist
4060Furn	ishing without prescription
4059	Furnishing Dangerous Drugs or Devices Prohibited Without Prescription: Exceptions
4059.5	Ordering Who May Order Dangerous Drugs or Devices: Exceptions

Article 5. Authority of Inspectors

40	080	Stock of Dangerous Drugs and Devices Kept Open for Inspection	
4081 Records of Ac		Records of Acquisition and Dispensing; Dangerous Drugs and Devices Kept Open	
		for Inspection; Maintenance of Records, Current Inventory	
40	85(a)	Unlawful to Remove, Sell, Dispose of Embargoed Dangerous Drug or Dangerous	
		Device	

Article 7. Pharmacies

4110	Requirement of License Required; Temporary Licenses Permit Upon Transfer	
	Ownership	
4111	Restrictions on Prescriber Ownership by Prescribers Prohibited	

Article 11. Wholesalers and Manufacturers

4169(a)(2) to 4169(a)(5) Prohibited Acts

Article 15. Veterinary Food-Animal Retailers

4199 Labeling, Recordkeeping Requirements; Maintaining Prescription Records

Article 19. Disciplinary Proceedings

ı	4301	<u>Unprofessional Conduct - Ssubsections (i) and (k) and (o)</u>	
	4307	Prohibition against of Association with a of Individual with Entity License by Board:	
		Length of Prohibition; Individuals Covered; Imposition of Prohibition Through	
		Administrative Act Proceeding	
	4308	Notification of Licensee Person is Prohibited from Association:	
		Replacement Notification of Affected Licensees Known to Board	

Article 20. Prohibitions and Offenses

4322	Misdemeanor or Infraction: False Representations to ObtainSecure License for Self
	or Others; False Representation of Licensure; Penalties
4323	Misdemeanor: False Representation of Self as Physician, Agent of Physician, etc. by
	Telephone or Electronic Transmission to Obtain a Drug
4324	Felony or Misdemeanor: Forgery of Prescription; Possession of Drugs Obtained
	Through Forged Prescriptionor Alteration
4325	Misdemeanor: Manufacture, Possession, etc. of False Producing-Prescription
	Blanks Without Authorization
4327	Misdemeanor: Sale, Dispensing, or Compounding While Under the Influence Use of
	Alcohol or Drugs while on Dutyor Alcoholic Beverages
4329	Misdemeanor: Non-pharmacist Taking Charge Acting as Manager, Compounding,
	Dispensing or Furnishing Drugs
4332	Misdemeanor: Failure or Refusal to Maintain or Produce or Provide Required Drug or
	Device Records; Willful Production of False Records
4335	Voided License: Knowing Failure to Arrange for Disposition of Stock as
	<u>Misdemeanor</u>
4336	Felony: Knowing or Willful Use of Minor to Violate Specified Sections of Pharmacy
	Law: Exception for Pharmacist Furnishing Pursuant to a Prescription
4337Failu	ure to Arrange for Transfer of Stock after Closure
4338Use	of Minor as Agent to Violate Pharmacy Law

Article 22. Unfair Trade Practices

4380 Resale of Preferentially Priced Drugs: Prohibition; Exceptions

CALIFORNIA CODE OF REGULATIONS, TITLE 16

1718	Current inventory dDefined - audit accountability of dangerous drugs	
1761(b)	Controlled substance prescriptionprofessional judgment Erroneous or Uncertain	
, ,	Prescriptions	
1771 to		
1774	Disciplinary conditions of suspension and probation	
1771	Posting of Notice of Suspension	
1772	Disciplinary Condition of Suspension	
1773	Disciplinary Conditions of Probation of Pharmacist	

HEALTH AND SAFETY CODE, TITLE 22

11104	4 Providing Chemical for Illicit Manufacturing; Evasion of Reporting Requirements	
	Penalties controlled substances for manufacturing	
11105	False Statement in Report	
11122	Storage of Controlled Substances	
11150	Persons aAuthorized to wWrite or ilssue a pPrescription	
11153	Responsibility for Legitimacy of controlled substance pPrescription; Corresponding	
	Responsibility of Pharmacist - corresponding responsibility of a pharmacist	
11153.5	Wholesaler or Manufacturer Furnishing a cControlled sSubstance for oOther tThan	
	for a Legitimate mMedical pPurpose; Knowing Violation; Factors in Assessing	
	Legitimacy - corresponding responsibility of a wholesaler or manufacturer	
11157	No False or fFictitious pPrescriptions - issuing a false or fictitious prescription	
11162.5	Counterfeiting or pPossession of eCounterfeit Triplicate pPrescription bBlank;	
	<u>Penalty</u>	
<u>11167.5</u>	Pharmacy Generated Prescription for Schedule II Controlled Substance in a Skilled	
	Nursing Facility	
11173	Fraud, dDeceit, mMisrepresentation or fFalse sStatement; False Representation;	
	False Label - obtaining controlled Substances by fraud or deceit	
11174	Prohibition on Providing False nName or aAddress in Connection with Prescription,	
	etc false name or address on prescription	
11351	Possession or pPurchase for sSale of sSpecified eControlled sSubstance - illegal	
	possession for sale of a narcotic	
11368	Forged or aAltered pPrescriptions-forging a narcotic prescription	
11375	Possession for <u>sSale</u> or <u>sSelling</u> <u>sSpecified</u> <u>sSubstance</u>	
11378	Possession for sSale-illegal possession for sale of a nonnarcotic	
11550	Useing or beging uUnder the influence of controlled substance	
111295	Manufacturing, Selling or Offering for Sale an Adulterated Drug or Device	
111300	Unlawful to Adulterate a Drug	
111305	Unlawful to Receive in Commerce an Adulterated Drug	
111440	Unlawful Manufacturer, selling a misbranded Drug	
111445	Unlawful for a Person to Misbrand	
111450	Unlawful to Receive into Commerce a Drug that is Misbranded	

CATEGORY IV

Penalty: Revocation

Revocation is recommend<u>ed</u> for violations<u>of</u> the Uniform Controlled Substance Act (Heath and Safety Code 11000 et seq.) involving:

- possession for sale
- transportation
- importation
- sale
- use of a minor for the unlawful sale of controlled substances

Revocation is also recommended when:

a respondent fails to file a notice of defense or to appear at a disciplinary hearing

- where the board has requested revocation in the accusation
- a respondent violates the terms and conditions of probation from a previous disciplinary order
- prior discipline has been imposed, as progressive discipline unless the respondent can demonstrate satisfactory evidence of rehabilitation.

Violations of the following codes are as follows representative of this category:

HEALTH AND SAFETY CODE, TITLE 22

11352	Importing, sSelling, fFurnishing eControlled sSubstance - illegal sale of a narcotic
11353	Adult inducing m Minor to v Violate controlled substances p Provisions
11379	Transporting, ilmporting, sSelling controlled sSubstances - illegal sale of a non-
	narcotic
11380	Adult <u>uUsing</u> , <u>sSoliciting</u> or <u>iIntimidating</u> <u>mMinor for <u>vViolation</u> <u>- violation of non-</u></u>
	narcotic provisions or the use of a minor

MODEL DISCIPLINARY LANGUAGE - PREMISES

The following standardized language shall be used in every decision where the order or condition is imposed.

Revocation - Single Cause			
License number	, issued to respondent	, is revoked.	
For premises: Respondent owner shall, by the effective date of this decision, arrange for the destruction of, the transfer to, sale of or storage in a facility licensed by the board of all controlled substances and dangerous drugs and devices. Respondent owner shall provide written proof of such disposition, submit a completed Discontinuance of Business form and return the wall and renewal license to the board within five days of disposition.			
Revocation - Multiple Ca	uses		
License number pursuant to Determination of	, issue to respondent, separat	is revoked tely and together.	
destruction of, the transfer to	shall, by the effective date of this decision, sale of or storage in a facility licensed by drugs and devices. Respondent shall pron five days of disposition.	y the board of all controlled	
Suspension - Single Cau	ISO		
License number period ofdays	, issued to respondentbeginning the effective of this decision.	is suspended for a	
Suspension - Multiple Ca	auses		
Respondent is suspended from effective date of this decision	om operations for n.	beginning the	
Standard Stay/Probation	Order		
the <u>revocation</u>	, issued to respondent is <u>revoked</u> is stayed and respondent is placed on the following terms and conditions:	; however, on probation for	
Issuance of Probationary	y License (In cases where a Statement of Is	ssues has been filed.)	
The application for licensure conditions:	of respondent is hereby granted, on the f	ollowing terms and	
a license to	rst meet all statutory and regulatory requir		
	satisfaction of #1, respondent's license be revocation being stayed and respondent		

period of years on the following terms and conditions: Upon satisfaction of all statutory and regulatory requirements for issuance of a license, a license shall be issued to respondent and immediately revoked; the order of revocation is stayed and respondent is placed on probation for years upon the following terms and conditions:
Surrender
Respondent <u>owner</u> surrenders license number as of the effective date of this decision. Respondent <u>owner</u> shall relinquish <u>his or herthe premises</u> wall license and pocket renewal license to the board within <u>ten (10)</u> days of the effective date of this decision.
The surrender of respondent's license and the acceptance of the surrendered license by the board shall constitute the imposition of discipline against respondent. This decision constitutes a record of discipline and shall become a part of respondent's license history with the board.
Respondent owner shall, within ten (10) days of the effective date, arrange for the destruction of, the transfer to, sale of or storage in a facility licensed by the board of all controlled substances and dangerous drugs and devices. Respondent owner shall further provide written proof of such disposition and submit a completed Discontinuance of Business form according to board guidelines.
Respondent owner understands and agrees that if he or she ever files an application for a licensed premises or a petition for reinstatement in the State of California, the board shall treat it as a new application for licensure.
Respondent <u>owner</u> may not reapply for any license, <u>permit</u> , <u>or registration</u> from the board for three (3) years from the effective date of this decision. Respondent <u>owner</u> stipulates that should he or she apply for any license from the board on or after the effective date of this decision, all allegations set forth in the [accusation or petition to revoke probation] shall be deemed to be true, <u>correct and admitted by respondent when the board determines whether to grant or deny the application</u> . Respondent shall satisfy all requirements applicable to that license as of the date the application is submitted to the board, <u>including</u> , <u>but not limited to taking and passing the California Pharmacist Licensure Examination prior to the issuance of a new license</u> . Respondent is <u>obligated required</u> to report this surrender as disciplinary action.
Respondent

Adoption of Stipulation

It is understood by respondent <a href="https://www.new.numer.com/owner.com/

STANDARD CONDITIONS - To be included in all probation decisions/orders.

Term Number: (Numbers reflect actual term and condition numbers as listed beginning with page ...)

- 1. Obey aAll laws
- 2. Reporting to the Board
- 3. Interview with the Board
- 4. Cooperatione with Board Staff
- 5. Reimbursement of Board Costs
- 6. Probation Monitoring Costs
- 7. Status of License
- 8. License Surrender wWhile on Probation/Suspension
- 9. Notice to Employees
- 10. Owners and Officers: Knowledge of the Law
- 11. Posted Notice of Probation
- 41.12. Violation of Probation
- 12. Completion of Probation

OPTIONAL CONDITIONS

Term Number: (Numbers reflect actual term and condition numbers as listed beginning with page ______.)

- **1.Actual Suspension**
- 2.14. Community Services Program
- 3.15. Restitution
- 4.16. Separate File of Records
- 5.17. Report of Controlled Substances
- 6.18. Surrender of DEA Permit
- 7.19. Posted Notice of Suspension

STANDARD CONDITIONS: TO BE INCLUDED IN ALL PROBATIONS

4.1. Obey All Laws

Respondent <u>owner</u> shall obey all state and federal laws and regulations <u>substantially related to or governing the practice of pharmacy</u>.

Respondent <u>owner</u> shall report any of the following occurrences to the board, in writing, within <u>seventy-two</u> (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state and or federal agency which involves respondent's _____ license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling or distributiong, or charging for of any drug, device or controlled substance.

Failure to timely report any such occurrence shall be considered a violation of probation.

2.2. Reporting to the Board

Respondent <u>owner</u> shall report to the board quarterly, <u>on a schedule as directed by the board or its designee</u>. The report shall be made either in person or in writing, as directed. <u>Among other requirements</u>, <u>Rrespondent owner</u> shall state <u>in each report</u> under penalty of perjury whether there has been compliance with all the terms and conditions of probation. <u>Failure to submit timely reports in a form as directed shall be considered a violation of probation.</u> Any period(s) of <u>delinquency in submission of reports as directed may be added to the total period of probation.</u> <u>Moreover</u>, <u>lif</u> the final probation report <u>is not</u> is <u>not</u> made as directed, probation shall be <u>automatically</u> extended <u>automatically</u> until such time as the final report is made and accepted by the board.

3.3. Interview with the Board

Upon receipt of reasonable <u>prior</u> notice, respondent <u>owner</u> shall appear in person for interviews with the board <u>or its designee</u>, <u>upon request</u> at <u>various_such</u> intervals <u>at aand</u> locations <u>to be as are</u> determined by the board <u>or its designee</u>. Failure to appear for any scheduled interview without prior notification to board staff, <u>or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.</u>

4.4. Cooperatione with Board Staff

Respondent <u>owner</u> shall cooperate with the board's inspectional program and <u>in-with</u> the board's monitoring and investigation of respondent's compliance with the terms and conditions of his or her probation. Failure to comply cooperate shall be considered a violation of probation.

5.5. Reimbursement of Board Costs

As a condition precedent to successful completion of probation, Rrespondent owner shall pay to the board its costs of investigation and prosecution in the amount of . Respondent owner shall make said payments as follows: _______. There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by respondent <u>owner</u> shall not relieve respondent of his or her responsibility to reimburse the board its costs of investigation and prosecution.

Option: If respondent owner fails to make any payment by the directed deadline(s), the stay shall terminate and the license shall be revoked without further notice or opportunity to be heard.

6.6. Probation Monitoring Costs

Respondent <u>owner</u> shall pay <u>the any</u> costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board <u>at the end of each year of probation on a schedule as directed by the board or its designee</u>. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

7.7. Status of License

Respondent <u>owner</u> shall, at all times while on probation, maintain <u>a</u>-current licens<u>ure</u> with the board. If respondent <u>owner</u> submits an application to the board, and the application is approved, for a change of location, change of permit or change of ownership, the board shall retain continuing jurisdiction over the license, and the respondent shall remain on probation as determined by the board. <u>Failure to maintain current licensure shall be considered a violation of probation</u>.

If respondent license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof or otherwise, upon renewal or reapplication respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

8.8. License Surrender wWhile on Probation/Suspension

Following the effective date of this decision, should respondent <u>cease practice due to retirement</u> or health, or be otherwise unable to satisfy the terms and conditions of probation<u>owner</u> <u>discontinue business</u>, respondent <u>owner may tender his or her the premises</u> license to the board for surrender. The board <u>or its designee</u> shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation.

Upon acceptance of the surrender, respondent <u>owner</u> shall relinquish <u>his or her pocket the</u> <u>premises wall and renewal</u> license to the board within <u>ten (10)</u> days of notification by the board that the surrender is accepted. <u>Respondent owner shall further submit a completed</u> <u>Discontinuance of Business form according to board guidelines and shall notify the board of the records inventory transfer.</u> Respondent owner may not reapply for any license new licensure

from the board for three (3) years from the effective date of the surrender. Respondent owner shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board.

Respondent owner further stipulates that he or she shall reimburse the board for its costs of investigation and prosecution prior to the acceptance of the surrender.

9.9. Notice to Employees

Respondent <u>owner</u> shall, upon or before the effective date of this decision, ensure that all employees involved in permit operations are made aware of all the terms and conditions of probation, either by posting a notice of the terms and conditions, circulating such notice, or both. If the notice required by this provision is posted, it shall be posted in a prominent place and shall remain posted throughout the probation period. Respondent <u>owner</u> shall ensure that any employees hired or used after the effective date of this decision are made aware of the terms and conditions <u>of probation</u> by posting a notice, circulating a notice, or both. <u>Additionally, respondent owner shall submit written notification to the board, within fifteen (15) days of the effective date of this decision, that this term has been satisfied. Failure to submit such notification to the board shall be considered a violation of probation.</u>

"Employees" as used in this provision includes all full-time, part-time, volunteer, temporary and relief employees and independent contractors employed or hired at any time during probation.

10.10. Owners and Officers: Knowledge of the Law

Respondent shall provide, within thirty (30) days after the effective date of this decision, signed and dated statements from its owners, including any owner or holder of ten percent (10%) or more of the interest in respondent or respondent's stock, and any officer, stating under penalty of perjury that said individuals have read and are familiar with state and federal laws and regulations governing the practice of pharmacy. The failure to timely provide said statements under penalty of perjury shall be considered a violation of probation.

11. Posted Notice of Probation

Respondent owner shall prominently post a probation notice provided by the board in a place conspicuous and readable to the public. The probation notice shall remain posted during the entire period of probation.

Respondent owner shall not, directly or indirectly, engage in any conduct or make any statement which is intended to mislead or is likely to have the effect of misleading any patient, customer, member of the public, or other person(s) as to the nature of and reason for the probation of the licensed entity.

Failure to post such notice shall be considered a violation of probation.

11.12. Violation of Probation

If a respondent owner has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent license, and probation shall be automatically extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent <u>owner</u> violates probation in any respect, the board, after giving respondent <u>owner</u> notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order <u>which-that</u> was stayed. <u>Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of <u>the license</u>. If a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction and the period of probation shall be <u>automatically</u> extended, until the petition to revoke probation or accusation is heard and decided.</u>

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty which was staved.

12.13. Completion of Probation

Upon <u>written notice by the board or its designee indicating</u> successful completion of probation, respondent's license will be fully restored.

OPTIONAL CONDITIONS OF PROBATION

1. Actual Suspension

As part of probation, respondent pharmacy is suspended from the operation of pharmacy for days beginning the effective date of this decision.

During suspension, respondent pharmacy may not order, maintain or dispose of any dangerous drugs and devices or controlled substances. The pharmacy may not make demand or bill for any drugs or services during the period of suspension and may not process any claims for pharmacy services during the period of suspension, except as to services rendered prior to the effective date of the suspension period. The pharmacy shall not receive or transmit any prescription, new or refill, during the period of suspension. Where the pharmacy does not maintain dangerous drugs and devices or controlled substances in an area which can be closed off from the rest of the pharmacy and locked, the entire pharmacy must be closed during the period of suspension.

2.14. Community Services Program

Within <u>sixty (60)</u> days of the effective date of this decision, respondent <u>owner shall submit to the board or its designee</u> , for <u>its-prior approval</u> , a community service program in which respondent shall provide free health-care related services on a regular basis to a community or charitable facility or agency for at least hours per for the first of probation.						
Within thirty (30) days of board approval thereof, respondent owner shall submit documentation to the board demonstrating commencement of the community service program. Respondent owner shall report on progress with the community service program in the quarterly reports.						
Failure to timely submit, commence, or comply with the program shall be considered a violation of probation.						
3.15. Restitution (Appropriate in cases of drug diversion, theft, fraudulent billing, or patient harm resulting from negligence or incompetence.)						
Within days of the effective date of this decision, respondent <u>owner</u> shall pay restitution to in the amount of \$ <u>Failure to make restitution by this deadline shall be considered a violation of probation.</u>						

4.16. Separate File of Records

Respondent <u>owner</u> shall maintain <u>and make available for inspection</u> a separate file of all records pertaining to the acquisition or disposition of all controlled substances. <u>Failure to maintain such file or make it available for inspection shall be considered a violation of probation.</u>

5.17. Report of Controlled Substances

Respondent owner shall submit quarterly reports to the board detailing the total acquisition and

disposition of such controlled substances as the board may direct. Respondent <u>owner</u> shall specify the manner of disposition (e.g., by prescription, due to burglary, etc.) or acquisition (e.g., from a manufacturer, from another retailer, etc.) of such controlled substances. Respondent <u>owner</u> shall report on a quarterly basis or as directed by the board. The report shall be delivered or mailed to the board no later than <u>ten (10)</u> days following the end of the reporting period. <u>Failure to timely prepare or submit such reports shall be considered a violation of probation.</u>

6.18. Surrender of DEA Permit

Within thirty (30) days of the effective date of this decision, Rrespondent pharmacy shall surrender its federal Drug Enforcement Administration (DEA) permit to the DEA, for cancellation within 30 days of the effective date of this decision. Respondent pharmacy shall provide documentary proof of such cancellation to the board or its designee. Thereafter, respondent pharmacy shall not apply/reapply for a DEA registration number without the prior written consent of the board or its designee.

Option: Respondent <u>pharmacy</u> may obtain a DEA permit restricted to Schedule(s) _____ controlled substance(s).

Option: Respondent <u>pharmacy</u> shall not order, receive, or retain any federal order forms, including 222 forms, for controlled substances.

7.19. Posted Notice of Suspension

Respondent <u>owner</u> shall prominently post a suspension notice provided by the board in a place conspicuous and readable to the public. The suspension notice shall remain posted during the entire period of <u>actual</u> suspension <u>ordered</u> by this <u>decision</u>.

Respondent www.ncm.nih.gov/orind/color: blue/ not directly or indirectly, engage in any conduct or make any statement, orally, electronically or in writing, which is intended to mislead or is likely to have the effect of misleading any patient, customer, member of the public, or other person(s) as to the nature of and reason for the closure of the licensed entity.

2/27/20016/2007

Attachment 3

California State Board of Pharmacy July 1, 2006 – June 15, 2007 Citation and Fine Statistics

765 citations have been issued so far this fiscal year

Total dollar amount of fines issued this fiscal year \$ 126,550.00

Total dollar amount of fines collected

'This amount also reflects payment of the citations issued before July 1, 2006.

The average number of days from date case is opened until a citation is issued is **158**

Average number of days from date citation is issued to date citation is closed is **45**

Citation Breakdown by license type

TCH no fine	5
TCH with fine	24
PIC no fine	26
PIC with fine	103
PHY no fine	104
PHY with fine	177
RPH no fine	39
RPH with fine	129
Total issued	765

Citation Breakdown by Miscellaneous license type

								,
Wholesalers	Exemptee's	Clinics	Drug room	Exempt Hosp.	Hosp. pharmacy	Misc.	Unlicensed Premises	Unlicensed person
2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -								
37	24	2	₩	יכ	∞	61	24	3
``								

*Licensed Correctional Facilities, Exempt Pharmacies, Non-Resident Pharmacies, and Vet Retailers

Top Ten Violations for the fourth quarter of 2006/2007 by license type

Pharmacists %	%	Pharmacies	%	Pharmacists in charge	%
1716 - Variation from prescription	45%	1716 - Variation from prescription	36%	1716 - Variation from prescription	%6
ption, or or	%6	1714(b)- Operational standards and security; pharmacy responsible for pharmacy security	18%	1715 – Self-assessment of a pharmacy by the pharmacist-in-charge	%6
1714(d)- Operational standards and security; pharmacist responsible for pharmacy security	%6	1716/1761(a) – Variation from prescription/No pharmacist shall compound or dispense any prescription, which contains any significant error or omission	7%	1714(d)- Operational standards and security; pharmacist responsible for pharmacy security	%6
4339 - Non-pharmacist acting as manager, compounding, dispensing, or furnishing drugs	%4	4342 - Actions by board to prevent sales of preparations or drugs lacking quality or strength; Penalties for knowing or willful violation of regulations governing those sales	2%	4342 - Actions by board to prevent sales of preparations or drugs lacking quality or strength; Penalties for knowing or willful violation of regulations governing those sales	%8
4342 - Actions by board to prevent sales of preparations or drugs lacking quality or strength; Penalties for knowing or willful violation of regulations governing those sales	3%	1764/56.10et seq Unauthorized disclosure of prescription and medical information	4%	1716/1761(a) – Variation from prescription/No pharmacist shall compound or dispense any prescription, which contains any significant error or omission	%9
1707.3 – Duty to review drug therapy	3%	1714(c)- Operational standards and security; the pharmacy must be maintained in a sanitary condition	3%	4063 - Refill of prescription for dangerous drug or device; prescriber authorization	2%
4322 - Misdemeanor or infraction: false representation to secure license for self or others; false representation of licensure	3%	1716/1761 - Variation from Rx / Erroneous Rx	3%	1714(b)- Operational standards and security; pharmacy responsible for pharmacy security	2%
4059(a)- Furnishing dangerous drugs without a prescription	3%	4063 - Refill of prescription for dangerous drug or device; prescriber authorization	2%	1304.11- Inventory requirements	4%
1764/56.10et seq Unauthorized disclosure of prescription and medical information	2%	4081(a)- Records of dangerous drugs kept open for inspection	2%	1707.2- Duty to consult	4%
4081(a)- Records of dangerous drugs kept open for inspection	2%	4115(e) - Pharmacy technician license required	2%	1711- Quality assurance programs	3%

California State Board of Pharmacy Citation Statistics Page 2 of 3

Contested Citations Office Conference

(These statistics also include contested Letters of Admonishment)

There were twenty office conferences held this fiscal year

Number of requests 255 Number	Number	148*	Number appeared
sts			
	Numb	255	Number of requests

*Please note on three occasions unscheduled citations were heard with a related case at office conference. 64^{**} **Please note these are added back into the number of requests and scheduled case totals above. er Postponed

255

er scheduled

wn 31	33
Fotal number of requests withdray	Failed to appear

held between July 1, 2006 and June 12, 2007 Office Conference results Total number of citations affirmed

Total dollar amount reduced	\$10,375.00	\$4,000.00	\$0.00
Total citations	30	30	1
Decision	Modified	Dismissed	Reduced to Letter of Admonishment

Please note due to additional investigation being required, Seven cases are pending a decision